UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
| | | | | |
☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 20202021
or
| | | | | |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File Number: 001-37702
Amgen Inc.
(Exact name of registrant as specified in its charter)
| | | | | | | | |
Delaware | | 95-3540776 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
| | |
One Amgen Center Drive | | 91320-1799 |
Thousand Oaks | | |
California | | |
(Address of principal executive offices) | | (Zip Code) |
(805) 447-1000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common stock, $0.0001 par value | AMGN | The NASDAQ Global SelectNasdaq Stock Market LLC |
1.250% Senior Notes Duedue 2022 | AMGN22 | New YorkThe Nasdaq Stock ExchangeMarket LLC |
2.00% Senior Notes Duedue 2026 | AMGN26 | New YorkThe Nasdaq Stock ExchangeMarket LLC |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | | | | | | |
Large accelerated filer | ☑ | Accelerated filer | ☐ | Non-accelerated filer | ☐ |
Smaller reporting company | ☐ | Emerging growth company | ☐ | | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
No ☑
As of July 23, 2020,29, 2021, the registrant had 585,693,775567,852,353 shares of common stock, $0.0001 par value, outstanding.
AMGEN INC.
INDEX
| | | | | | | | |
| | Page No. |
| | |
Item 1. | | |
| | |
| | |
| | |
| | |
| | |
| | |
Item 2. | | |
Item 3. | | |
Item 4. | | |
| | |
Item 1. | | |
Item 1A. | | |
Item 2. | | |
Item 6. | | |
| | |
| | |
PART I — FINANCIAL INFORMATION
| | | | | |
Item 1. | FINANCIAL STATEMENTS |
AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per-share data)
(Unaudited)
| | | Three months ended June 30, | | | Six months ended June 30, | | | Three months ended June 30, | | Six months ended June 30, |
| | 2020 | | 2019 | | 2020 | | 2019 | | 2021 | | 2020 | | 2021 | | 2020 |
Revenues: | Revenues: | | | | | | | | Revenues: | | | | | | | |
Product sales | Product sales | $ | 5,908 | | | $ | 5,574 | | | $ | 11,802 | | | $ | 10,860 | | Product sales | $ | 6,114 | | | $ | 5,908 | | | $ | 11,706 | | | $ | 11,802 | |
Other revenues | Other revenues | 298 | | | 297 | | | 565 | | | 568 | | Other revenues | 412 | | | 298 | | | 721 | | | 565 | |
Total revenues | Total revenues | 6,206 | | | 5,871 | | | 12,367 | | | 11,428 | | Total revenues | 6,526 | | | 6,206 | | | 12,427 | | | 12,367 | |
| Operating expenses: | Operating expenses: | | Operating expenses: | |
Cost of sales | Cost of sales | 1,488 | | | 1,012 | | | 3,001 | | | 2,067 | | Cost of sales | 1,637 | | | 1,488 | | | 3,127 | | | 3,001 | |
Research and development | Research and development | 964 | | | 924 | | | 1,916 | | | 1,803 | | Research and development | 1,082 | | | 964 | | | 2,049 | | | 1,916 | |
Acquired in-process research and development | | Acquired in-process research and development | 1,505 | | | 0 | | | 1,505 | | | 0 | |
Selling, general and administrative | Selling, general and administrative | 1,295 | | | 1,260 | | | 2,611 | | | 2,414 | | Selling, general and administrative | 1,384 | | | 1,295 | | | 2,638 | | | 2,611 | |
Other | Other | 136 | | | (3) | | | 161 | | | (6) | | Other | 90 | | | 136 | | | 151 | | | 161 | |
Total operating expenses | Total operating expenses | 3,883 | | | 3,193 | | | 7,689 | | | 6,278 | | Total operating expenses | 5,698 | | | 3,883 | | | 9,470 | | | 7,689 | |
| Operating income | Operating income | 2,323 | | | 2,678 | | | 4,678 | | | 5,150 | | Operating income | 828 | | | 2,323 | | | 2,957 | | | 4,678 | |
| Other income (expense): | | Other income (expense): | |
Interest expense, net | Interest expense, net | 296 | | | 332 | | | 642 | | | 675 | | Interest expense, net | (281) | | | (296) | | | (566) | | | (642) | |
Interest and other income, net | 3 | | | 218 | | | 14 | | | 403 | | |
Other income, net | | Other income, net | 11 | | | 3 | | | 24 | | | 14 | |
| Income before income taxes | Income before income taxes | 2,030 | | | 2,564 | | | 4,050 | | | 4,878 | | Income before income taxes | 558 | | | 2,030 | | | 2,415 | | | 4,050 | |
| Provision for income taxes | Provision for income taxes | 227 | | | 385 | | | 422 | | | 707 | | Provision for income taxes | 94 | | | 227 | | | 305 | | | 422 | |
| Net income | Net income | $ | 1,803 | | | $ | 2,179 | | | $ | 3,628 | | | $ | 4,171 | | Net income | $ | 464 | | | $ | 1,803 | | | $ | 2,110 | | | $ | 3,628 | |
| Earnings per share: | Earnings per share: | | Earnings per share: | |
Basic | Basic | $ | 3.07 | | | $ | 3.59 | | | $ | 6.16 | | | $ | 6.78 | | Basic | $ | 0.81 | | | $ | 3.07 | | | $ | 3.67 | | | $ | 6.16 | |
Diluted | Diluted | $ | 3.05 | | | $ | 3.57 | | | $ | 6.12 | | | $ | 6.75 | | Diluted | $ | 0.81 | | | $ | 3.05 | | | $ | 3.65 | | | $ | 6.12 | |
| Shares used in calculation of earnings per share: | Shares used in calculation of earnings per share: | | Shares used in calculation of earnings per share: | |
Basic | Basic | 588 | | | 607 | | | 589 | | | 615 | | Basic | 573 | | | 588 | | | 575 | | | 589 | |
Diluted | Diluted | 592 | | | 610 | | | 593 | | | 618 | | Diluted | 576 | | | 592 | | | 578 | | | 593 | |
See accompanying notes.
AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
(Unaudited)
| | | Three months ended June 30, | | | Six months ended June 30, | | | Three months ended June 30, | | Six months ended June 30, |
| | 2020 | | 2019 | | 2020 | | 2019 | | 2021 | | 2020 | | 2021 | | 2020 |
Net income | Net income | $ | 1,803 | | | $ | 2,179 | | | $ | 3,628 | | | $ | 4,171 | | Net income | $ | 464 | | | $ | 1,803 | | | $ | 2,110 | | | $ | 3,628 | |
Other comprehensive (loss) income, net of reclassification adjustments and taxes: | Other comprehensive (loss) income, net of reclassification adjustments and taxes: | | Other comprehensive (loss) income, net of reclassification adjustments and taxes: | |
Losses on foreign currency translation | (3) | | | (4) | | | (55) | | | (17) | | |
Losses on cash flow hedges | (116) | | | (104) | | | (177) | | | (59) | | |
(Losses) gains on available-for-sale securities | (2) | | | 153 | | | (21) | | | 374 | | |
Gains (losses) on foreign currency translation | | Gains (losses) on foreign currency translation | 14 | | | (3) | | | (25) | | | (55) | |
(Losses) gains on cash flow hedges | | (Losses) gains on cash flow hedges | (48) | | | (116) | | | 142 | | | (177) | |
Losses on available-for-sale securities | | Losses on available-for-sale securities | 0 | | | (2) | | | 0 | | | (21) | |
Other | Other | — | | | 6 | | | (2) | | | 6 | | Other | (1) | | | 0 | | | 0 | | | (2) | |
Other comprehensive (loss) income, net of taxes | Other comprehensive (loss) income, net of taxes | (121) | | | 51 | | | (255) | | | 304 | | Other comprehensive (loss) income, net of taxes | (35) | | | (121) | | | 117 | | | (255) | |
Comprehensive income | Comprehensive income | $ | 1,682 | | | $ | 2,230 | | | $ | 3,373 | | | $ | 4,475 | | Comprehensive income | $ | 429 | | | $ | 1,682 | | | $ | 2,227 | | | $ | 3,373 | |
See accompanying notes.
AMGEN INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except per-share data)
| | | June 30, 2020 | | December 31, 2019 | | June 30, 2021 | | December 31, 2020 |
| | (Unaudited) | | | | (Unaudited) | | |
ASSETS | ASSETS | | ASSETS |
Current assets: | Current assets: | | Current assets: | |
Cash and cash equivalents | Cash and cash equivalents | $ | 9,145 | | | $ | 6,037 | | Cash and cash equivalents | $ | 6,630 | | | $ | 6,266 | |
Marketable securities | Marketable securities | 2,276 | | | 2,874 | | Marketable securities | 1,452 | | | 4,381 | |
Trade receivables, net | Trade receivables, net | 5,366 | | | 4,057 | | Trade receivables, net | 4,479 | | | 4,525 | |
Inventories | Inventories | 3,840 | | | 3,584 | | Inventories | 4,115 | | | 3,893 | |
Other current assets | Other current assets | 2,268 | | | 1,888 | | Other current assets | 2,423 | | | 2,079 | |
Total current assets | Total current assets | 22,895 | | | 18,440 | | Total current assets | 19,099 | | | 21,144 | |
| Property, plant and equipment, net | Property, plant and equipment, net | 4,843 | | | 4,928 | | Property, plant and equipment, net | 4,906 | | | 4,889 | |
Intangible assets, net | Intangible assets, net | 17,948 | | | 19,413 | | Intangible assets, net | 15,308 | | | 16,587 | |
Goodwill | Goodwill | 14,678 | | | 14,703 | | Goodwill | 14,676 | | | 14,689 | |
Other assets | 4,647 | | | 2,223 | | |
Other noncurrent assets | | Other noncurrent assets | 5,784 | | | 5,639 | |
Total assets | Total assets | $ | 65,011 | | | $ | 59,707 | | Total assets | $ | 59,773 | | | $ | 62,948 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | LIABILITIES AND STOCKHOLDERS’ EQUITY | | LIABILITIES AND STOCKHOLDERS’ EQUITY |
Current liabilities: | Current liabilities: | | Current liabilities: | |
Accounts payable | Accounts payable | $ | 1,150 | | | $ | 1,371 | | Accounts payable | $ | 1,277 | | | $ | 1,421 | |
Accrued liabilities | Accrued liabilities | 9,282 | | | 8,511 | | Accrued liabilities | 8,984 | | | 10,141 | |
Current portion of long-term debt | Current portion of long-term debt | 91 | | | 2,953 | | Current portion of long-term debt | 4,324 | | | 91 | |
Total current liabilities | Total current liabilities | 10,523 | | | 12,835 | | Total current liabilities | 14,585 | | | 11,653 | |
| Long-term debt | Long-term debt | 34,133 | | | 26,950 | | Long-term debt | 28,458 | | | 32,895 | |
Long-term deferred tax liabilities | 259 | | | 606 | | |
Long-term tax liabilities | Long-term tax liabilities | 7,556 | | | 8,037 | | Long-term tax liabilities | 6,428 | | | 6,968 | |
Other noncurrent liabilities | Other noncurrent liabilities | 1,881 | | | 1,606 | | Other noncurrent liabilities | 2,055 | | | 2,023 | |
| Contingencies and commitments | Contingencies and commitments | | Contingencies and commitments | 0 | | 0 |
| Stockholders’ equity: | Stockholders’ equity: | | Stockholders’ equity: | |
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding — 586.4 shares in 2020 and 591.4 shares in 2019 | 31,610 | | | 31,531 | | |
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—569.6 shares in 2021 and 578.3 shares in 2020 | | Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—569.6 shares in 2021 and 578.3 shares in 2020 | 31,877 | | | 31,802 | |
Accumulated deficit | Accumulated deficit | (20,168) | | | (21,330) | | Accumulated deficit | (22,762) | | | (21,408) | |
Accumulated other comprehensive loss | Accumulated other comprehensive loss | (783) | | | (528) | | Accumulated other comprehensive loss | (868) | | | (985) | |
Total stockholders’ equity | Total stockholders’ equity | 10,659 | | | 9,673 | | Total stockholders’ equity | 8,247 | | | 9,409 | |
Total liabilities and stockholders’ equity | Total liabilities and stockholders’ equity | $ | 65,011 | | | $ | 59,707 | | Total liabilities and stockholders’ equity | $ | 59,773 | | | $ | 62,948 | |
See accompanying notes.
AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In millions, except per-share data)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Number of shares of common stock | | Common stock and additional paid-in capital | | Accumulated deficit | | Accumulated other comprehensive loss | | Total |
Balance as of December 31, 2019 | 591.4 | | | $ | 31,531 | | | $ | (21,330) | | | $ | (528) | | | $ | 9,673 | |
Cumulative effect of changes in accounting principles, net of tax | — | | | — | | | (2) | | | — | | | (2) | |
Net income | — | | | — | | | 1,825 | | | — | | | 1,825 | |
Other comprehensive loss, net of taxes | — | | | — | | | — | | | (134) | | | (134) | |
Dividends declared on common stock ($1.60 per share) | — | | | — | | | (938) | | | — | | | (938) | |
Issuance of common stock in connection with the Company’s equity award programs | 0.9 | | | 10 | | | — | | | — | | | 10 | |
Stock-based compensation expense | — | | | 52 | | | — | | | — | | | 52 | |
Tax impact related to employee stock-based compensation expense | — | | | (68) | | | — | | | — | | | (68) | |
Repurchases of common stock | (4.3) | | | — | | | (933) | | | — | | | (933) | |
Balance as of March 31, 2020 | 588.0 | | | 31,525 | | | (21,378) | | | (662) | | | 9,485 | |
| | | | | | | | | |
Net income | — | | | — | | | 1,803 | | | — | | | 1,803 | |
Other comprehensive loss, net of taxes | — | | | — | | | — | | | (121) | | | (121) | |
| | | | | | | | | |
Issuance of common stock in connection with the Company’s equity award programs | 1.0 | | | 65 | | | — | | | — | | | 65 | |
Stock-based compensation expense | — | | | 101 | | | — | | | — | | | 101 | |
Tax impact related to employee stock-based compensation expense | — | | | (81) | | | — | | | — | | | (81) | |
Repurchases of common stock | (2.6) | | | — | | | (591) | | | — | | | (591) | |
Other | — | | | — | | | (2) | | | — | | | (2) | |
Balance as of June 30, 2020 | 586.4 | | | $ | 31,610 | | | $ | (20,168) | | | $ | (783) | | | $ | 10,659 | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Number of shares of common stock | | Common stock and additional paid-in capital | | Accumulated deficit | | Accumulated other comprehensive loss | | Total |
Balance as of December 31, 2020 | 578.3 | | | $ | 31,802 | | | $ | (21,408) | | | $ | (985) | | | $ | 9,409 | |
| | | | | | | | | |
Net income | — | | | — | | | 1,646 | | | — | | | 1,646 | |
Other comprehensive income, net of taxes | — | | | — | | | — | | | 152 | | | 152 | |
Dividends declared on common stock ($1.76 per share) | — | | | — | | | (1,012) | | | — | | | (1,012) | |
Issuance of common stock in connection with the Company’s equity award programs | 0.7 | | | 6 | | | — | | | — | | | 6 | |
Stock-based compensation expense | — | | | 57 | | | — | | | — | | | 57 | |
Tax impact related to employee stock-based compensation expense | — | | | (59) | | | — | | | — | | | (59) | |
Repurchases of common stock | (3.7) | | | — | | | (865) | | | — | | | (865) | |
Balance as of March 31, 2021 | 575.3 | | | 31,806 | | | (21,639) | | | (833) | | | 9,334 | |
| | | | | | | | | |
Net income | — | | | — | | | 464 | | | — | | | 464 | |
Other comprehensive loss, net of taxes | — | | | — | | | — | | | (35) | | | (35) | |
| | | | | | | | | |
Issuance of common stock in connection with the Company’s equity award programs | 0.8 | | | 47 | | | — | | | — | | | 47 | |
Stock-based compensation expense | — | | | 100 | | | — | | | — | | | 100 | |
Tax impact related to employee stock-based compensation expense | — | | | (76) | | | — | | | — | | | (76) | |
Repurchases of common stock | (6.5) | | | — | | | (1,592) | | | — | | | (1,592) | |
Other | — | | | — | | | 5 | | | — | | | 5 | |
Balance as of June 30, 2021 | 569.6 | | | $ | 31,877 | | | $ | (22,762) | | | $ | (868) | | | $ | 8,247 | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (continued)
(In millions, except per-share data)
(Unaudited)
| | | Number of shares of common stock | | Common stock and additional paid-in capital | | Accumulated deficit | | Accumulated other comprehensive loss | | Total | | Number of shares of common stock | | Common stock and additional paid-in capital | | Accumulated deficit | | Accumulated other comprehensive loss | | Total |
Balance as of December 31, 2018 | 629.6 | | | $ | 31,246 | | | $ | (17,977) | | | $ | (769) | | | $ | 12,500 | | |
| Balance as of December 31, 2019 | | Balance as of December 31, 2019 | 591.4 | | | $ | 31,531 | | | $ | (21,330) | | | $ | (528) | | | $ | 9,673 | |
Cumulative effect of changes in accounting principles, net of taxes | | Cumulative effect of changes in accounting principles, net of taxes | — | | | — | | | (2) | | | — | | | (2) | |
Net income | Net income | — | | | — | | | 1,992 | | | — | | | 1,992 | | Net income | — | | | — | | | 1,825 | | | — | | | 1,825 | |
Other comprehensive income, net of taxes | — | | | — | | | — | | | 253 | | | 253 | | |
Dividends declared on common stock ($1.45 per share) | — | | | — | | | (879) | | | — | | | (879) | | |
Other comprehensive loss, net of taxes | | Other comprehensive loss, net of taxes | — | | | — | | | — | | | (134) | | | (134) | |
Dividends declared on common stock ($1.60 per share) | | Dividends declared on common stock ($1.60 per share) | — | | | — | | | (938) | | | — | | | (938) | |
Issuance of common stock in connection with the Company’s equity award programs | Issuance of common stock in connection with the Company’s equity award programs | 0.7 | | | 6 | | | — | | | — | | | 6 | | Issuance of common stock in connection with the Company’s equity award programs | 0.9 | | | 10 | | | — | | | — | | | 10 | |
Stock-based compensation expense | Stock-based compensation expense | — | | | 64 | | | — | | | — | | | 64 | | Stock-based compensation expense | — | | | 52 | | | — | | | — | | | 52 | |
Tax impact related to employee stock-based compensation expense | Tax impact related to employee stock-based compensation expense | — | | | (73) | | | — | | | — | | | (73) | | Tax impact related to employee stock-based compensation expense | — | | | (68) | | | — | | | — | | | (68) | |
Repurchases of common stock | Repurchases of common stock | (15.9) | | | — | | | (3,031) | | | — | | | (3,031) | | Repurchases of common stock | (4.3) | | | — | | | (933) | | | — | | | (933) | |
Balance as of March 31, 2019 | 614.4 | | | 31,243 | | | (19,895) | | | (516) | | | 10,832 | | |
Balance as of March 31, 2020 | | Balance as of March 31, 2020 | 588.0 | | | $ | 31,525 | | | $ | (21,378) | | | $ | (662) | | | $ | 9,485 | |
| Net income | Net income | — | | | — | | | 2,179 | | | — | | | 2,179 | | Net income | — | | | — | | | 1,803 | | | — | | | 1,803 | |
Other comprehensive income, net of taxes | — | | | — | | | — | | | 51 | | | 51 | | |
Other comprehensive loss, net of taxes | | Other comprehensive loss, net of taxes | — | | | — | | | — | | | (121) | | | (121) | |
| Issuance of common stock in connection with the Company’s equity award programs | Issuance of common stock in connection with the Company’s equity award programs | 0.8 | | | 23 | | | — | | | — | | | 23 | | Issuance of common stock in connection with the Company’s equity award programs | 1.0 | | | 65 | | | — | | | — | | | 65 | |
Stock-based compensation expense | Stock-based compensation expense | — | | | 97 | | | — | | | — | | | 97 | | Stock-based compensation expense | — | | | 101 | | | — | | | — | | | 101 | |
Tax impact related to employee stock-based compensation expense | Tax impact related to employee stock-based compensation expense | — | | | (50) | | | — | | | — | | | (50) | | Tax impact related to employee stock-based compensation expense | — | | | (81) | | | — | | | — | | | (81) | |
Repurchases of common stock | Repurchases of common stock | (13.1) | | | — | | | (2,349) | | | — | | | (2,349) | | Repurchases of common stock | (2.6) | | | — | | | (591) | | | — | | | (591) | |
Other | Other | — | | | — | | | 11 | | | — | | | 11 | | Other | — | | | — | | | (2) | | | — | | | (2) | |
Balance as of June 30, 2019 | 602.1 | | | $ | 31,313 | | | $ | (20,054) | | | $ | (465) | | | $ | 10,794 | | |
Balance as of June 30, 2020 | | Balance as of June 30, 2020 | 586.4 | | | $ | 31,610 | | | $ | (20,168) | | | $ | (783) | | | $ | 10,659 | |
|
See accompanying notes.
AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)
| | | Six months ended June 30, | | | Six months ended June 30, |
| | 2020 | | 2019 | | 2021 | | 2020 |
Cash flows from operating activities: | Cash flows from operating activities: | | | | Cash flows from operating activities: | | | |
Net income | Net income | $ | 3,628 | | | $ | 4,171 | | Net income | $ | 2,110 | | | $ | 3,628 | |
Depreciation, amortization and other | Depreciation, amortization and other | 1,827 | | | 996 | | Depreciation, amortization and other | 1,696 | | | 1,827 | |
| Deferred income taxes | Deferred income taxes | (261) | | | (70) | | Deferred income taxes | (137) | | | (261) | |
Acquired in-process research and development | | Acquired in-process research and development | 1,505 | | | 0 | |
Other items, net | Other items, net | 245 | | | 32 | | Other items, net | 170 | | | 245 | |
Changes in operating assets and liabilities, net of acquisition: | | |
Changes in operating assets and liabilities, net of acquisitions: | | Changes in operating assets and liabilities, net of acquisitions: | |
Trade receivables, net | Trade receivables, net | (1,177) | | | (228) | | Trade receivables, net | 35 | | | (1,177) | |
Inventories | Inventories | (226) | | | (118) | | Inventories | (167) | | | (226) | |
Other assets | Other assets | 143 | | | (158) | | Other assets | (258) | | | 143 | |
Accounts payable | Accounts payable | (216) | | | (205) | | Accounts payable | (156) | | | (216) | |
Accrued income taxes, net | Accrued income taxes, net | 452 | | | (257) | | Accrued income taxes, net | (930) | | | 452 | |
Long-term tax liabilities | Long-term tax liabilities | 106 | | | (322) | | Long-term tax liabilities | 47 | | | 106 | |
Other liabilities | Other liabilities | 455 | | | (582) | | Other liabilities | 120 | | | 455 | |
Net cash provided by operating activities | Net cash provided by operating activities | 4,976 | | | 3,259 | | Net cash provided by operating activities | 4,035 | | | 4,976 | |
Cash flows from investing activities: | Cash flows from investing activities: | | | | Cash flows from investing activities: | | | |
| Cash paid for acquisitions, net of cash acquired | | Cash paid for acquisitions, net of cash acquired | (1,626) | | | 0 | |
Purchases of marketable securities | Purchases of marketable securities | (2,229) | | | (7,250) | | Purchases of marketable securities | (8,000) | | | (2,229) | |
Proceeds from sales of marketable securities | Proceeds from sales of marketable securities | 2,598 | | | 217 | | Proceeds from sales of marketable securities | 4,404 | | | 2,598 | |
Proceeds from maturities of marketable securities | Proceeds from maturities of marketable securities | 238 | | | 13,617 | | Proceeds from maturities of marketable securities | 6,528 | | | 238 | |
| Purchases of property, plant and equipment | Purchases of property, plant and equipment | (300) | | | (260) | | Purchases of property, plant and equipment | (351) | | | (300) | |
Purchases of equity method investments | Purchases of equity method investments | (2,648) | | | (12) | | Purchases of equity method investments | (3) | | | (2,648) | |
Other | Other | (48) | | | (12) | | Other | (62) | | | (48) | |
Net cash (used in) provided by investing activities | (2,389) | | | 6,300 | | |
Net cash provided by (used in) investing activities | | Net cash provided by (used in) investing activities | 890 | | | (2,389) | |
Cash flows from financing activities: | Cash flows from financing activities: | | | | Cash flows from financing activities: | | | |
Net proceeds from issuance of debt | Net proceeds from issuance of debt | 9,002 | | | — | | Net proceeds from issuance of debt | 0 | | | 9,002 | |
Repayment of debt | Repayment of debt | (5,000) | | | (3,650) | | Repayment of debt | 0 | | | (5,000) | |
| Repurchases of common stock | Repurchases of common stock | (1,516) | | | (5,447) | | Repurchases of common stock | (2,452) | | | (1,516) | |
Dividends paid | Dividends paid | (1,887) | | | (1,781) | | Dividends paid | (2,024) | | | (1,887) | |
| Other | Other | (78) | | | (101) | | Other | (85) | | | (78) | |
Net cash provided by (used in) financing activities | 521 | | | (10,979) | | |
Increase (decrease) in cash and cash equivalents | 3,108 | | | (1,420) | | |
Net cash (used in) provided by financing activities | | Net cash (used in) provided by financing activities | (4,561) | | | 521 | |
Increase in cash and cash equivalents | | Increase in cash and cash equivalents | 364 | | | 3,108 | |
Cash and cash equivalents at beginning of period | Cash and cash equivalents at beginning of period | 6,037 | | | 6,945 | | Cash and cash equivalents at beginning of period | 6,266 | | | 6,037 | |
Cash and cash equivalents at end of period | Cash and cash equivalents at end of period | $ | 9,145 | | | $ | 5,525 | | Cash and cash equivalents at end of period | $ | 6,630 | | | $ | 9,145 | |
See accompanying notes.
AMGEN INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 20202021
(Unaudited)
1. Summary of significant accounting policies
Business
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in 1 business segment: human therapeutics.
Basis of presentation
The financial information for the three and six months ended June 30, 20202021 and 2019,2020, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.
The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2019,2020, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Report on Form 10-Q for the period ended March 31, 2020.2021.
Principles of consolidation
The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates
The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net
Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $8.7$9.1 billion and $8.4$9.0 billion as of June 30, 20202021 and December 31, 2019,2020, respectively.
Equity method investments
The equity method of accounting is used for equity investments that give us the ability to exert significant influence, but not control, over an investee based on such factors as our ownership percentage, voting and other shareholder rights, board of director representation and the existence of other collaborative or business relationships. The equity method of accounting requires us to allocate the difference between the fair value of securities acquired and our proportionate share of the carrying value of the underlying assets (the basis difference) to various items and amortize such differences over their useful lives. Our share of the investees’ earnings or losses and amortization of basis differences, if any, are recorded one quarter in arrears in Interest and other income, net, in the Condensed Consolidated Statements of Income.
We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors including, but not limited to, the length of time the fair value is below the carrying value, volatility of the security price and our intent and ability to retain the investment to allow for a recovery in fair value.
Recent accounting pronouncements
In June 2016,March 2020, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. We adopted this standard as of January 1, 2020, using a modified-retrospective approach. Adoption of the standard did not have a material impact on our condensed consolidated financial statements.
In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens ofcaused by the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform.reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity mayis permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022, as2022. In January 2021, the FASB issued a resultnew accounting standard to expand on the scope of reference rate reform.the original March 2020 standard to include derivative instruments on discounting transactions. We are currently evaluating the impact that this new standardboth standards will have on our condensed consolidated financial statements.
2. Acquisitions
On April 16, 2021, Amgen completed its acquisition of Five Prime Therapeutics, Inc. (Five Prime) for total consideration of $1.6 billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a phase 3 trial-ready, first-in-class program for gastric cancer. Five Prime’s operations have been included in our condensed consolidated financial statements commencing after the acquisition date.
We allocated the consideration to acquire Five Prime to: the bemarituzumab in-process research and development (IPR&D) program of $1.5 billion, which was expensed immediately in Acquired IPR&D expense in the Condensed Consolidated Statements of Income; deferred tax assets of $177 million; and other net liabilities of $47 million. The acquired IPR&D expense was not tax deductible.
2.3. Revenues
We operate in 1 business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-worldThe majority of rest-of-world (ROW) revenues relaterelates to products that are sold primarily in Europe.
Revenues were as follows (in millions):
| | | Three months ended June 30, | | | Three months ended June 30, |
| | 2020 | | | 2019 | | | 2021 | | 2020 |
| | US | | ROW | | Total | | US | | ROW | | Total | | U.S. | | ROW | | Total | | U.S. | | ROW | | Total |
Enbrel® (etanercept) | Enbrel® (etanercept) | | $ | 1,213 | | | $ | 33 | | | $ | 1,246 | | | $ | 1,315 | | | $ | 48 | | | $ | 1,363 | | Enbrel® (etanercept) | | $ | 1,113 | | | $ | 31 | | | $ | 1,144 | | | $ | 1,213 | | | $ | 33 | | | $ | 1,246 | |
Prolia® (denosumab) | Prolia® (denosumab) | | 441 | | | 218 | | | 659 | | | 458 | | | 240 | | | 698 | | Prolia® (denosumab) | | 538 | | | 276 | | | 814 | | | 441 | | | 218 | | | 659 | |
Otezla® (apremilast) | | Otezla® (apremilast) | | 423 | | | 111 | | | 534 | | | 464 | | | 97 | | | 561 | |
Neulasta® (pegfilgrastim) | Neulasta® (pegfilgrastim) | | 520 | | | 73 | | | 593 | | | 719 | | | 105 | | | 824 | | Neulasta® (pegfilgrastim) | | 434 | | | 52 | | | 486 | | | 520 | | | 73 | | | 593 | |
Otezla® (apremilast) | | 464 | | | 97 | | | 561 | | | — | | | — | | | — | | |
XGEVA® (denosumab) | XGEVA® (denosumab) | | 318 | | | 117 | | | 435 | | | 379 | | | 120 | | | 499 | | XGEVA® (denosumab) | | 355 | | | 133 | | | 488 | | | 318 | | | 117 | | | 435 | |
Aranesp® (darbepoetin alfa) | Aranesp® (darbepoetin alfa) | | 156 | | | 231 | | | 387 | | | 192 | | | 244 | | | 436 | | Aranesp® (darbepoetin alfa) | | 135 | | | 232 | | | 367 | | | 156 | | | 231 | | | 387 | |
Repatha® (evolocumab) | | Repatha® (evolocumab) | | 143 | | | 143 | | | 286 | | | 115 | | | 85 | | | 200 | |
KYPROLIS® (carfilzomib) | KYPROLIS® (carfilzomib) | | 167 | | | 86 | | | 253 | | | 166 | | | 101 | | | 267 | | KYPROLIS® (carfilzomib) | | 190 | | | 90 | | | 280 | | | 167 | | | 86 | | | 253 | |
Repatha® (evolocumab) | | 115 | | | 85 | | | 200 | | | 91 | | | 61 | | | 152 | | |
Other products | Other products | | 1,034 | | | 540 | | | 1,574 | | | 822 | | | 513 | | | 1,335 | | Other products | | 1,043 | | | 672 | | | 1,715 | | | 1,034 | | | 540 | | | 1,574 | |
Total product sales(1) | Total product sales(1) | | $ | 4,428 | | | $ | 1,480 | | | 5,908 | | | $ | 4,142 | | | $ | 1,432 | | | 5,574 | | Total product sales(1) | | $ | 4,374 | | | $ | 1,740 | | | 6,114 | | | $ | 4,428 | | | $ | 1,480 | | | 5,908 | |
Other revenues | Other revenues | | | | | | 298 | | | | | | | 297 | | Other revenues | | | | | | 412 | | | | | | | 298 | |
Total revenues | Total revenues | | $ | 6,206 | | | $ | 5,871 | | Total revenues | | $ | 6,526 | | | $ | 6,206 | |
| | | | Six months ended June 30, |
| | | 2021 | | 2020 |
| | | U.S. | | ROW | | Total | | U.S. | | ROW | | Total |
ENBREL | | ENBREL | | $ | 2,007 | | | $ | 61 | | | $ | 2,068 | | | $ | 2,330 | | | $ | 69 | | | $ | 2,399 | |
Prolia® | | Prolia® | | 1,039 | | | 533 | | | 1,572 | | | 863 | | | 450 | | | 1,313 | |
Otezla® | | Otezla® | | 789 | | | 221 | | | 1,010 | | | 841 | | | 199 | | | 1,040 | |
Neulasta® | | Neulasta® | | 855 | | | 113 | | | 968 | | | 1,054 | | | 148 | | | 1,202 | |
XGEVA® | | XGEVA® | | 689 | | | 267 | | | 956 | | | 673 | | | 243 | | | 916 | |
Aranesp® | | Aranesp® | | 260 | | | 462 | | | 722 | | | 331 | | | 478 | | | 809 | |
Repatha® | | Repatha® | | 282 | | | 290 | | | 572 | | | 239 | | | 190 | | | 429 | |
KYPROLIS® | | KYPROLIS® | | 349 | | | 182 | | | 531 | | | 354 | | | 179 | | | 533 | |
Other products | | Other products | | 2,007 | | | 1,300 | | | 3,307 | | | 2,022 | | | 1,139 | | | 3,161 | |
Total product sales(1) | | Total product sales(1) | | $ | 8,277 | | | $ | 3,429 | | | 11,706 | | | $ | 8,707 | | | $ | 3,095 | | | 11,802 | |
Other revenues | | Other revenues | | | | | | 721 | | | | | | | 565 | |
Total revenues | | Total revenues | | $ | 12,427 | | | $ | 12,367 | |
|
____________
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Six months ended June 30, | | | | | | | | | | |
| | 2020 | | | | | | 2019 | | | | |
| | US | | ROW | | Total | | US | | ROW | | Total |
ENBREL | | $ | 2,330 | | | $ | 69 | | | $ | 2,399 | | | $ | 2,421 | | | $ | 93 | | | $ | 2,514 | |
Prolia® | | 863 | | | 450 | | | 1,313 | | | 848 | | | 442 | | | 1,290 | |
Neulasta® | | 1,054 | | | 148 | | | 1,202 | | | 1,612 | | | 233 | | | 1,845 | |
Otezla® | | 841 | | | 199 | | | 1,040 | | | — | | | — | | | — | |
XGEVA® | | 673 | | | 243 | | | 916 | | | 735 | | | 235 | | | 970 | |
Aranesp® | | 331 | | | 478 | | | 809 | | | 374 | | | 476 | | | 850 | |
KYPROLIS® | | 354 | | | 179 | | | 533 | | | 320 | | | 192 | | | 512 | |
Repatha® | | 239 | | | 190 | | | 429 | | | 174 | | | 119 | | | 293 | |
Other products | | 2,022 | | | 1,139 | | | 3,161 | | | 1,649 | | | 937 | | | 2,586 | |
Total product sales(1) | | $ | 8,707 | | | $ | 3,095 | | | 11,802 | | | $ | 8,133 | | | $ | 2,727 | | | 10,860 | |
Other revenues | | | | | | 565 | | | | | | | 568 | |
Total revenues | | | | | | $ | 12,367 | | | | | | | $ | 11,428 | |
____________
(1) Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 20202021 and 2019.2020.
3.4. Income taxes
The effective tax rates for the three and six months ended June 30, 2020,2021, were 11.2%16.8% and 10.4%12.6%, respectively, compared with 15.0%11.2% and 14.5%10.4%, respectively, for the corresponding periods of the prior year.
The decreaseincrease in our effective tax rate for the three and six months ended June 30, 2020,2021, was due primarily to net favorable items in the quarter, amortization relateddue to the Otezla®non-deductible IPR&D expense arising from the acquisition and changes in jurisdictional mix of earnings.Five Prime. The effective tax rates differ from the federal statutory rate primarily as a result of foreign earnings from the Company’s operations conducted in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes, andthat are subject to a tax incentive grantsgrant through 2035. In addition, the Company’s operations conducted in Singapore are subject to a tax incentive grant through 2034. These earnings are also subject to U.S. tax at a reduced rate of 10.5%.
The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.
One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. As previously disclosed,In 2017, we received a Revenue Agent Report (RAR) and a modified RAR from the Internal Revenue Service (IRS) for the years 2010, 2011 and 2012. The RAR proposes to make2012 proposing significant adjustments that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. In November 2017, we received a modified RAR that revised the IRS’s calculations but continued to propose substantial adjustments. We disagree with the proposed adjustments and calculations and are pursuing resolution with the IRS administrative appeals office, which currently has jurisdiction over the matter. If unable to reach resolution, we will vigorously contest the proposed adjustments through the judicial process. In addition, as previously reported, in April 2020, we received draft notices of proposed adjustments (NOPAs) and subsequently in May 2020, we received an RAR from the IRS for the years 2013, 2014 and 2015, which are similar to the proposed adjustments for the years 2010, 2011 and 2012 that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued a resolution with the IRS administrative appeals office. As previously reported, we were unable to reach resolution with the IRS appeals office. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for 2010, 2011 and 2012 that we received in May and July 2021. The duplicate Notices seek to increase our U.S. taxable income by an amount that would result in additional federal tax of approximately $3.6 billion, plus interest. Any additional tax that could be imposed would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings. In any event, we firmly believe that the IRS’s positions in the Notices are without merit and we will vigorously contest the Notices through the judicial process.
In addition, in 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015 also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico, similar to those proposed for the years 2010, 2011 and 2012. We disagree with the proposed adjustments and calculations and will pursueare pursuing resolution with the IRS administrative appeals office. We are currently under examination by the IRS for the years 2016, 2017 and 2018. We are also currently under examination by a number of other state and foreign tax jurisdictions.
Final resolution of these complex matters is not likely within the next 12 months and could have a material impact on our condensed consolidated financial statements.months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate resolutionoutcome of any tax matters may result in payments substantially greater or less than amounts accrued.accrued and could have a material adverse impact on our condensed consolidated financial statements. We are no longer subject to U.S. federal income tax examinations for the years ended on or before December 31, 2009.
During the three and six months ended June 30, 2020,2021, the gross amounts of our unrecognized tax benefits (UTBs) increased $55$50 million and $105$110 million, respectively, as a result of tax positions taken during the current year. Substantially all of the UTBs as of June 30, 2020,2021, if recognized, would affect our effective tax rate.
4.5. Earnings per share
The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include primarily shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.
The computations for basic and diluted EPS were as follows (in millions, except per-share data):
| | | Three months ended June 30, | | | Six months ended June 30, | | | Three months ended June 30, | | Six months ended June 30, |
| | 2020 | | 2019 | | 2020 | | 2019 | | 2021 | | 2020 | | 2021 | | 2020 |
Income (Numerator): | Income (Numerator): | | | | | | | | Income (Numerator): | | | | | | | |
Net income for basic and diluted EPS | Net income for basic and diluted EPS | $ | 1,803 | | | $ | 2,179 | | | $ | 3,628 | | | $ | 4,171 | | Net income for basic and diluted EPS | $ | 464 | | | $ | 1,803 | | | $ | 2,110 | | | $ | 3,628 | |
| Shares (Denominator): | Shares (Denominator): | | Shares (Denominator): | |
Weighted-average shares for basic EPS | Weighted-average shares for basic EPS | 588 | | | 607 | | | 589 | | | 615 | | Weighted-average shares for basic EPS | 573 | | | 588 | | | 575 | | | 589 | |
Effect of dilutive securities | Effect of dilutive securities | 4 | | | 3 | | | 4 | | | 3 | | Effect of dilutive securities | 3 | | | 4 | | | 3 | | | 4 | |
Weighted-average shares for diluted EPS | Weighted-average shares for diluted EPS | 592 | | | 610 | | | 593 | | | 618 | | Weighted-average shares for diluted EPS | 576 | | | 592 | | | 578 | | | 593 | |
| Basic EPS | Basic EPS | $ | 3.07 | | | $ | 3.59 | | | $ | 6.16 | | | $ | 6.78 | | Basic EPS | $ | 0.81 | | | $ | 3.07 | | | $ | 3.67 | | | $ | 6.16 | |
Diluted EPS | Diluted EPS | $ | 3.05 | | | $ | 3.57 | | | $ | 6.12 | | | $ | 6.75 | | Diluted EPS | $ | 0.81 | | | $ | 3.05 | | | $ | 3.65 | | | $ | 6.12 | |
For the three and six months ended June 30, 20202021 and 2019,2020, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.
5. Collaborations
On January 2, 2020, we closed our strategic collaboration with BeiGene, Ltd. (BeiGene) to expand our oncology presence in China. Under the collaboration, BeiGene will commercialize XGEVA®, KYPROLIS® and BLINCYTO® (blinatumomab) in China, and Amgen will share profits and losses equally during the initial product-specific commercialization periods; thereafter, product rights may revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China.
In addition, we will jointly develop a portion of our oncology portfolio with BeiGene sharing in global research and development (R&D) costs by providing cash and development services up to $1.25 billion. Upon regulatory approval, BeiGene will assume commercialization rights in China for a specified period, and Amgen and BeiGene will share profits equally until certain of these product rights revert to Amgen. Upon return of the product rights, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside of China, Amgen will also pay BeiGene royalties.
For the three and six months ended June 30, 2020, net costs recovered from BeiGene for oncology product candidates were $55 million and $112 million, respectively, and were recorded in R&D expense in the Condensed Consolidated Statements of Income. For the six months ended June 30, 2020, no profit share payments or product sales were recorded between Amgen and BeiGene. In connection with this collaboration, we acquired an ownership interest in BeiGene. See Note 6, Investments.
6. Investments
Available-for-sale investments
The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Types of securities as of June 30, 2020 | | Amortized cost | | Gross unrealized gains | | Gross unrealized losses | | Fair values |
U.S. Treasury notes | | $ | 172 | | | $ | 3 | | | $ | — | | | $ | 175 | |
U.S. Treasury bills | | 3,399 | | | — | | | — | | | 3,399 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Corporate debt securities: | | | | | | | | |
Financial | | — | | | — | | | — | | | — | |
Industrial | | 3 | | | — | | | (1) | | | 2 | |
Other | | — | | | — | | | — | | | — | |
Residential-mortgage-backed securities | | — | | | — | | | — | | | — | |
| | | | | | | | |
Money market mutual funds | | 7,158 | | | — | | | — | | | 7,158 | |
Other short-term interest-bearing securities | | — | | | — | | | — | | | — | |
| | | | | | | | |
| | | | | | | | |
Total interest-bearing securities | | $ | 10,732 | | | $ | 3 | | | $ | (1) | | | $ | 10,734 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Types of securities as of June 30, 2021 | | Amortized cost | | Gross unrealized gains | | Gross unrealized losses | | Fair values |
U.S. Treasury notes | | $ | 51 | | | $ | 1 | | | $ | 0 | | | $ | 52 | |
U.S. Treasury bills | | 1,400 | | | 0 | | | 0 | | | 1,400 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Money market mutual funds | | 5,707 | | | 0 | | | 0 | | | 5,707 | |
Other short-term interest-bearing securities | | 0 | | | 0 | | | 0 | | | 0 | |
| | | | | | | | |
| | | | | | | | |
Total interest-bearing securities | | $ | 7,158 | | | $ | 1 | | | $ | 0 | | | $ | 7,159 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Types of securities as of December 31, 2019 | | Amortized cost | | Gross unrealized gains | | Gross unrealized losses | | Fair values |
U.S. Treasury notes | | $ | 359 | | | $ | 1 | | | $ | — | | | $ | 360 | |
U.S. Treasury bills | | — | | | — | | | — | | | — | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Corporate debt securities: | | | | | | | | |
Financial | | 1,108 | | | 13 | | | — | | | 1,121 | |
Industrial | | 824 | | | 10 | | | — | | | 834 | |
Other | | 195 | | | 3 | | | — | | | 198 | |
Residential-mortgage-backed securities | | 181 | | | 1 | | | — | | | 182 | |
| | | | | | | | |
Money market mutual funds | | 5,250 | | | — | | | — | | | 5,250 | |
Other short-term interest-bearing securities | | 289 | | | — | | | — | | | 289 | |
Total interest-bearing securities | | $ | 8,206 | | | $ | 28 | | | $ | — | | | $ | 8,234 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Types of securities as of December 31, 2020 | | Amortized cost | | Gross unrealized gains | | Gross unrealized losses | | Fair values |
U.S. Treasury notes | | $ | 129 | | | $ | 1 | | | $ | 0 | | | $ | 130 | |
U.S. Treasury bills | | 4,948 | | | 0 | | | 0 | | | 4,948 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Money market mutual funds | | 4,765 | | | 0 | | | 0 | | | 4,765 | |
Other short-term interest-bearing securities | | 2 | | | 0 | | | 0 | | | 2 | |
Total interest-bearing securities | | $ | 9,844 | | | $ | 1 | | | $ | 0 | | | $ | 9,845 | |
The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):
| Condensed Consolidated Balance Sheets locations | Condensed Consolidated Balance Sheets locations | | June 30, 2020 | | December 31, 2019 | Condensed Consolidated Balance Sheets locations | | June 30, 2021 | | December 31, 2020 |
Cash and cash equivalents | Cash and cash equivalents | | $ | 8,458 | | | $ | 5,360 | | Cash and cash equivalents | | $ | 5,707 | | | $ | 5,464 | |
Marketable securities | Marketable securities | | 2,276 | | | 2,874 | | Marketable securities | | 1,452 | | | 4,381 | |
Total interest-bearing securities | Total interest-bearing securities | | $ | 10,734 | | | $ | 8,234 | | Total interest-bearing securities | | $ | 7,159 | | | $ | 9,845 | |
Cash and cash equivalents in the above table excludes bank account cash of $687$923 million and $677$802 million as of June 30, 20202021 and December 31, 2019,2020, respectively.
The fair values of interest-bearing securitiesavailable-for-sale investments by contractual maturity except for residential-mortgage-backed securities that do not have a single maturity date, were as follows (in millions):
| Contractual maturities | Contractual maturities | | June 30, 2020 | | December 31, 2019 | Contractual maturities | | June 30, 2021 | | December 31, 2020 |
Maturing in one year or less | Maturing in one year or less | | $ | 10,681 | | | $ | 5,629 | | Maturing in one year or less | | $ | 7,159 | | | $ | 9,795 | |
Maturing after one year through three years | Maturing after one year through three years | | 53 | | | 2,304 | | Maturing after one year through three years | | 0 | | | 50 | |
Maturing after three years through five years | | — | | | 119 | | |
| Residential-mortgage-backed securities | | — | | | 182 | | |
Total interest-bearing securities | | $ | 10,734 | | | $ | 8,234 | | |
| Total available-for-sale investments | | Total available-for-sale investments | | $ | 7,159 | | | $ | 9,845 | |
For the three and six months ended June 30, 20202021 and 2019,2020, realized gains and losses on interest-bearing securities were not material. For the six months ended June 30, 2020 and 2019, realized gains on interest-bearing securities were $37 million and $2 million, respectively, and realized losses on interest-bearing securities were $4 million and $8 million, respectively. Realized gains and losses on interest-bearing securities are recorded in Interest and otherOther income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.
The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.
As of June 30, 2020 and December 31, 2019, aggregated gross unrealized losses of available-for-sale investments were not material, and accordingly, no allowance for credit losses was recorded as of June 30, 2020.
Equity securities
We held investments in equity securities with readily determinable fair values (publicly traded securities) of $297$403 million and $303$477 million as of June 30, 20202021 and December 31, 2019,2020, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. GainsFor the three months ended June 30, 2021 and losses recognized2020, net unrealized gains on equitypublicly traded securities with readily determinable fair values, includingwere $25 million and $80 million, respectively. For the six months ended June 30, 2021 and 2020, net unrealized gains and losses recognized on sales,publicly traded securities were not materiala $31 million net loss and a $5 million net gain, respectively. Realized gains and losses on publicly traded securities for the three and six months ended June 30, 2021 and 2020, and 2019.were not material.
We held investments of $183$245 million and $176$203 million in equity securities without readily determinable fair values as of June 30, 20202021 and December 31, 2019,2020, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. Gains and losses recognized on these securities, including adjustments to the carrying values of these securities, were not material for the three and six months ended June 30, 2020 and 2019.2021.
Equity method investments
Limited partnerships
We held limited partnership investments of $311$616 million and $320$496 million as of June 30, 20202021 and December 31, 2019,2020, respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of June 30, 2020,2021, unfunded additional commitments to be made for these investments during the next several years were not material. GainsFor the three months ended June 30, 2021 and 2020, net unrealized losses recognized from our limited partnership investments were not material for$43 million and $10 million, respectively. For the three and six months ended June 30, 2021 and 2020, net unrealized gains from our limited partnership investments were $165 million and 2019.
$10 million, respectively.BeiGene, Ltd.
On January 2, 2020,As of June 30, 2021, we acquired a 20.5%had an ownership interest of approximately 20.3% in BeiGene, for $2.8 billion, ofLtd. (BeiGene), which $2.6 billion was attributed to the fair value of equity securities upon closing, with the remainder attributed to prepaid R&D. Our equity investment in BeiGene is included in Other assets in the Condensed Consolidated Balance Sheets. TheSheets and accounted for under the equity method of accounting. We amortize the difference between the fair value of equity securities acquired exceededand our proportionate share of the carrying value of the underlying net assets of BeiGene by approximately $2.4 billion. This investment is accounted for by usingover the equity methoduseful lives of accounting, which requires us to identify and allocate amounts to the itemsassets that givegave rise to thethis basis difference and to amortize these items over their useful lives.difference. This amortization along withand our share of the results of operations of BeiGene are included in Interest and otherOther income, net, in ourthe Condensed Consolidated Statements of Income. Recognition occursIncome one quarter in arrears, which began in the second quarter of 2020. The basis difference was allocated to finite-lived intangible assets, indefinite-lived intangible assets, equity-method goodwill and related deferred taxes. The finite-lived intangible assets are being amortized over a period ranging from 8 to 15 years.
ForDuring the three and six months ended June 30, 2020, we recognized a reduction in2021, the carrying value of our equity investment of $111 million. This reduction consists ofwas adjusted by our share of BeiGene’s net income of $14 million and net loss totaling $75of $83 million, respectively, and amortization of the basis difference of $36 million.$42 million and $84 million, respectively. In addition, during the three and six months ended June 30, 2021, the carrying value increased by $21 million and $38 million, respectively, from the impact of BeiGene ownership transactions. As of June 30, 2020,2021, the carrying value and fair valuesvalue of our approximately 20.4% ownership interestinvestment in BeiGene totaled $2.5$2.8 billion and $3.0$6.4 billion, respectively. As of June 30, 2020,2021, we believe the carrying value of our equity investment in BeiGene is fully recoverable. See Note 1, Summary of significant accounting policies, for factors considered in determining our conclusion. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 5, Collaborations.
On July 15, 2020, in connection with BeiGene’s equity offering, Amgen made an additional investment of approximately $421 million to maintain our current pro rata ownership of BeiGene.
7. Inventories
Inventories consisted of the following (in millions):
| | | June 30, 2020 | | December 31, 2019 | | June 30, 2021 | | December 31, 2020 |
Raw materials | Raw materials | $ | 463 | | | $ | 358 | | Raw materials | $ | 641 | | | $ | 486 | |
Work in process | Work in process | 2,376 | | | 2,227 | | Work in process | 2,443 | | | 2,437 | |
Finished goods | Finished goods | 1,001 | | | 999 | | Finished goods | 1,031 | | | 970 | |
Total inventories | Total inventories | $ | 3,840 | | | $ | 3,584 | | Total inventories | $ | 4,115 | | | $ | 3,893 | |
8. Goodwill and other intangible assets
Goodwill
The change in the carrying amount of goodwill was as follows (in millions):
| | | | | | | |
| Six months ended June 30, 20202021 | | |
Beginning balance | $ | 14,70314,689 | | | |
Currency translation adjustment | (25)(13) | | | |
Ending balance | $ | 14,67814,676 | | | |
Other intangible assets
Other intangible assets consisted of the following (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| June 30, 2020 | | | | | | December 31, 2019 | | | | |
| Gross carrying amounts | | Accumulated amortization | | Other intangible assets, net | | Gross carrying amounts | | Accumulated amortization | | Other intangible assets, net |
Finite-lived intangible assets: | | | | | | | | | | | |
Developed-product-technology rights | $ | 25,559 | | | $ | (9,436) | | | $ | 16,123 | | | $ | 25,575 | | | $ | (8,322) | | | $ | 17,253 | |
Licensing rights | 3,746 | | | (2,602) | | | 1,144 | | | 3,761 | | | (2,398) | | | 1,363 | |
Marketing-related rights | 1,371 | | | (1,003) | | | 368 | | | 1,382 | | | (965) | | | 417 | |
Research and development technology rights | 1,279 | | | (996) | | | 283 | | | 1,273 | | | (947) | | | 326 | |
Total finite-lived intangible assets | 31,955 | | | (14,037) | | | 17,918 | | | 31,991 | | | (12,632) | | | 19,359 | |
Indefinite-lived intangible assets: | | | | | | | | | | | |
In-process research and development | 30 | | | — | | | 30 | | | 54 | | | — | | | 54 | |
Total other intangible assets | $ | 31,985 | | | $ | (14,037) | | | $ | 17,948 | | | $ | 32,045 | | | $ | (12,632) | | | $ | 19,413 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| June 30, 2021 | | December 31, 2020 |
| Gross carrying amounts | | Accumulated amortization | | Other intangible assets, net | | Gross carrying amounts | | Accumulated amortization | | Other intangible assets, net |
Finite-lived intangible assets: | | | | | | | | | | | |
Developed-product-technology rights | $ | 25,584 | | | $ | (11,673) | | | $ | 13,911 | | | $ | 25,591 | | | $ | (10,564) | | | $ | 15,027 | |
Licensing rights | 3,766 | | | (2,886) | | | 880 | | | 3,743 | | | (2,791) | | | 952 | |
Marketing-related rights | 1,363 | | | (1,079) | | | 284 | | | 1,367 | | | (1,041) | | | 326 | |
Research and development technology rights | 1,308 | | | (1,105) | | | 203 | | | 1,317 | | | (1,065) | | | 252 | |
Total finite-lived intangible assets | 32,021 | | | (16,743) | | | 15,278 | | | 32,018 | | | (15,461) | | | 16,557 | |
Indefinite-lived intangible assets: | | | | | | | | | | | |
In-process research and development | 30 | | | — | | | 30 | | | 30 | | | — | | | 30 | |
Total other intangible assets | $ | 32,051 | | | $ | (16,743) | | | $ | 15,308 | | | $ | 32,048 | | | $ | (15,461) | | | $ | 16,587 | |
Developed-product-technology rights consists of rights related to marketed products. Licensing rights primarily consists primarily of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-frontupfront payments associated with royalty obligations for marketed products. Marketing-related rights primarily consists primarily of rights related to the sale and distribution of marketed products. R&DResearch and development (R&D) technology rights pertains to technologies used in R&D that have alternative future uses.
In-process research and development (IPR&D)IPR&D consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.
During the three months ended June 30, 20202021 and 2019,2020, we recognized amortization associated with our finite-lived intangible assets of $713$652 million and $315$713 million, respectively. During the six months ended June 30, 20202021 and 2019,2020, we recognized amortization associated with our finite-lived intangible assets of $1.3 billion and $1.4 billion, and $630 million, respectively.Amortization of intangible assets is primarily included primarily in Cost of sales in the Condensed Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the remaining six months ending December 31, 2020,2021, and the years ending December 31, 2021, 2022, 2023, 2024, 2025 and 2025,2026, are $1.4 billion, $2.6$1.2 billion, $2.5 billion, $2.4 billion, $2.4 billion, and $2.2 billion and $1.8 billion, respectively.
9. Financing arrangements
Our borrowings consisted of the following (in millions):
| | | | | | | | | | | |
| June 30, 2020 | | December 31, 2019 |
4.50% notes due 2020 (4.50% 2020 Notes) | $ | — | | | $ | 300 | |
2.125% notes due 2020 (2.125% 2020 Notes) | — | | | 750 | |
Floating Rate Notes due 2020 | — | | | 300 | |
2.20% notes due 2020 (2.20% 2020 Notes) | — | | | 700 | |
3.45% notes due 2020 (3.45% 2020 Notes) | — | | | 900 | |
4.10% notes due 2021 (4.10% 2021 Notes) | — | | | 1,000 | |
1.85% notes due 2021 (1.85% 2021 Notes) | — | | | 750 | |
3.875% notes due 2021 (3.875% 2021 Notes) | 1,450 | | | 1,750 | |
1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) | 1,404 | | | 1,402 | |
2.70% notes due 2022 (2.70% 2022 Notes) | 500 | | | 500 | |
2.65% notes due 2022 (2.65% 2022 Notes) | 1,500 | | | 1,500 | |
3.625% notes due 2022 (3.625% 2022 Notes) | 750 | | | 750 | |
0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) | 739 | | | 725 | |
2.25% notes due 2023 (2.25% 2023 Notes) | 750 | | | 750 | |
3.625% notes due 2024 (3.625% 2024 Notes) | 1,400 | | | 1,400 | |
1.90% notes due 2025 (1.90% 2025 Notes) | 500 | | | — | |
3.125% notes due 2025 (3.125% 2025 Notes) | 1,000 | | | 1,000 | |
2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) | 843 | | | 841 | |
2.60% notes due 2026 (2.60% 2026 Notes) | 1,250 | | | 1,250 | |
5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) | 589 | | | 630 | |
2.20% notes due 2027 (2.20% 2027 Notes) | 1,750 | | | — | |
3.20% notes due 2027 (3.20% 2027 Notes) | 1,000 | | | 1,000 | |
4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) | 868 | | | 928 | |
2.45% notes due 2030 (2.45% 2030 Notes) | 1,250 | | | — | |
2.30% notes due 2031 (2.30% 2031 Notes) | 1,250 | | | — | |
6.375% notes due 2037 (6.375% 2037 Notes) | 552 | | | 552 | |
6.90% notes due 2038 (6.90% 2038 Notes) | 291 | | | 291 | |
6.40% notes due 2039 (6.40% 2039 Notes) | 466 | | | 466 | |
3.15% notes due 2040 (3.15% 2040 Notes) | 2,000 | | | — | |
5.75% notes due 2040 (5.75% 2040 Notes) | 412 | | | 412 | |
4.95% notes due 2041 (4.95% 2041 Notes) | 600 | | | 600 | |
5.15% notes due 2041 (5.15% 2041 Notes) | 974 | | | 974 | |
5.65% notes due 2042 (5.65% 2042 Notes) | 487 | | | 487 | |
5.375% notes due 2043 (5.375% 2043 Notes) | 261 | | | 261 | |
4.40% notes due 2045 (4.40% 2045 Notes) | 2,250 | | | 2,250 | |
4.563% notes due 2048 (4.563% 2048 Notes) | 1,415 | | | 1,415 | |
3.375% notes due 2050 (3.375% 2050 Notes) | 2,250 | | | — | |
4.663% notes due 2051 (4.663% 2051 Notes) | 3,541 | | | 3,541 | |
Other notes due 2097 | 100 | | | 100 | |
Unamortized bond discounts, premiums and issuance costs, net | (849) | | | (868) | |
Fair value adjustments | 678 | | | 296 | |
Other | 3 | | | — | |
Total carrying value of debt | 34,224 | | | 29,903 | |
Less current portion | (91) | | | (2,953) | |
Total long-term debt | $ | 34,133 | | | $ | 26,950 | |
| | | | | | | | | | | |
| June 30, 2021 | | December 31, 2020 |
1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) | $ | 1,482 | | | $ | 1,527 | |
2.70% notes due 2022 (2.70% 2022 Notes) | 500 | | | 500 | |
2.65% notes due 2022 (2.65% 2022 Notes) | 1,500 | | | 1,500 | |
3.625% notes due 2022 (3.625% 2022 Notes) | 750 | | | 750 | |
0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) | 757 | | | 791 | |
2.25% notes due 2023 (2.25% 2023 Notes) | 750 | | | 750 | |
3.625% notes due 2024 (3.625% 2024 Notes) | 1,400 | | | 1,400 | |
1.90% notes due 2025 (1.90% 2025 Notes) | 500 | | | 500 | |
3.125% notes due 2025 (3.125% 2025 Notes) | 1,000 | | | 1,000 | |
2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) | 889 | | | 916 | |
2.60% notes due 2026 (2.60% 2026 Notes) | 1,250 | | | 1,250 | |
5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) | 657 | | | 649 | |
2.20% notes due 2027 (2.20% 2027 Notes) | 1,750 | | | 1,750 | |
3.20% notes due 2027 (3.20% 2027 Notes) | 1,000 | | | 1,000 | |
4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) | 968 | | | 957 | |
2.45% notes due 2030 (2.45% 2030 Notes) | 1,250 | | | 1,250 | |
2.30% notes due 2031 (2.30% 2031 Notes) | 1,250 | | | 1,250 | |
6.375% notes due 2037 (6.375% 2037 Notes) | 478 | | | 478 | |
6.90% notes due 2038 (6.90% 2038 Notes) | 254 | | | 254 | |
6.40% notes due 2039 (6.40% 2039 Notes) | 333 | | | 333 | |
3.15% notes due 2040 (3.15% 2040 Notes) | 2,000 | | | 2,000 | |
5.75% notes due 2040 (5.75% 2040 Notes) | 373 | | | 373 | |
4.95% notes due 2041 (4.95% 2041 Notes) | 600 | | | 600 | |
5.15% notes due 2041 (5.15% 2041 Notes) | 729 | | | 729 | |
5.65% notes due 2042 (5.65% 2042 Notes) | 415 | | | 415 | |
5.375% notes due 2043 (5.375% 2043 Notes) | 185 | | | 185 | |
4.40% notes due 2045 (4.40% 2045 Notes) | 2,250 | | | 2,250 | |
4.563% notes due 2048 (4.563% 2048 Notes) | 1,415 | | | 1,415 | |
3.375% notes due 2050 (3.375% 2050 Notes) | 2,250 | | | 2,250 | |
4.663% notes due 2051 (4.663% 2051 Notes) | 3,541 | | | 3,541 | |
2.77% notes due 2053 (2.77% 2053 Notes) | 940 | | | 940 | |
Other notes due 2097 | 100 | | | 100 | |
Unamortized bond discounts, premiums and issuance costs, net | (1,174) | | | (1,188) | |
Fair value adjustments | 424 | | | 566 | |
Other | 16 | | | 5 | |
Total carrying value of debt | 32,782 | | | 32,986 | |
Less current portion | (4,324) | | | (91) | |
Total long-term debt | $ | 28,458 | | | $ | 32,895 | |
There are no material differences between the effective interest rates and coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, and the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.6%5.2%, respectively.
Debt issuances and repayments
During the sixthree months ended June 30, 2020,2021, we issued debt securities inentered into the following offerings:
• In February 2020, we issued $5.0interest rate swap contracts: (i) $1.0 billion of debt consisting of $500 million of the 1.90% 2025 Notes, $750 million of the 2.20% 2027 Notes, $1.25 billion ofnotional amount with respect to the 2.45% 2030 Notes, $1.25 billionresulting in an effective interest rate of the 3.15% 2040 Notes and $1.25 billion of the 3.375% 2050 Notes.
• In May 2020, we issued $4.0 billion of debt, including $1.0 billion of the 2.20% 2027 Notes, $750 million of the 3.15% 2040 Notes and $1.0 billion of the 3.375% 2050 Notes, which represents a further issuance of, and which forms a single series with, each of the corresponding series of notes issued in February 2020, and $1.25 billion of 2.30% 2031 Notes.
In the event of a change-in-control triggering event, as defined in the termsthree-month LIBOR plus 1.0% for that portion of the notes, we may be required to purchase all or a portion of these notes at a price equal to 101% of the principaland (ii) $500 million notional amount of the notes plus accrued and unpaid interest. In addition, these notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued and unpaid interest and a “make-whole” amount, which are defined by the terms of the notes. The notes may be redeemed without payment of make-whole amounts if redemption occurs during specified periods of time immediately priorwith respect to the maturity2.30% 2031 Notes, resulting in an effective interest rate of the notes. Such time periods range from one month to six months prior to maturity.
Athree-month LIBOR plus 0.8% for that portion of the proceeds from the issuance of the notes in February 2020 were used to redeem the 3.45% 2020 Notes, the 4.10% 2021 Notes, the 1.85% 2021 Notes and the $300 million aggregate principal amount of our 3.875% 2021 Notes. In connection with the redemption of these notes, we paid a total of $50 million in make-whole amounts plus associated accrued and unpaid interest, all of which was recognized in Interest expense, net, in the Condensed Consolidated Statements of Income. In addition to these redemptions, the 4.50% 2020 Notes, 2.125% 2020 Notes, Floating Rate 2020 Notes and 2.20% 2020 Notes matured and were repaid during the six months ended June 30, 2020.
Interest rate swaps
In connection with the redemption of certain of the notes discussed above, associated interest rate swap contracts with an aggregate notional value of $2.2 billion were terminated. In addition, because of historically low interest rates, during the three months ended March 31, 2020, we terminated interest rate swaps with an aggregate notional amount of $5.2 billion that hedged the 3.625% 2024 Notes, the 2.60% 2026 Notes, the 4.663% 2051 Notes and portions of the 3.625% 2022 Notes and 3.125% 2025 Notes, which resulted in the receipt of $576 million of cash and reduced counterparty credit risk. Immediately following the terminations of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 12, Derivative instruments.
The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | |
| | June 30, 2020 | | | December 31, 2019 | |
Notes | | Notional amounts | Effective interest rates | | Notional amounts | Effective interest rates |
3.45% 2020 Notes | | $ | — | | LIBOR + 1.1% | | $ | 900 | | LIBOR + 1.1% |
4.10% 2021 Notes | | — | | LIBOR + 1.7% | | 1,000 | | LIBOR + 1.7% |
3.875% 2021 Notes | | 1,450 | | LIBOR + 2.0% | | 1,750 | | LIBOR + 2.0% |
3.625% 2022 Notes | | 750 | | LIBOR + 2.7% | | 750 | | LIBOR + 1.6% |
3.625% 2024 Notes | | 1,400 | | LIBOR + 3.2% | | 1,400 | | LIBOR + 1.4% |
3.125% 2025 Notes | | 1,000 | | LIBOR + 1.8% | | 1,000 | | LIBOR + 0.9% |
2.60% 2026 Notes | | 1,250 | | LIBOR + 1.8% | | 1,250 | | LIBOR + 0.3% |
4.663% 2051 Notes(1) | | 1,500 | | LIBOR + 2.6% | | 1,500 | | LIBOR + 0.0% |
Total notional amounts | | $ | 7,350 | | | | $ | 9,550 | | |
____________
(1) Excludes an additional 1.5% of interest for the difference between the coupon rate paid to note holders and the fixed rate received under the interest rate swap contracts.
10. Stockholders’ equity
Stock repurchase program
Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):
| | | 2020 | | | 2019 | | | 2021 | | 2020 |
| | Shares | | Dollars | | Shares * | | Dollars | | Shares | | Dollars | | Shares | | Dollars |
First quarter | First quarter | 4.3 | | | $ | 933 | | | 15.9 | | | $ | 3,031 | | First quarter | 3.7 | | | $ | 865 | | | 4.3 | | | $ | 933 | |
Second quarter | Second quarter | 2.6 | | | 591 | | | 13.1 | | | 2,349 | | Second quarter | 6.5 | | | 1,592 | | | 2.6 | | | 591 | |
| Total stock repurchases | Total stock repurchases | 6.9 | | | $ | 1,524 | | | 28.9 | | | $ | 5,380 | | Total stock repurchases | 10.2 | | | $ | 2,457 | | | 6.9 | | | $ | 1,524 | |
* Total shares do not add due to rounding.
In December 2019,March 2021, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $4.0$3.4 billion. As of June 30, 2020, $4.92021, $3.9 billion of authorization remained available under our stock repurchase program.
Dividends
In March 20202021 and December 2019, the Board of Directors declared quarterly cash dividends of $1.60 per share, which were paid in June 2020 and March 2020, respectively. In July 2020, the Board of Directors declared a quarterly cash dividend of $1.60$1.76 per share, which were paid in June 2021 and March 2021, respectively. In July 2021, the Board of Directors declared a quarterly cash dividend of $1.76 per share, which will be paid on September 8, 2020.2021.
Accumulated other comprehensive income (loss)
The components of Accumulated other comprehensive income (loss) (AOCI) were as follows (in millions):
| | | Foreign currency translation | | Cash flow hedges | | Available-for-sale securities | | Other | | AOCI | | Foreign currency translation | | Cash flow hedges | | Available-for-sale securities | | Other | | AOCI |
Balance as of December 31, 2019 | $ | (718) | | | $ | 175 | | | $ | 22 | | | $ | (7) | | | $ | (528) | | |
Balance as of December 31, 2020 | | Balance as of December 31, 2020 | $ | (709) | | | $ | (263) | | | $ | 1 | | | $ | (14) | | | $ | (985) | |
| Foreign currency translation adjustments | Foreign currency translation adjustments | (52) | | | — | | | — | | | — | | | (52) | | Foreign currency translation adjustments | (39) | | | — | | | — | | | — | | | (39) | |
Unrealized (losses) gains | — | | | (162) | | | 8 | | | — | | | (154) | | |
Unrealized gains | | Unrealized gains | — | | | 108 | | | 0 | | | 0 | | | 108 | |
Reclassification adjustments to income | Reclassification adjustments to income | — | | | 84 | | | (33) | | | — | | | 51 | | Reclassification adjustments to income | — | | | 133 | | | 0 | | | — | | | 133 | |
Other | Other | — | | | — | | | — | | | (2) | | | (2) | | Other | — | | | — | | | — | | | 1 | | | 1 | |
Income taxes | Income taxes | — | | | 17 | | | 6 | | | — | | | 23 | | Income taxes | 0 | | | (51) | | | 0 | | | — | | | (51) | |
Balance as of March 31, 2020 | (770) | | | 114 | | | 3 | | | (9) | | | (662) | | |
Balance as of March 31, 2021 | | Balance as of March 31, 2021 | (748) | | | (73) | | | 1 | | | (13) | | | (833) | |
| Foreign currency translation adjustments | Foreign currency translation adjustments | (3) | | | — | | | — | | | — | | | (3) | | Foreign currency translation adjustments | 14 | | | — | | | — | | | — | | | 14 | |
Unrealized losses | Unrealized losses | — | | | (30) | | | (2) | | | — | | | (32) | | Unrealized losses | — | | | (31) | | | 0 | | | 0 | | | (31) | |
Reclassification adjustments to income | Reclassification adjustments to income | — | | | (119) | | | — | | | — | | | (119) | | Reclassification adjustments to income | — | | | (28) | | | 0 | | | — | | | (28) | |
Other | Other | — | | | — | | | — | | | — | | | — | | Other | — | | | — | | | — | | | (1) | | | (1) | |
Income taxes | Income taxes | — | | | 33 | | | — | | | — | | | 33 | | Income taxes | 0 | | | 11 | | | 0 | | | — | | | 11 | |
Balance as of June 30, 2020 | $ | (773) | | | $ | (2) | | | $ | 1 | | | $ | (9) | | | $ | (783) | | |
Balance as of June 30, 2021 | | Balance as of June 30, 2021 | $ | (734) | | | $ | (121) | | | $ | 1 | | | $ | (14) | | | $ | (868) | |
|
Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):
| | | Three months ended June 30, | | | | Three months ended June 30, | |
Components of AOCI | Components of AOCI | | 2020 | | 2019 | | Condensed Consolidated Statements of Income locations | Components of AOCI | | 2021 | | 2020 | | Condensed Consolidated Statements of Income locations |
Cash flow hedges: | Cash flow hedges: | | | | | | | Cash flow hedges: | | | | | | |
Foreign currency contract gains | | $ | 68 | | | $ | 22 | | | Product sales | |
Foreign currency contract (losses) gains | | Foreign currency contract (losses) gains | | $ | (18) | | | $ | 68 | | | Product sales |
Cross-currency swap contract gains | Cross-currency swap contract gains | | 51 | | | 14 | | | Interest and other income, net | Cross-currency swap contract gains | | 46 | | | 51 | | | Other income, net |
| | | 119 | | | 36 | | | Income before income taxes | | 28 | | | 119 | | | Income before income taxes |
| | (26) | | | (8) | | | Provision for income taxes | | (6) | | | (26) | | | Provision for income taxes |
| | $ | 93 | | | $ | 28 | | | Net income | | $ | 22 | | | $ | 93 | | | Net income |
Available-for-sale securities: | Available-for-sale securities: | | | | | | Available-for-sale securities: | | | | | |
Net realized losses | | $ | — | | | $ | (2) | | | Interest and other income, net | |
Net realized gains | | Net realized gains | | $ | 0 | | | $ | 0 | | | Other income, net |
| | — | | | — | | | Provision for income taxes | | 0 | | | 0 | | | Provision for income taxes |
| | $ | — | | | $ | (2) | | | Net income | | $ | 0 | | | $ | 0 | | | Net income |
| | | | Six months ended June 30, | |
Components of AOCI | | Components of AOCI | | 2021 | | 2020 | | Condensed Consolidated Statements of Income locations |
Cash flow hedges: | | Cash flow hedges: | | | | | | |
Foreign currency contract (losses) gains | | Foreign currency contract (losses) gains | | $ | (19) | | | $ | 117 | | | Product sales |
Cross-currency swap contract losses | | Cross-currency swap contract losses | | (86) | | | (82) | | | Other income, net |
| | | | (105) | | | 35 | | | Income before income taxes |
| | | 22 | | | (8) | | | Provision for income taxes |
| | | $ | (83) | | | $ | 27 | | | Net income |
Available-for-sale securities: | | Available-for-sale securities: | | | | | |
Net realized gains | | Net realized gains | | $ | 0 | | | $ | 33 | | | Other income, net |
| | | 0 | | | (7) | | | Provision for income taxes |
| | | $ | 0 | | | $ | 26 | | | Net income |
| | | | | | | | | | | | | | | | | | | | |
| | Six months ended June 30, | | | | |
Components of AOCI | | 2020 | | 2019 | | Condensed Consolidated Statements of Income locations |
Cash flow hedges: | | | | | | |
Foreign currency contract gains | | $ | 117 | | | $ | 36 | | | Product sales |
Cross-currency swap contract losses | | (82) | | | (28) | | | Interest and other income, net |
| | | | | | |
| | 35 | | | 8 | | | Income before income taxes |
| | (8) | | | (2) | | | Provision for income taxes |
| | $ | 27 | | | $ | 6 | | | Net income |
Available-for-sale securities: | | | | | | |
Net realized gains (losses) | | $ | 33 | | | $ | (6) | | | Interest and other income, net |
| | (7) | | | — | | | Provision for income taxes |
| | $ | 26 | | | $ | (6) | | | Net income |
11. Fair value measurement
To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:
| | | | | | | | |
Level 1 | — | Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access |
Level 2 | — | Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs |
Level 3 | — | Valuations based on inputs that are unobservable and significant to the overall fair value measurement |
The availability of observable inputs can vary among the variousdifferent types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.
The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
| | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable inputs (Level 3) | | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable inputs (Level 3) | |
| | | | | | | | | Quoted prices in active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | | Significant unobservable inputs (Level 3) | |
Fair value measurement as of June 30, 2020, using: | | | | | | | | Total | |
Fair value measurement as of June 30, 2021, using: | | Fair value measurement as of June 30, 2021, using: | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | Total |
Assets: | Assets: | | | | | | | | | Assets: | | |
Available-for-sale securities: | Available-for-sale securities: | | Available-for-sale securities: | |
U.S. Treasury notes | U.S. Treasury notes | | $ | 175 | | | $ | — | | | $ | — | | | $ | 175 | | U.S. Treasury notes | | $ | 52 | | | $ | 0 | | | $ | 0 | | | $ | 52 | |
U.S. Treasury bills | U.S. Treasury bills | | 3,399 | | | — | | | — | | | 3,399 | | U.S. Treasury bills | | 1,400 | | | 0 | | | 0 | | | 1,400 | |
| Corporate debt securities: | | |
Financial | | — | | | — | | | — | | | — | | |
Industrial | | — | | | 2 | | | — | | | 2 | | |
Other | | — | | | — | | | — | | | — | | |
Residential-mortgage-backed securities | | — | | | — | | | — | | | — | | |
| | Money market mutual funds | Money market mutual funds | | 7,158 | | | — | | | — | | | 7,158 | | Money market mutual funds | | 5,707 | | | 0 | | | 0 | | | 5,707 | |
Other short-term interest-bearing securities | Other short-term interest-bearing securities | | — | | | — | | | — | | | — | | Other short-term interest-bearing securities | | 0 | | | 0 | | | 0 | | | 0 | |
Equity securities | Equity securities | | 297 | | | — | | | — | | | 297 | | Equity securities | | 403 | | | 0 | | | 0 | | | 403 | |
Derivatives: | Derivatives: | | Derivatives: | |
Foreign currency contracts | Foreign currency contracts | | — | | | 236 | | | — | | | 236 | | Foreign currency contracts | | 0 | | | 62 | | | 0 | | | 62 | |
Cross-currency swap contracts | Cross-currency swap contracts | | — | | | 27 | | | — | | | 27 | | Cross-currency swap contracts | | 0 | | | 182 | | | 0 | | | 182 | |
Interest rate swap contracts | Interest rate swap contracts | | — | | | 121 | | | — | | | 121 | | Interest rate swap contracts | | 0 | | | 45 | | | 0 | | | 45 | |
| Total assets | Total assets | | $ | 11,029 | | | $ | 386 | | | $ | — | | | $ | 11,415 | | Total assets | | $ | 7,562 | | | $ | 289 | | | $ | 0 | | | $ | 7,851 | |
| Liabilities: | Liabilities: | | Liabilities: | |
Derivatives: | Derivatives: | | Derivatives: | |
Foreign currency contracts | Foreign currency contracts | | $ | — | | | $ | 26 | | | $ | — | | | $ | 26 | | Foreign currency contracts | | $ | 0 | | | $ | 119 | | | $ | 0 | | | $ | 119 | |
Cross-currency swap contracts | Cross-currency swap contracts | | — | | | 604 | | | — | | | 604 | | Cross-currency swap contracts | | 0 | | | 305 | | | 0 | | | 305 | |
Interest rate swap contracts | Interest rate swap contracts | | — | | | 2 | | | — | | | 2 | | Interest rate swap contracts | | 0 | | | 90 | | | 0 | | | 90 | |
Contingent consideration obligations | Contingent consideration obligations | | — | | | — | | | 55 | | | 55 | | Contingent consideration obligations | | 0 | | | 0 | | | 48 | | | 48 | |
Total liabilities | Total liabilities | | $ | — | | | $ | 632 | | | $ | 55 | | | $ | 687 | | Total liabilities | | $ | 0 | | | $ | 514 | | | $ | 48 | | | $ | 562 | |
| | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable inputs (Level 3) | | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable inputs (Level 3) | |
| | | | | | | | | Quoted prices in active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | | Significant unobservable inputs (Level 3) | |
Fair value measurement as of December 31, 2019, using: | | | | | | | | Total | |
Fair value measurement as of December 31, 2020, using: | | Fair value measurement as of December 31, 2020, using: | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | Total |
Assets: | Assets: | | | | | | | | | Assets: | | |
Available-for-sale securities: | Available-for-sale securities: | | Available-for-sale securities: | |
U.S. Treasury notes | U.S. Treasury notes | | $ | 360 | | | $ | — | | | $ | — | | | $ | 360 | | U.S. Treasury notes | | $ | 130 | | | $ | 0 | | | $ | 0 | | | $ | 130 | |
U.S. Treasury bills | U.S. Treasury bills | | — | | | — | | | — | | | — | | U.S. Treasury bills | | 4,948 | | | 0 | | | 0 | | | 4,948 | |
| Corporate debt securities: | | |
Financial | | — | | | 1,121 | | | — | | | 1,121 | | |
Industrial | | — | | | 834 | | | — | | | 834 | | |
Other | | — | | | 198 | | | — | | | 198 | | |
Residential-mortgage-backed securities | | — | | | 182 | | | — | | | 182 | | |
| | Money market mutual funds | Money market mutual funds | | 5,250 | | | — | | | — | | | 5,250 | | Money market mutual funds | | 4,765 | | | 0 | | | 0 | | | 4,765 | |
Other short-term interest-bearing securities | Other short-term interest-bearing securities | | — | | | 289 | | | — | | | 289 | | Other short-term interest-bearing securities | | 0 | | | 2 | | | 0 | | | 2 | |
Equity securities | Equity securities | | 303 | | | — | | | — | | | 303 | | Equity securities | | 477 | | | 0 | | | 0 | | | 477 | |
Derivatives: | Derivatives: | | Derivatives: | |
Foreign currency contracts | Foreign currency contracts | | — | | | 224 | | | — | | | 224 | | Foreign currency contracts | | 0 | | | 28 | | | 0 | | | 28 | |
Cross-currency swap contracts | Cross-currency swap contracts | | — | | | 66 | | | — | | | 66 | | Cross-currency swap contracts | | 0 | | | 255 | | | 0 | | | 255 | |
Interest rate swap contracts | Interest rate swap contracts | | — | | | 259 | | | — | | | 259 | | Interest rate swap contracts | | 0 | | | 66 | | | 0 | | | 66 | |
Total assets | Total assets | | $ | 5,913 | | | $ | 3,173 | | | $ | — | | | $ | 9,086 | | Total assets | | $ | 10,320 | | | $ | 351 | | | $ | 0 | | | $ | 10,671 | |
| Liabilities: | Liabilities: | | Liabilities: | |
Derivatives: | Derivatives: | | Derivatives: | |
Foreign currency contracts | Foreign currency contracts | | $ | — | | | $ | 31 | | | $ | — | | | $ | 31 | | Foreign currency contracts | | $ | 0 | | | $ | 237 | | | $ | 0 | | | $ | 237 | |
Cross-currency swap contracts | Cross-currency swap contracts | | — | | | 315 | | | — | | | 315 | | Cross-currency swap contracts | | 0 | | | 318 | | | 0 | | | 318 | |
Interest rate swap contracts | Interest rate swap contracts | | — | | | — | | | — | | | — | | Interest rate swap contracts | | 0 | | | 15 | | | 0 | | | 15 | |
Contingent consideration obligations | Contingent consideration obligations | | — | | | — | | | 61 | | | 61 | | Contingent consideration obligations | | 0 | | | 0 | | | 33 | | | 33 | |
Total liabilities | Total liabilities | | $ | — | | | $ | 346 | | | $ | 61 | | | $ | 407 | | Total liabilities | | $ | 0 | | | $ | 570 | | | $ | 33 | | | $ | 603 | |
Interest-bearing and equity securities
The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets, with no valuation adjustment.
As of June 30, 2020, our corporate debt securities are not material. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.
Derivatives
All of our foreign currency forward derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A– or equivalent by Standard & Poor’s Financial Services LLC (S&P), Moody’s Investors Service, Inc. (Moody’s) or Fitch Ratings, Inc. (Fitch). We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments.
Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency-basis swap spreads. See Note 12, Derivative instruments.
Our interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 12, Derivative instruments.
During the three and six months ended June 30, 20202021 and 2019,2020, there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.
Summary of the fair values of other financial instruments
Cash equivalents
The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.
Borrowings
We estimated the fair values of our borrowings by using Level 2 inputs. As of June 30, 20202021 and December 31, 2019,2020, the aggregate fair values of our borrowings were $40.0$37.9 billion and $33.7$39.4 billion, respectively, and the carrying values were $34.2$32.8 billion and $29.9$33.0 billion, respectively.
12. Derivative instruments
The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.
Cash flow hedges
We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset partially by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales—primarily oversales up to a three-year time horizon, with,maximum of three years into the future, and at any given point in time, a higher percentage of nearer-term projected product sales are being hedged than in successive periods.
As of both June 30, 20202021 and December 31, 2019,2020, we had outstanding foreign currency forward contracts with aggregate notional amounts of $5.0 billion.$5.2 billion and $5.1 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.
To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Interest and otherOther income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.
The notional amounts and interest rates of our cross-currency swaps as of June 30, 2020,2021, were as follows (notional amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Foreign currency | | U.S. dollars |
Hedged notes | | Notional amounts | | Interest rates | | Notional amounts | | Interest rates |
| | | | | | | | |
1.25% 2022 euro Notes | | € | 1,250 | | | 1.3 | % | | $ | 1,388 | | | 3.2 | % |
0.41% 2023 Swiss franc Bonds | | CHF | 700 | | | 0.4 | % | | $ | 704 | | | 3.4 | % |
2.00% 2026 euro Notes | | € | 750 | | | 2.0 | % | | $ | 833 | | | 3.9 | % |
5.50% 2026 pound sterling Notes | | £ | 475 | | | 5.5 | % | | $ | 747 | | | 6.0 | % |
4.00% 2029 pound sterling Notes | | £ | 700 | | | 4.0 | % | | $ | 1,111 | | | 4.5 | % |
In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Condensed Consolidated Balance Sheets and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the six months ended June 30, 2020,2021, and amounts expected to be recognized during the subsequent 12 months are not material.
The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):
| | | | Three months ended June 30, | | | Six months ended June 30, | | | | Three months ended June 30, | | Six months ended June 30, |
Derivatives in cash flow hedging relationships | Derivatives in cash flow hedging relationships | | 2020 | | 2019 | | 2020 | | 2019 | Derivatives in cash flow hedging relationships | | 2021 | | 2020 | | 2021 | | 2020 |
Foreign currency contracts | Foreign currency contracts | | $ | (101) | | | $ | (16) | | | $ | 138 | | | $ | 69 | | Foreign currency contracts | | $ | (46) | | | $ | (101) | | | $ | 137 | | | $ | 138 | |
Cross-currency swap contracts | Cross-currency swap contracts | | 71 | | | (80) | | | (330) | | | (135) | | Cross-currency swap contracts | | 15 | | | 71 | | | (60) | | | (330) | |
| Total unrealized losses | | $ | (30) | | | $ | (96) | | | $ | (192) | | | $ | (66) | | |
Total unrealized (losses) gains | | Total unrealized (losses) gains | | $ | (31) | | | $ | (30) | | | $ | 77 | | | $ | (192) | |
Fair value hedges
To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of June 30, 20202021 and December 31, 2019,2020, we had interest rate swap contracts with aggregate notional amounts of $7.4 billion and $9.6$5.9 billion, respectively, that hedge certain portions of our long-term debt issuances.
Interest rate swaps with an aggregate notional value of $2.2 billion were terminated during During the sixthree months ended June 30, 2020, in connection with the redemption2021, we entered into $1.5 billion of certain of our notes. The terminations of these interest rate swaps resulted in a gain of $17 million, recognized in Interest expense, net, in the Condensed Consolidated Statements of Income. Additionally, we terminated $5.2 billion aggregate notional amount of interest rate swaps, which resulted in the receipt of $576 million from the counterparties that was included in Net cash provided by operating activities in the Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2020. This amount will be recognized as a reduction in Interest expense, net, in the Condensed Consolidated Statements of Income over the remaining life of the underlying notes. Immediately following the terminations of these interest rate swap contracts we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amountto hedge portions of notes. Seeour 2.45% 2030 Notes and 2.30% 2031 Notes (see Note 9, Financing arrangements, for information on our interest rate swaps.arrangements).
For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.
The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):
| | | Carrying amounts of hedged liabilities(1) | | | Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2) | | | Carrying amounts of hedged liabilities(1) | | Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2) |
Condensed Consolidated Balance Sheets locations | Condensed Consolidated Balance Sheets locations | | June 30, 2020 | | December 31, 2019 | | June 30, 2020 | | December 31, 2019 | Condensed Consolidated Balance Sheets locations | | June 30, 2021 | | December 31, 2020 | | June 30, 2021 | | December 31, 2020 |
Current portion of long-term debt | Current portion of long-term debt | | $ | 89 | | | $ | 903 | | | $ | 89 | | | $ | 4 | | Current portion of long-term debt | | $ | 844 | | | $ | 89 | | | $ | 94 | | | $ | 89 | |
Long-term debt | Long-term debt | | $ | 7,816 | | | $ | 8,814 | | | $ | 589 | | | $ | 292 | | Long-term debt | | $ | 6,857 | | | $ | 6,258 | | | $ | 330 | | | $ | 477 | |
____________
(1) Current portion of long-term debt includes $89 million of carrying value with discontinued hedging relationships as of both June 30, 2021 and December 31, 2020. Long-term debt includes $569$481 million and $136$525 million of carrying value with discontinued hedging relationships as of June 30, 20202021 and December 31, 2019,2020, respectively.
(2) Current portion of long-term debt includes $89 million of hedging adjustments on discontinued hedging relationships as of both June 30, 2021 and December 31, 2020. Long-term debt includes $469$381 million and $36$425 million of hedging adjustments on discontinued hedging relationships as of June 30, 20202021 and December 31, 2019,2020, respectively.
Impact of hedging transactions
The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):
| | | | Three months ended June 30, 2020 | | | Six months ended June 30, 2020 | | | Three months ended June 30, 2021 | | Six months ended June 30, 2021 |
| | Product sales | | Interest and other income, net | | Interest (expense), net | | Product sales | | Interest and other income, net | | Interest (expense), net | | Product sales | | Other income, net | | Interest expense, net | | Product sales | | Other income, net | | Interest expense, net |
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income | Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income | | $ | 5,908 | | | $ | 3 | | | $ | (296) | | | $ | 11,802 | | | $ | 14 | | | $ | (642) | | Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income | | $ | 6,114 | | | $ | 11 | | | $ | (281) | | | $ | 11,706 | | | $ | 24 | | | $ | (566) | |
The effects of cash flow and fair value hedging: | The effects of cash flow and fair value hedging: | | The effects of cash flow and fair value hedging: | |
Gains (losses) on cash flow hedging relationships reclassified out of AOCI: | | |
(Losses) gains on cash flow hedging relationships reclassified out of AOCI: | | (Losses) gains on cash flow hedging relationships reclassified out of AOCI: | |
Foreign currency contracts | Foreign currency contracts | | $ | 68 | | | $ | — | | | $ | — | | | $ | 117 | | | $ | — | | | $ | — | | Foreign currency contracts | | $ | (18) | | | $ | — | | | $ | — | | | $ | (19) | | | $ | — | | | $ | — | |
Cross-currency swap contracts | Cross-currency swap contracts | | $ | — | | | $ | 51 | | | $ | — | | | $ | — | | | $ | (82) | | | $ | — | | Cross-currency swap contracts | | $ | — | | | $ | 46 | | | $ | — | | | $ | — | | | $ | (86) | | | $ | — | |
| (Losses) gains on fair value hedging relationships—interest rate swap agreements: | (Losses) gains on fair value hedging relationships—interest rate swap agreements: | | (Losses) gains on fair value hedging relationships—interest rate swap agreements: | |
Hedged items(1) | Hedged items(1) | | $ | — | | | $ | — | | | $ | (30) | | | $ | — | | | $ | — | | | $ | 180 | | Hedged items(1) | | $ | — | | | $ | — | | | $ | (34) | | | $ | — | | | $ | — | | | $ | 141 | |
Derivatives designated as hedging instruments | Derivatives designated as hedging instruments | | $ | — | | | $ | — | | | $ | 53 | | | $ | — | | | $ | — | | | $ | (137) | | Derivatives designated as hedging instruments | | $ | — | | | $ | — | | | $ | 55 | | | $ | — | | | $ | — | | | $ | (97) | |
| | | | Three months ended June 30, 2019 | | | Six months ended June 30, 2019 | | | Three months ended June 30, 2020 | | Six months ended June 30, 2020 |
| | Product sales | | Interest and other income, net | | Interest (expense), net | | Product sales | | Interest and other income, net | | Interest (expense), net | | Product sales | | Other income, net | | Interest expense, net | | Product sales | | Other income, net | | Interest expense, net |
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income | Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income | | $ | 5,574 | | | $ | 218 | | | $ | (332) | | | $ | 10,860 | | | $ | 403 | | | $ | (675) | | Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income | | $ | 5,908 | | | $ | 3 | | | $ | (296) | | | $ | 11,802 | | | $ | 14 | | | $ | (642) | |
The effects of cash flow and fair value hedging: | The effects of cash flow and fair value hedging: | | The effects of cash flow and fair value hedging: | |
Gains (losses) on cash flow hedging relationships reclassified out of AOCI: | Gains (losses) on cash flow hedging relationships reclassified out of AOCI: | | Gains (losses) on cash flow hedging relationships reclassified out of AOCI: | |
Foreign currency contracts | Foreign currency contracts | | $ | 22 | | | $ | — | | | $ | — | | | $ | 36 | | | $ | — | | | $ | — | | Foreign currency contracts | | $ | 68 | | | $ | — | | | $ | — | | | $ | 117 | | | $ | — | | | $ | — | |
Cross-currency swap contracts | Cross-currency swap contracts | | $ | — | | | $ | 14 | | | $ | — | | | $ | — | | | $ | (28) | | | $ | — | | Cross-currency swap contracts | | $ | — | | | $ | 51 | | | $ | — | | | $ | — | | | $ | (82) | | | $ | — | |
| (Losses) gains on fair value hedging relationships—interest rate swap agreements: | (Losses) gains on fair value hedging relationships—interest rate swap agreements: | | (Losses) gains on fair value hedging relationships—interest rate swap agreements: | |
Hedged items(1) | Hedged items(1) | | $ | — | | | $ | — | | | $ | (218) | | | $ | — | | | $ | — | | | $ | (348) | | Hedged items(1) | | $ | — | | | $ | — | | | $ | (30) | | | $ | — | | | $ | — | | | $ | 180 | |
Derivatives designated as hedging instruments | Derivatives designated as hedging instruments | | $ | — | | | $ | — | | | $ | 218 | | | $ | — | | | $ | — | | | $ | 351 | | Derivatives designated as hedging instruments | | $ | — | | | $ | — | | | $ | 53 | | | $ | — | | | $ | — | | | $ | (137) | |
__________
(1) (Losses) gainsGains on hedged items do not completelyexactly offset gains (losses)losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges wherewhen the corresponding hedged item was paid down in the period.
No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of June 30, 2020, we2021, the net gains expected to reclassify $95 million of net gainsbe reclassified on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months.months are not material.
Derivatives not designated as hedges
To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of June 30, 20202021 and December 31, 2019,2020, the total notional amounts of these foreign currency forward contracts were $1.3$0.8 billion and $1.2$1.0 billion, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three and six months ended June 30, 20202021 and 2019.
The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):
| | | | Derivative assets | | | Derivative liabilities | | | | Derivative assets | | Derivative liabilities |
June 30, 2020 | | Condensed Consolidated Balance Sheets locations | | Fair values | | Condensed Consolidated Balance Sheets locations | | Fair values | |
June 30, 2021 | | June 30, 2021 | | Condensed Consolidated Balance Sheets locations | | Fair values | | Condensed Consolidated Balance Sheets locations | | Fair values |
Derivatives designated as hedging instruments: | Derivatives designated as hedging instruments: | | | | | | | | | Derivatives designated as hedging instruments: | | | | | | | | |
Foreign currency contracts | Foreign currency contracts | | Other current assets/ Other assets | | $ | 236 | | | Accrued liabilities/ Other noncurrent liabilities | | $ | 26 | | Foreign currency contracts | | Other current assets/ Other assets | | $ | 62 | | | Accrued liabilities/ Other noncurrent liabilities | | $ | 119 | |
Cross-currency swap contracts | Cross-currency swap contracts | | Other current assets/ Other assets | | 27 | | | Accrued liabilities/ Other noncurrent liabilities | | 604 | | Cross-currency swap contracts | | Other current assets/ Other assets | | 182 | | | Accrued liabilities/ Other noncurrent liabilities | | 305 | |
Interest rate swap contracts | Interest rate swap contracts | | Other current assets/ Other assets | | 121 | | | Accrued liabilities/ Other noncurrent liabilities | | 2 | | Interest rate swap contracts | | Other current assets/ Other assets | | 45 | | | Accrued liabilities/ Other noncurrent liabilities | | 90 | |
| Total derivatives designated as hedging instruments | Total derivatives designated as hedging instruments | | 384 | | | 632 | | Total derivatives designated as hedging instruments | | $ | 289 | | | $ | 514 | |
Derivatives not designated as hedging instruments: | | | | | |
Foreign currency contracts | | Other current assets | | — | | | Accrued liabilities | | — | | |
Total derivatives not designated as hedging instruments | | — | | | — | | |
Total derivatives | | $ | 384 | | | $ | 632 | | |
|
| | | | Derivative assets | | | Derivative liabilities | | | | Derivative assets | | Derivative liabilities |
December 31, 2019 | | Condensed Consolidated Balance Sheets locations | | Fair values | | Condensed Consolidated Balance Sheets locations | | Fair values | |
December 31, 2020 | | December 31, 2020 | | Condensed Consolidated Balance Sheets locations | | Fair values | | Condensed Consolidated Balance Sheets locations | | Fair values |
Derivatives designated as hedging instruments: | Derivatives designated as hedging instruments: | | | | | | | | | Derivatives designated as hedging instruments: | | | | | | | | |
Foreign currency contracts | Foreign currency contracts | | Other current assets/ Other assets | | $ | 223 | | | Accrued liabilities/ Other noncurrent liabilities | | $ | 31 | | Foreign currency contracts | | Other current assets/ Other assets | | $ | 28 | | | Accrued liabilities/ Other noncurrent liabilities | | $ | 237 | |
Cross-currency swap contracts | Cross-currency swap contracts | | Other current assets/ Other assets | | 66 | | | Accrued liabilities/ Other noncurrent liabilities | | 315 | | Cross-currency swap contracts | | Other current assets/ Other assets | | 255 | | | Accrued liabilities/ Other noncurrent liabilities | | 318 | |
| Interest rate swap contracts | Interest rate swap contracts | | Other current assets/ Other assets | | 259 | | | Accrued liabilities/ Other noncurrent liabilities | | — | | Interest rate swap contracts | | Other current assets/ Other assets | | 66 | | | Accrued liabilities/ Other noncurrent liabilities | | 15 | |
Total derivatives designated as hedging instruments | Total derivatives designated as hedging instruments | | 548 | | | 346 | | Total derivatives designated as hedging instruments | | $ | 349 | | | $ | 570 | |
Derivatives not designated as hedging instruments: | | | | | |
Foreign currency contracts | | Other current assets | | 1 | | | Accrued liabilities | | — | | |
Total derivatives not designated as hedging instruments | | 1 | | | — | | |
Total derivatives | | $ | 549 | | | $ | 346 | | |
|
Our derivative contracts that were in liability positions as of June 30, 2020,2021, contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then-current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.
The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash provided by (used in)used in financing activities.
13. Contingencies and commitments
Contingencies
In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2019,2020, Part I, Item 1A. Risk Factors—Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019;2020; and in Note 13,12, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2020.2021.
We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.
Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019;2020; or in Note 13,12, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2020,2021, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019;2020; or in Note 13,12, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2020,2021, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.
Certain recent developments concerning our legal proceedings and other matters are discussed below:
Abbreviated New Drug Application (ANDA) Patent Litigation
KYPROLIS® (carfilzomib) ANDA Patent Litigation
Onyx Therapeutics, Inc. v. Cipla Limited, et alOtezla.®
On May 8, 2020, consistent with its May 4, 2020 decision and order, the U.S. District Court for the District of Delaware (the Delaware District Court) entered final judgment in favor of Onyx Therapeutics, Inc. (Onyx, a wholly-owned subsidiary of Amgen) and against Cipla Limited and Cipla USA, Inc. (collectively, Cipla) on infringement, validity and enforceability of claims 23 and 24 of U.S. Patent No. 7,417,042; claim 1 of U.S. Patent No. 8,207,125; and claim 31 of U.S. Patent No. 7,737,112 (the ’112 Patent). The Delaware District Court entered judgment in favor of Cipla and against Onyx on Cipla’s counterclaim for invalidity of claim 32 of the ’112 Patent and ordered that the effective date of any final approval by the U.S. Food and Drug Administration (FDA) of Cipla’s ANDA must be after expiration of the 3 asserted patents and any regulatory exclusivity to which Onyx may become entitled. The final judgment includes an injunction prohibiting Cipla from making, using, offering to sell, selling or importing into the United States Cipla’s carfilzomib product during the term of the three asserted patents.
On May 29, 2020, Cipla filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court).
Otezla® (apremilast) ANDA Patent Litigation
Amgen Inc. v. Sandoz Inc., et al.
On May 28, 2020,5, 2021, based on a joint request by Amgen and Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. (collectively, Emcure)Cipla Limited (Cipla Ltd), the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Emcure’sCipla Ltd’s apremilast product during the term of U.S. Patent Nos. 6,962,940 (the ’940 Patent); 7,427,638 (the ’638 Patent); 7,893,101, 7,659,302 (the ’101’302 Patent); 9,872,854, 8,455,536 (the ’854’536 Patent);, 9,724,330 (the ’330 Patent) and 10,092,541 (the ’541 Patent), unless authorized pursuant to a confidential settlement agreement. On May 14, 2021, based on a joint request by Amgen and Torrent Pharmaceuticals Ltd. (Torrent), the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Torrent’s apremilast product during the term of the U.S. Patent Nos. 7,893,101 (the ’101 Patent), 9,872,854 (the ’854 Patent) and the ’638 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 19, 2021, based on a joint request by Amgen and Alkem Laboratories Ltd. (Alkem), the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Alkem’s apremilast product during the term of the ’940, ’638, ’302, ’536, ’330 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On May 25, 2021, based on a joint request by Amgen and MSN Laboratories Private Limited (MSN), the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of MSN’s apremilast product during the term of the ’940, ’638, ’302, ’536, ’330 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 11, 2021, based on a joint request by Amgen and Pharmascience Inc. (Pharmascience), the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of Pharmascience’s apremilast product during the term of U.S. Patent No. 9,018,243 (the ’243 Patent) and the ’940, ’638, ’302, ’101, ’536, ’330 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement. On June 17, 2021, based on a joint request by Amgen and Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, DRL) , the New Jersey District Court entered a consent judgment and injunction prohibiting the making, using, selling, offering to sell, or importing of DRL’s
apremilast product during the term of the ’638, ’101, ’536 and ’541 Patents, unless authorized pursuant to a confidential settlement agreement.
On July 7, 2020,Trial on the consolidated patent infringement action was held at the New Jersey District Court ordered a stipulated dismissal without prejudice of all claims, counterclaims, and affirmative defenses between Amgen andfrom June 14 to 25, 2021 with closing arguments on July 28, 2021. The remaining defendants are Sandoz Inc. (Sandoz) with respect to U.S. Patent Nos. 8,802,717; 7,208,516; and the ’854 Patent, leaving U.S. Patent Nos. 6,962,940; 7,659,302; 8,455,536; 9,018,243; and 9,724,330; the ’638 Patent; the ’101 Patent; and the ’541 Patent asserted by Amgen against Sandoz in the litigation.
Sensipar® (cinacalcet) ANDA Patent Litigation
AmgenZydus Pharmaceuticals (USA) Inc. v. Amneal Pharmaceuticals LLC, et al. (formerly, Amgen Inc. v. Aurobindo Pharma Ltd. et al.) Consolidated Case
On July 9, 2020, the Federal Circuit Court granted a motion filed by Watson Laboratories, Inc. and Actavis Pharma, Inc. (collectively, Watson) and Amgen to dismiss Amgen’s appeals of the Delaware District Court’s judgment of noninfringement as to Watson and denial of the joint motion for indicative ruling.
A hearing on the request by Piramal Healthcare UK Limited to recover damages for being enjoined during the pendency of Amgen’s appeal will be held by the Delaware District Court during the week of December 14, 2020. No trial date has been set for the patent infringement and validity issues to be tried in the remanded case against Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC.
ENBREL (etanercept) Patent Litigation
Immunex Corporation, et al. v. Sandoz Inc., et al.
On July 1, 2020,May 17, 2021, the U.S. Supreme Court denied the petition of Sandoz Inc., Sandoz International GmbH and Sandoz GmbH for certiorari seeking review of the Federal Circuit Court affirmed the judgmentCourt’s affirmance of the New Jersey District Court upholding the validity of U.S. Patent Nos. 8,063,182 and 8,163,522.
Repatha® (evolocumab) Patent Litigation
Patent Disputes in the International RegionAmgen Inc., et al. v. Sanofi, et al.
As previously disclosed, we are involved in and expect future involvement in additional disputes regarding our proprotein convertase subtilisin/kexin type 9 (PCSK9) patents in other jurisdictions and regions. This includes matters filed against us and that we have filed in the United Kingdom, Germany, France, the Netherlands, Italy, Spain and Japan.
On June 24, 2020, Amgen filed written answers21, 2021, the Federal Circuit Court denied our petition for rehearing en banc of the Federal Circuit Court’s ruling that claims 19 and 29 of our U.S. Patent No. 8,829,165 and claim 7 of our U.S. Patent No. 8,859,741 are invalid for failing to meet the invalidity trials initiated by Regeneron on February 12, 2020 before the Japan Patent Office seeking to invalidate Amgen’s Japanese patents that were previously held infringed by PRALUENT® and valid over challenges filed by Sanofi K.K.enablement requirement.
NEUPOGEN® (filgrastim)/Neulasta®(pegfilgrastim) Patent Litigation
Fresenius Amgen Inc., et al. v. Hospira Inc. et al.
On June 11, 2021, after having held a claim construction hearing, the U.S. District Court for the District of Delaware (Delaware District Court) determined that the term at issue required no construction, and on July 14, the Delaware District Court set a briefing schedule for summary judgment motions.
Patent Trial and Appeal Board (PTAB) Challenge
Lupin PTAB Challenge
On June 23, 2020,July 12, 2021, the PTAB of the U.S. Patent and Trademark Office terminated two proceedings filed by Fresenius Kabi USA, LLC and Fresenius Kabi SwissBioSim GmbH (collectively, Fresenius) challenging the patentabilityissued a decision denying institution of Amgen’sLupin Limited’s petition for inter partes review of U.S. Patent Nos. 9,643,997No. 9,856,287.
Apotex PTAB Challenge
On June 21, 2021, the U.S. Supreme Court decided United States v. Arthrex, Inc. On June 28, 2021, the Supreme Court granted the government’s pending certiorari petition and 9,856,287 due to a settlement between Amgenvacated and Fresenius.
Litigation relating to our Biosimilar Products
KANJINTI® (trastuzumab-anns) Patent Litigation
Genentech, Inc. v. Amgen Inc.
On July 7, 2020, pursuant to a settlement and license agreement, Amgen and Genentech, Inc. stipulated to dismissal of the lawsuit. On July 9, 2020, the Delaware District Court closed the matter.
MVASI®(bevacizumab-awwb) Patent Litigation
Genentech, Inc. and City of Hope v. Amgen Inc.
On July 7, 2020, pursuant to a settlement and license agreement, Genentech, Inc. and City of Hope (collectively, Genentech) and Amgen stipulated to dismissal of the lawsuit. On July 9, 2020, the Delaware District Court closed the matter.
Genentech, Inc. and City of Hope v. Immunex Rhode Island Corp. and Amgen Inc.
On July 6, 2020,remanded the Federal Circuit Court affirmed the Delaware District Court’s denial of Genentech’s requestjudgment for injunction. On July 7, 2020, pursuant to a settlement and license agreement, the parties stipulated to dismissal of the lawsuit. On July 9, 2020, the Delaware District Court closed the matter.further consideration under Arthrex.
Breach of Contract Action
Cipla Ltd. et al. v. Amgen Inc.
On July 16, 2020, Amgen and Cipla filed a stipulation of dismissal. On July 21, 2020, the Delaware District Court issued an order dismissing all pending claims between Amgen and Cipla.
Novartis Pharma AG v. Amgen Inc.
On June 9, 2020,2, 2021, the U.S. District Court forparties executed agreements to settle 2 claims in the Southern District of New York (the New York Southern District Court) entered an order grantinglitigation, relating to the 2018 budget overrun dispute and certain counterclaims alleging breaches by Novartis Pharma AG’sAG (Novartis) motion for judgment on the pleadings as to count II of Novartis’s amended complaint and denying Amgen’s motions for judgment on the pleadings as to counts I, II and IV of Novartis’s amended complaint. On June 23, 2020, Amgen filed a motion for clarification and/or reconsideration of the New York Southern District Court’s June 9, 2020 order. On July 7,2015 and July 14, 2020, respectively,2017 collaboration agreements related to the development and commercialization of Aimovig® (erenumab-aooe), and to amend and restate the 2017 collaboration agreement. As part of the agreement, Amgen paid $48 million to Novartis to resolve the 2018 budget dispute, and Amgen each filed its response. No trial date has been set.Novartis is in the process of transitioning U.S. commercial operations to Amgen.
Antitrust Class Action
Sensipar® (cinacalcet) Antitrust Class Actions
On July 22, 2020, the U.S. Magistrate Judge for the District of Delaware issued a recommendationApril 27, 2021, plaintiffs filed their oppositions to defendants’ (including Amgen’s) motion to dismiss, and defendants’ reply was filed on May 25, 2021. A hearing on defendants’ motion to dismiss was held in the Delaware District Court thaton July 13, 2021.
U.S. Tax Litigation
Amgen Inc. & Subsidiaries v. Commissioner of Internal Revenue
See Note 4, Income taxes, for discussion of the claims against Amgen be dismissed but recommended that leave be given to plaintiffs to amend their complaints.IRS tax dispute and the Company’s petition in the U.S. Tax Court.
Humira
® Biosimilar Antitrust Class Actions
14. Subsequent events
On June 8, 2020, the U.S. District Court for the Northern District of Illinois (the Illinois Northern District Court) issued an order granting the motion by the defendants1, 2021, Amgen along with AbbVie Inc. and AbbVie Biotechnology Ltd., Samsung BioepisKyowa Kirin Co., Ltd., Sandoz (KKC) announced a collaboration and Fresenius Kabi USA LLC.,licensing agreement to dismissjointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody, worldwide, except in Japan. The transaction closed on July 30, 2021, upon expiration of the consolidated class action complaint. On June 29, 2020,waiting period under the plaintiffsHart-Scott-Rodino Antitrust Improvements Act. Amgen will make an upfront payment of $400 million to KKC, to be recognized as R&D expense in the antitrust class action lawsuit filed a status report asking the Illinois Northern District Court to convert the dismissal to one with prejudice. On June 30, 2020, the Illinois Northern District Court granted the motion and the plaintiffs have 30 days therefrom to file their noticethird quarter of appeal.2021.
| | | | | |
Item 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to assist the reader in understanding Amgen’s business. MD&A is provided as a supplement to and should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2019,2020, and our Quarterly Report on Form 10-Q for the period ended March 31, 2020.2021. Our results of operations discussed in MD&A are presented in conformity with GAAP. Amgen operates in one business segment: human therapeutics. Therefore, our results of operations are discussed on a consolidated basis.
Forward-looking statements
This report and other documents we file with the Securities and Exchange Commission (SEC) contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management’s assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases, written statements or our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls and conference calls. Such words as “expect,” “anticipate,” “outlook,” “could,” “target,” “project,” “intend,” “plan,” “believe,” “seek,” “estimate,” “should,” “may,” “assume” and “continue” as well as variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and they involve certain risks, uncertainties and assumptions that are difficult to predict. We describe our respective risks, uncertainties and assumptions that could affect the outcome or results of operations in Item 1A. Risk Factors in Part II herein and in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 20192020, and in Part II, Item 1A. Risk Factors of our Quarterly Report on Form 10-Q for the period ended March 31, 2020.2021. We have based our forward-looking statements on our management’s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecasted by our forward-looking statements. Reference is made in particular to forward-looking statements regarding product sales, regulatory activities, clinical trial results, reimbursement, expenses, EPS, liquidity and capital resources, trends, planned dividends, stock repurchases, collaborations and effects of pandemics. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise.
Overview
Amgen is a biotechnology company committed to unlocking the potential of biology for patients suffering from serious illnesses. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. In 2020, we are celebrating our 40th anniversary, continuing our history of focusing on innovative medicines that have the potential to be first-in-class molecules and that have a large-effect size on serious diseases.
Our principal products—those with the most significant annual commercial sales—are ENBREL, Prolia®,Neulasta®, Otezla®,Neulasta®, XGEVA®, Aranesp®, KYPROLISRepatha® and RepathaKYPROLIS®. We also market a number of other products, including MVASI® (bevacizumab-awwb), Nplate® (romiplostim), Vectibix® (panitumumab), ParsabivKANJINTI® (etelcalcetide)(trastuzumab-anns), EPOGEN® (epoetin alfa), EVENITYMVASI® (romosozumab-aqqg), BLINCYTO®(blinatumomab), AMGEVITA™ (adalimumab), Parsabiv® (etelcalcetide), Aimovig®, KANJINTINEUPOGEN®,and Sensipar®/Mimpara®, EVENITY™®(romosozumab-aqqg),BLINCYTO®, Aimovig® (erenumab-aooe), AMGEVITATM (adalimumab),NEUPOGEN®, IMLYGIC® (talimogene laherparepvec) and Corlanor® (ivabradine).
COVID-19 pandemic
A novel strain of coronavirus (COVID-19)(SARS-CoV-2, or severe acute respiratory syndrome coronavirus 2, causing coronavirus disease 19, or COVID-19) was declared a global pandemic by the World Health Organization (WHO) on March 11, 2020. WeSince the onset of the pandemic in 2020, we have been carefullyclosely monitoring the COVID-19 pandemic and its impactpandemic’s effects on our global operations. We have takencontinue to take appropriate steps to minimize the riskrisks to our employees. Mostemployees, a significant number of our employeeswhom have been working remotely, with the exception of certain essential staff that continuecontinued to reportwork virtually. Employee access to Amgen locations. The essential staff are primarily at our manufacturing sites, workingcompany facilities has been in accordance with applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic. To date, our remote working arrangements have not significantly affected our ability to maintain critical business operations, and we have not experienced disruptions to or shortages of our supply of medicines.
Since the beginning of the COVID-19 pandemic, we have seen changes in demand trends for some of our products including lower demand for certain products as continuingdriven by changes in patient accessvisits to those productsdoctors’ offices that has impacted providing treatments to existing patients and reduced diagnoses in new patients. Through the second quarter, there has been affected bygradual recovery in both patients resuming treatments and in new patient starts, although overall these remain below pre-COVID-19 levels. The cumulative decrease in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which we expect to continue to impact our business during the second half of the year. We are closely monitoring the effects of the emerging COVID-19 particularly invariants on patient behavior and access.
Since early 2021, global vaccination efforts have been underway to control the early phasespandemic. However, uncertainty remains as to the length of time required for vaccinating a meaningful portion of the population as well as the efficacy of such vaccinations on the trajectory of the pandemic. For example, near the endChallenges to vaccination efforts, new variants and other causes of March, we beganvirus spread may require governments to observe a declineissue additional restrictions and/or shutdowns in sales of Prolia®, as elderly patients, who are relatively vulnerable to COVID-19, avoided doctors’ offices. Demand has since recovered to varying degrees by product as local conditions improved in certain geographies that opened after an initial improvement in COVID-19 infection rates, allowing patients to resume receiving their treatments. However, a resurgence of infections has been observed, which may further restrict demand similar to early phases of the pandemic.various geographies. As a result, we expect to see continued volatility throughfor at least the duration of the pandemic as geographiesgovernments respond to current local conditions.
To respond to COVID-19, we are managing our clinical development on a case-by-case basis. Patients who are already enrolled in studies continue to receive study drug, including through direct-to-patient shipments. The majority ofAt this time, the clinical trials that were paused at the onset of the pandemic to ensure subject safety or data integrity have resumed. Study enrollment was most affected negatively in the second quarter of 2020 but by the end of the year resumed however weto around pre-pandemic levels. We are continuingcontinuously monitoring COVID-19 infection rates and working to experience impact tomitigate effects on future study enrollment. We continuously monitor and reevaluate the status of studies, pausing when there is uncertainty with regard to the trial sites’ ability to ensure safety or data integrity. We remain focused on supporting our active clinical sites in their providing care for these patients and in our providing investigational drug supply. In addition, our R&D organization is supporting efforts to combat the COVID-19 pandemic, including by manufacturing therapeutic antibodies in a number of ways, including: (i) conducting research in support of therapeutic antibodies that could diminish the impact of COVID-19 on patients, (ii)supply arrangement with Eli Lilly and Company (Lilly) and joining a public–private partnership between leading companies in our industry and U.S. government health agencies to develop a strategy for a coordinated research response, (iii) investigating Otezla® as a potential immunomodulatory treatment in adult patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections through platform trialsresponse.
Despite the ongoing pandemic and (iv) through our subsidiary deCODE Genetics, conducting a population-based study.
We continue tobusiness impacts noted above, we believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditures and debt service requirements as well as to engage in the capital-return and other business initiatives that we plan to strategically pursue. To respond to some of the challenges experienced in the healthcare community as a result of the pandemic, we recently extended credit terms with certain customers for a subset of our products globally. In addition, in the second quarter of this year, we issued $4.0 billion of long-term debt, for general corporate purposes, including, enhancing our working capital position. For a discussion of the risks presented by the COVID-19 pandemic presents to our results, see Risk Factors in Item 1A. Risk Factors in Part II herein and in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2020, and in Part II, Item 1A. Risk Factors of thisour Quarterly Report on Form 10-Q.
10-Q for the period ended March 31, 2021.
Significant developments
Following is a summary of selected significant developments affecting our business that have occurred since the filing of our Quarterly Report on Form 10-Q for the period ended March 31, 2020.2021. For additional developments or for a more comprehensive discussion of certain developments discussed below, see our Annual Report on Form 10-K for the year ended December 31, 2019,2020, and our Quarterly Report on Form 10-Q for the period ended March 31, 2020.2021.
Business Development
Kyowa Kirin Co., Ltd. collaboration
•In June 2021, we and KKC, announced an agreement to jointly develop and commercialize KKC’s potential first-in-class, phase 3-ready anti-OX40 fully human monoclonal antibody in development for the treatment of atopic dermatitis, with potential in other autoimmune diseases. The transaction closed on July 30, 2021, upon expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Teneobio, Inc. acquisition
•In July 2021, we and Teneobio, Inc. (Teneobio), announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. Under the terms of the agreement, Amgen will acquire all outstanding shares of Teneobio at closing in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments to Teneobio equity holders potentially worth up to an additional $1.6 billion in cash. The acquisition is subject to customary closing conditions, including applicable regulatory approvals. The transaction is expected to close in the second half of 2021.
Products/Pipeline
Inflammation
Otezla®
•In May 2020,2021, we announced positive top-line results from a phase 3 study to assessthat the efficacyU.S. Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application for Otezla® for the treatment of Otezla® in adults with mild-to-moderate plaque psoriasis.psoriasis who are candidates for phototherapy or systemic therapy. The study showedFDA has set a Prescription Drug User Fee Act (PDUFA) date of December 19, 2021.
Tezepelumab
•In May 2021, Amgen announced that oral Otezla® 30 mg twice daily achievedits partner AstraZeneca had submitted a Biologics License Application to the FDA for tezepelumab, a potential first-in-class medicine in severe asthma. The submission is supported by positive clinical trial results including a phase 3 trial, which demonstrated a statistically significant improvement, compared with placebo,and clinically meaningful reduction in the primary endpoint of the static Physician's Global Assessment (sPGA) response (defined as an sPGA score of clear (0) or almost clear (1)annualized asthma exacerbation rate (AAER) in patients with at least a 2-point reduction from baseline) at week 16.severe, uncontrolled asthma compared to placebo.
ENBREL
•In July 2020,2021, we announced that the Federal Circuit Court affirmedFDA had granted Priority Review for tezepelumab in the judgmenttreatment of asthma. The PDUFA date for a decision by the New Jersey District Court upholdingFDA is during the validityfirst quarter of the two patents that describe and claim ENBREL and methods for making it. See Note 13, Contingencies and commitments, to the condensed consolidated financial statements.2022.
CardiovascularOncology/Hematology
Omecamtiv MecarbilLUMAKRAS™ (sotorasib)
•In May 2020,2021, we and Cytokinetics, Incorporated, announced that the FDA granted fast-track designation for omecamtiv mecarbil, a small molecule, selective cardiac myosin activator, also called a myotrope, which directly targets the contractile mechanisms of the heart. It is being developedhad approved LUMAKRAS™ for the potential treatment of chronic heart failureadult patients with reduced ejection fraction (HFrEF)KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. LUMAKRAS™ received accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial or trials.
Operations
New manufacturing facilities
We announced plans to expand our United States-based manufacturing footprint:
•In June 2021, we announced plans to build an advanced assembly and packaging plant in Ohio. The new facility will assemble and package vials and syringes to support the growing demand for our medicines.
•In August 2021, we announced plans to build a drug substance plant in North Carolina that will increase our manufacturing network capacity to reliably supply more medicines for patients.
We expect that both of these facilities will be built faster and at a lower cost than traditional plants. Once completed, both will also utilize cutting-edge technologies to be more efficient and environmentally friendly than traditional plants.
Selected financial information
The following is an overview of our results of operations (in millions, except percentages and per-share data):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | | | Six months ended June 30, | | | | |
| 2020 | | 2019 | | Change | | 2020 | | 2019 | | Change |
Product sales | | | | | | | | | | | |
U.S. | $ | 4,428 | | | $ | 4,142 | | | 7 | % | | $ | 8,707 | | | $ | 8,133 | | | 7 | % |
ROW | 1,480 | | | 1,432 | | | 3 | % | | 3,095 | | | 2,727 | | | 13 | % |
Total product sales | 5,908 | | | 5,574 | | | 6 | % | | 11,802 | | | 10,860 | | | 9 | % |
Other revenues | 298 | | | 297 | | | — | % | | 565 | | | 568 | | | (1) | % |
Total revenues | $ | 6,206 | | | $ | 5,871 | | | 6 | % | | $ | 12,367 | | | $ | 11,428 | | | 8 | % |
Operating expenses | $ | 3,883 | | | $ | 3,193 | | | 22 | % | | $ | 7,689 | | | $ | 6,278 | | | 22 | % |
Operating income | $ | 2,323 | | | $ | 2,678 | | | (13) | % | | $ | 4,678 | | | $ | 5,150 | | | (9) | % |
Net income | $ | 1,803 | | | $ | 2,179 | | | (17) | % | | $ | 3,628 | | | $ | 4,171 | | | (13) | % |
Diluted EPS | $ | 3.05 | | | $ | 3.57 | | | (15) | % | | $ | 6.12 | | | $ | 6.75 | | | (9) | % |
Diluted shares | 592 | | | 610 | | | (3) | % | | 593 | | | 618 | | | (4) | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | Six months ended June 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
Product sales | | | | | | | | | | | |
U.S. | $ | 4,374 | | | $ | 4,428 | | | (1) | % | | $ | 8,277 | | | $ | 8,707 | | | (5) | % |
ROW | 1,740 | | | 1,480 | | | 18 | % | | 3,429 | | | 3,095 | | | 11 | % |
Total product sales | 6,114 | | | 5,908 | | | 3 | % | | 11,706 | | | 11,802 | | | (1) | % |
Other revenues | 412 | | | 298 | | | 38 | % | | 721 | | | 565 | | | 28 | % |
Total revenues | $ | 6,526 | | | $ | 6,206 | | | 5 | % | | $ | 12,427 | | | $ | 12,367 | | | — | % |
Operating expenses | $ | 5,698 | | | $ | 3,883 | | | 47 | % | | $ | 9,470 | | | $ | 7,689 | | | 23 | % |
Operating income | $ | 828 | | | $ | 2,323 | | | (64) | % | | $ | 2,957 | | | $ | 4,678 | | | (37) | % |
Net income | $ | 464 | | | $ | 1,803 | | | (74) | % | | $ | 2,110 | | | $ | 3,628 | | | (42) | % |
Diluted EPS | $ | 0.81 | | | $ | 3.05 | | | (73) | % | | $ | 3.65 | | | $ | 6.12 | | | (40) | % |
Diluted shares | 576 | | | 592 | | | (3) | % | | 578 | | | 593 | | | (3) | % |
In the following discussion of changes in product sales, any reference to unit demand growth or decline refers to changes in the purchases of our products by healthcare providers (such as physicians or their clinics), dialysis centers, hospitals and pharmacies. In addition, any reference to increases or decreases in inventory refers to changes in inventory held by wholesaler customers and end users (such as pharmacies).
Notwithstanding the effects of the COVID-19 pandemic, totalTotal product sales increased for the three months ended June 30, 2021, primarily driven by higher unit demand for certain brands, including Prolia®, Repatha®, XGEVA®and MVASI®, partially offset by declines in the net selling prices of certain products. Total product sales decreased for the six months ended June 30, 2020,2021, primarily driven primarily by unit demand increases from newer brands including Otezla®, acquired in November 2019, MVASI®, KANJINTI®, EVENITY® and Repatha®. These unit demand increases were offset partially by declines in net selling prices for certain products, as well as unit demand declines for mature brands that face biosimilar or generic competition. For the remainder of 2020, we expect continued competition against our mature brands to result in both unit demand and net selling price declines.of certain products, partially offset by higher unit demand for certain brands, including Prolia®, Repatha® and MVASI®. There has been gradual recovery through the second quarter of 2021 in patients resuming their treatments and in new patient starts, although overall both remain below pre-COVID-19 levels.
During the initial stages of the COVID-19 pandemic in early 2020, we experienced changes in demand trends for some of our products. The pandemic interrupted many physician-patientphysician–patient interactions, which led to delays in diagnosisdiagnoses and treatmenttreatments, with varying degrees of impact across our portfolio. In general, sales of negatively affected products fell the most in the early inpart of the second quarter of 2020, with product demand beginning to recovershow some recovery in the latter weekssecond half of 2020. In the first half of the quarter. However, givencurrent year, demand has been recovering compared with pre-pandemic levels as patients return to doctors’ offices. The cumulative decrease in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which we expect to continue to impact our business during the second half of the year. Given the unpredictable nature of the pandemic, it is possible thatwe expect there could be ongoing intermittent disruptions in physician-patientphysician–patient interactions, going forward.and as a result, we continue to expect quarter-to-quarter variability. See Risk Factors in Part II, Item 1A. of this Form 10-Q.10-Q and Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2020, and in Part II, Item 1A. Risk Factors of our Quarterly Report on Form 10-Q for the period ended March 31, 2021.
In addition, other changes in the healthcare eco-systemecosystem have the potential to introduce variability into product sales trends. A number of patient insurance plans (commercial and governmental) have been requiredFor example, we expect changes in U.S. employment to cover or have voluntarily covered 90-day prescription fills for a number of medicines, including some of our products that are used in chronic conditions. In responselead to changes to the challenges the healthcare community is facing, weinsured population. Growth in numbers of Medicaid enrollees and uninsured individuals may have extended credit terms for a subset of customersnegative impact on product demand and our products.sales. Overall, there is increased uncertainty remains around the timing and magnitude of our sales during the COVID-19 pandemic.
Other revenues were relatively flatincreased for the three and six months ended June 30, 2020.2021, primarily driven by the sale of COVID-19 antibody material.
Operating expenses increased for the three and six months ended June 30, 2020,2021, primarily driven primarily by acquisitionIPR&D expense related expenses and commercial-related support for Otezla®, offset partially by a reductionto the bemarituzumab program acquired as part of certain expenses as a result of COVID-19. For the remainder of 2020, we expect to continue to see the effects of our acquisition of OtezlaFive Prime acquisition.
® on our operating expenses, including increases to Cost of sales, R&D, and Selling, general and administrative (SG&A) expenses.
Although changes in foreign currency exchange rates result in increases or decreases in our reported international product sales, the benefit or detriment that such movements have on our international product sales is partially offset partially by corresponding increases or decreases in our international operating expenses and our related foreign currency hedging activities. Our hedging activities seek to offset the impacts, both positive and negative, that foreign currency exchange rate changes may have on our net income by hedging our net foreign currency exposure, primarily with respect to product sales denominated in euros. The net impact from changes in foreign currency exchange rates was not material for the three and six months ended June 30, 20202021 and 2019.2020.
Results of operations
Product sales
Worldwide product sales were as follows (dollar amounts in millions):
| | | Three months ended June 30, | | | Six months ended June 30, | | | | Three months ended June 30, | | Six months ended June 30, | |
| | 2020 | | 2019 | | Change | | 2020 | | 2019 | | Change | | 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
ENBREL | ENBREL | $ | 1,246 | | | $ | 1,363 | | | (9) | % | | $ | 2,399 | | | $ | 2,514 | | | (5) | % | ENBREL | $ | 1,144 | | | $ | 1,246 | | | (8) | % | | $ | 2,068 | | | $ | 2,399 | | | (14) | % |
Prolia® | Prolia® | 659 | | | 698 | | | (6) | % | | 1,313 | | | 1,290 | | | 2 | % | Prolia® | 814 | | | 659 | | | 24 | % | | 1,572 | | | 1,313 | | | 20 | % |
Otezla® | | Otezla® | 534 | | | 561 | | | (5) | % | | 1,010 | | | 1,040 | | | (3) | % |
Neulasta® | Neulasta® | 593 | | | 824 | | | (28) | % | | 1,202 | | | 1,845 | | | (35) | % | Neulasta® | 486 | | | 593 | | | (18) | % | | 968 | | | 1,202 | | | (19) | % |
Otezla® | 561 | | | — | | | * | | 1,040 | | | — | | | * | |
XGEVA® | XGEVA® | 435 | | | 499 | | | (13) | % | | 916 | | | 970 | | | (6) | % | XGEVA® | 488 | | | 435 | | | 12 | % | | 956 | | | 916 | | | 4 | % |
Aranesp® | Aranesp® | 387 | | | 436 | | | (11) | % | | 809 | | | 850 | | | (5) | % | Aranesp® | 367 | | | 387 | | | (5) | % | | 722 | | | 809 | | | (11) | % |
Repatha® | | Repatha® | 286 | | | 200 | | | 43 | % | | 572 | | | 429 | | | 33 | % |
KYPROLIS® | KYPROLIS® | 253 | | | 267 | | | (5) | % | | 533 | | | 512 | | | 4 | % | KYPROLIS® | 280 | | | 253 | | | 11 | % | | 531 | | | 533 | | | — | % |
Repatha® | 200 | | | 152 | | | 32 | % | | 429 | | | 293 | | | 46 | % | |
Other products | Other products | 1,574 | | | 1,335 | | | 18 | % | | 3,161 | | | 2,586 | | | 22 | % | Other products | 1,715 | | | 1,574 | | | 9 | % | | 3,307 | | | 3,161 | | | 5 | % |
Total product sales | Total product sales | $ | 5,908 | | | $ | 5,574 | | | 6 | % | | $ | 11,802 | | | $ | 10,860 | | | 9 | % | Total product sales | $ | 6,114 | | | $ | 5,908 | | | 3 | % | | $ | 11,706 | | | $ | 11,802 | | | (1) | % |
* Change in excess of 100%.
Future sales of our products will depend in part on the factors discussed below and in the following sections of this report: (i) Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview and Selected Financial Information; and (ii) Part II, Item 1A. Risk Factors; and in the following sections of our Annual Report on Form 10-K for the year ended December 31, 2019:2020: (i) Item 1. Business—Marketing, Distribution and Selected Marketed Products, (ii) Item 1A. Risk Factors and (iii) Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Results of Operations—Product Sales, as well as in our Quarterly Report on Form 10-Q for the period ended March 31, 2020,2021, in (i) Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations—Product Sales; and (ii) Part II, Item 1A. Risk Factors.
ENBREL
Total ENBREL sales by geographic region were as follows (dollar amounts in millions):
| | | Three months ended June 30, | | | Six months ended June 30, | | | | Three months ended June 30, | | Six months ended June 30, | |
| | 2020 | | 2019 | | Change | | 2020 | | 2019 | | Change | | 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
ENBREL — U.S. | ENBREL — U.S. | $ | 1,213 | | | $ | 1,315 | | | (8) | % | | $ | 2,330 | | | $ | 2,421 | | | (4) | % | ENBREL — U.S. | $ | 1,113 | | | $ | 1,213 | | | (8) | % | | $ | 2,007 | | | $ | 2,330 | | | (14) | % |
ENBREL — Canada | ENBREL — Canada | 33 | | | 48 | | | (31) | % | | 69 | | | 93 | | | (26) | % | ENBREL — Canada | 31 | | | 33 | | | (6) | % | | 61 | | | 69 | | | (12) | % |
Total ENBREL | Total ENBREL | $ | 1,246 | | | $ | 1,363 | | | (9) | % | | $ | 2,399 | | | $ | 2,514 | | | (5) | % | Total ENBREL | $ | 1,144 | | | $ | 1,246 | | | (8) | % | | $ | 2,068 | | | $ | 2,399 | | | (14) | % |
The decrease in ENBREL sales for the three and six months ended June 30, 2020,2021, was primarily driven primarily by lower unit demand, offset partially by favorablenet selling price and unfavorable changes to estimated sales deductions. The decline was due, in part, to a reduction in the growth rate of the rheumatology market as a result of COVID-19. For the remainder of 2020,2021, we expect the trend of lower unit demandnet selling price declines to continue.continue compared with the prior year.
In April 2019, the FDA approved a second biosimilar version of ENBREL, and we
We are involved in patent litigationslitigation with the two companiesa company seeking to market theirits FDA-approved biosimilar versionsversion of ENBREL. See Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019,2020, and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in ourthis Quarterly Reports on Form 10-Q for the periods ended March 31, 2020 and June 30, 2020. Other companies are also developing proposed biosimilar versions of ENBREL.Report. Companies with approved biosimilar versions of ENBREL may seek to enter the U.S. market if we are not ultimately successful in our litigations, or even earlier.
Other companies are also developing proposed biosimilar versions of ENBREL.Prolia®
Total Prolia® sales by geographic region were as follows (dollar amounts in millions):
| | | Three months ended June 30, | | | Six months ended June 30, | | | | Three months ended June 30, | | Six months ended June 30, | |
| | 2020 | | 2019 | | Change | | 2020 | | 2019 | | Change | | 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
Prolia® — U.S. | Prolia® — U.S. | $ | 441 | | | $ | 458 | | | (4) | % | | $ | 863 | | | $ | 848 | | | 2 | % | Prolia® — U.S. | $ | 538 | | | $ | 441 | | | 22 | % | | $ | 1,039 | | | $ | 863 | | | 20 | % |
Prolia® — ROW | Prolia® — ROW | 218 | | | 240 | | | (9) | % | | 450 | | | 442 | | | 2 | % | Prolia® — ROW | 276 | | | 218 | | | 27 | % | | 533 | | | 450 | | | 18 | % |
Total Prolia® | Total Prolia® | $ | 659 | | | $ | 698 | | | (6) | % | | $ | 1,313 | | | $ | 1,290 | | | 2 | % | Total Prolia® | $ | 814 | | | $ | 659 | | | 24 | % | | $ | 1,572 | | | $ | 1,313 | | | 20 | % |
Prior to the COVID-19 pandemic, Prolia® had exhibited a historical sales pattern, with the first and third quarters of each year representing lower sales than the second and fourth quarters of a year. This is primarily due to Prolia®’s six-month dosing interval. However, disruptions in patient visits as a result of COVID-19 have affected demand during the first half of 2020. Although unit demand trends improved in May and June, there was an overall decrease in global Prolia® sales for the three months ended June 30, 2020, driven primarily by lower unit demand. The increase in global Prolia® sales for the three and six months ended June 30, 2020,2021, was primarily driven by higher unit demand. Although disruptions from the effects of the COVID-19 pandemic on new and repeat patient visits have decreased, we anticipate that such disruptions will continue to affect demand in 2021—but to a lesser degree than that experienced in 2020.
Otezla®
Total Otezla® sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | Six months ended June 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
Otezla® — U.S. | $ | 423 | | | $ | 464 | | | (9) | % | | $ | 789 | | | $ | 841 | | | (6) | % |
Otezla® — ROW | 111 | | | 97 | | | 14 | % | | 221 | | | 199 | | | 11 | % |
Total Otezla® | $ | 534 | | | $ | 561 | | | (5) | % | | $ | 1,010 | | | $ | 1,040 | | | (3) | % |
The decrease in global Otezla® sales for the three and six months ended June 30, 2021, was primarily driven by lower net selling price and unfavorable changes to estimated sales deductions, partially offset by higher unit demand.
For a lesser extent, unit demand, as volume growth trends were diminished by COVID-19. We expect continued variabilitydiscussion of ongoing litigation related to Otezla®, see Note 19, Contingencies and commitments, to the consolidated financial statements in unit demand trendsour Annual Report on Form 10-K for at least the remainder ofyear ended December 31, 2020, and Note 12, Contingencies and commitments, to the year.condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2021, and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in this Quarterly Report.
Neulasta®
Total Neulasta® sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | | | Six months ended June 30, | | | | |
| 2020 | | 2019 | | Change | | 2020 | | 2019 | | Change |
Neulasta®— U.S. | $ | 520 | | | $ | 719 | | | (28) | % | | $ | 1,054 | | | $ | 1,612 | | | (35) | % |
Neulasta®— ROW | 73 | | | 105 | | | (30) | % | | 148 | | | 233 | | | (36) | % |
Total Neulasta® | $ | 593 | | | $ | 824 | | | (28) | % | | $ | 1,202 | | | $ | 1,845 | | | (35) | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | Six months ended June 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
Neulasta® — U.S. | $ | 434 | | | $ | 520 | | | (17) | % | | $ | 855 | | | $ | 1,054 | | | (19) | % |
Neulasta® — ROW | 52 | | | 73 | | | (29) | % | | 113 | | | 148 | | | (24) | % |
Total Neulasta® | $ | 486 | | | $ | 593 | | | (18) | % | | $ | 968 | | | $ | 1,202 | | | (19) | % |
The decrease in global Neulasta® sales for the three and six months ended June 30, 2020,2021, was driven by the impact of biosimilar competition on net selling price and unit demand, partially offset partially by increased prescribing of the Neulasta® Onpro® kit supported by the recently revised treatment recommendations from the National Comprehensive Cancer Network (NCCN) in responsefavorable changes to COVID-19 that recommend increased use of long-acting granulocyte colony-stimulating factors (G-CSFs) in intermediate risk febrile neutropenia cancer patients. Neulasta®estimated sales included a $98 million order from the U.S. government in the first quarter of 2019.deductions.
Increased competition in the United States and Europe as a result of launches of biosimilar versions of Neulasta®, which has had and will continue to have a materialsignificant adverse impact on sales.brand sales, including additional net price erosion. We also expect anotherother biosimilar versionversions to be approved in the future. For a discussion of ongoing patent litigations related to these and other biosimilars, see Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019,2020, Note 12, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2021, and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in ourthis Quarterly Reports on Form 10-Q for the periods ended March 31, 2020 and June 30, 2020.Report.
OtezlaXGEVA®
Total OtezlaXGEVA® sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | | | Six months ended June 30, | | | | |
| 2020 | | 2019 | | Change | | 2020 | | 2019 | | Change |
Otezla® — U.S. | $ | 464 | | | $ | — | | | * | | $ | 841 | | | $ | — | | | * |
Otezla® — ROW | 97 | | | — | | | * | | 199 | | | — | | | * |
Total Otezla® | $ | 561 | | | $ | — | | | * | | $ | 1,040 | | | $ | — | | | * |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | Six months ended June 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
XGEVA® — U.S. | $ | 355 | | | $ | 318 | | | 12 | % | | $ | 689 | | | $ | 673 | | | 2 | % |
XGEVA® — ROW | 133 | | | 117 | | | 14 | % | | 267 | | | 243 | | | 10 | % |
Total XGEVA® | $ | 488 | | | $ | 435 | | | 12 | % | | $ | 956 | | | $ | 916 | | | 4 | % |
* ChangeThe increase in excess of 100%.
global XGEVAOtezla® was acquired on November 21, 2019 and generated $561 million and $1.0 billion in sales for the three andmonths ended June 30, 2021, was driven by higher unit demand. The increase in global XGEVA® sales for the six months ended June 30, 2020, respectively.2021, was primarily driven by higher unit demand, partially offset by lower net selling price.
XGEVA®®
Total XGEVAAranesp® sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | | | Six months ended June 30, | | | | |
| 2020 | | 2019 | | Change | | 2020 | | 2019 | | Change |
XGEVA® — U.S. | $ | 318 | | | $ | 379 | | | (16) | % | | $ | 673 | | | $ | 735 | | | (8) | % |
XGEVA® — ROW | 117 | | | 120 | | | (3) | % | | 243 | | | 235 | | | 3 | % |
Total XGEVA® | $ | 435 | | | $ | 499 | | | (13) | % | | $ | 916 | | | $ | 970 | | | (6) | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | Six months ended June 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
Aranesp® — U.S. | $ | 135 | | | $ | 156 | | | (13) | % | | $ | 260 | | | $ | 331 | | | (21) | % |
Aranesp® — ROW | 232 | | | 231 | | | — | % | | 462 | | | 478 | | | (3) | % |
Total Aranesp® | $ | 367 | | | $ | 387 | | | (5) | % | | $ | 722 | | | $ | 809 | | | (11) | % |
The decrease in global XGEVAAranesp®sales for the three andmonths ended June 30, 2021, was driven by lower net selling price due to competition. The decrease in global Aranesp® sales for the six months ended June 30, 2020,2021, was primarily driven primarily by lower net selling price and unit demand as a result of the COVID-19 pandemic, including a decrease in patient visits and treatment recommendations from the NCCN in responsedue to COVID-19 to prioritize primary cancer treatments over bone targeting agents.competition.
Aranesp® continues to face competition from a long-acting erythropoiesis-stimulating agent (ESA) andalso faces competition from a biosimilar version of EPOGEN®, which will continue to impact sales in the future.
Repatha®
Total AranespRepatha® sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | | | Six months ended June 30, | | | | |
| 2020 | | 2019 | | Change | | 2020 | | 2019 | | Change |
Aranesp® — U.S. | $ | 156 | | | $ | 192 | | | (19) | % | | $ | 331 | | | $ | 374 | | | (11) | % |
Aranesp® — ROW | 231 | | | 244 | | | (5) | % | | 478 | | | 476 | | | — | % |
Total Aranesp® | $ | 387 | | | $ | 436 | | | (11) | % | | $ | 809 | | | $ | 850 | | | (5) | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | Six months ended June 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
Repatha® — U.S. | $ | 143 | | | $ | 115 | | | 24 | % | | $ | 282 | | | $ | 239 | | | 18 | % |
Repatha® — ROW | 143 | | | 85 | | | 68 | % | | 290 | | | 190 | | | 53 | % |
Total Repatha® | $ | 286 | | | $ | 200 | | | 43 | % | | $ | 572 | | | $ | 429 | | | 33 | % |
The decreaseincrease in global AranespRepatha® sales for the three months ended June 30, 2020, was driven by a decline in net selling price and lower unit demand. The decrease in global Aranesp® sales for the six months ended June 30, 2020,2021, was driven primarily by a decline inhigher unit demand, partially offset by lower net selling price. We expect further reduction in the net selling price on a sequential basis as the number of Medicare Part D patients receiving Repatha® increases.
faces competition fromFor a long-acting erythropoiesis-stimulating agent (ESA). Aranesp®also faces competition from a biosimilar versiondiscussion of EPOGENongoing litigation related to Repatha®. For, see Note 19, Contingencies and commitments, to the remainder of 2020, we expect salesconsolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020; Note 12, Contingencies and commitments, to decline at a faster rate thanthe condensed consolidated financial statements for the period ended March 31, 2021; and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in 2019 due to short- and long-acting competition.this Quarterly Report.
KYPROLIS®
Total KYPROLIS® sales by geographic region were as follows (dollar amounts in millions):
| | | Three months ended June 30, | | | Six months ended June 30, | | | | Three months ended June 30, | | Six months ended June 30, | |
| | 2020 | | 2019 | | Change | | 2020 | | 2019 | | Change | | 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
KYPROLIS® — U.S. | KYPROLIS® — U.S. | $ | 167 | | | $ | 166 | | | 1 | % | | $ | 354 | | | $ | 320 | | | 11 | % | KYPROLIS® — U.S. | $ | 190 | | | $ | 167 | | | 14 | % | | $ | 349 | | | $ | 354 | | | (1) | % |
KYPROLIS® — ROW | KYPROLIS® — ROW | 86 | | | 101 | | | (15) | % | | 179 | | | 192 | | | (7) | % | KYPROLIS® — ROW | 90 | | | 86 | | | 5 | % | | 182 | | | 179 | | | 2 | % |
Total KYPROLIS® | Total KYPROLIS® | $ | 253 | | | $ | 267 | | | (5) | % | | $ | 533 | | | $ | 512 | | | 4 | % | Total KYPROLIS® | $ | 280 | | | $ | 253 | | | 11 | % | | $ | 531 | | | $ | 533 | | | — | % |
The decreaseincrease in global KYPROLIS® sales for the three months ended June 30, 2020,2021, was primarily driven by lowerhigher unit demand as a result of the COVID-19 pandemic. Theand an increase in globalnet selling price. Global KYPROLIS® sales for the six months ended June 30, 2020, was driven by an increase in net selling price and favorable changes to inventory.2021 remained relatively flat compared with the prior period.
We are engaged in litigation with two related companies that are challenging certain of our material patents related to KYPROLIS® and that are seeking to market generic carfilzomib products. Separately, we have entered into confidential settlement agreements with other companies developing generic carfilzomib products, and the court has entered consent judgments enjoining those companies from infringing certain of our patents, subject to terms of the confidential settlement agreements. See Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019,2020; Note 12, Contingencies and commitments, to the condensed consolidated financial statements for the period ended March 31, 2021, and Note 13,13; Contingencies and commitments, to the condensed consolidated financial statements in ourthis Quarterly Reports on Form 10-Q for the periods ended March 31, 2020 and June 30, 2020.Report. The FDA has reported that it has finally approvedgranted tentative or final approval of ANDAs filed by two companies for generic carfilzomib products and tentatively approved ANDAs filed by two othera number of companies. The date of final approval of those ANDAs for generic carfilzomib products is governed by the Hatch-Waxman Act and any applicable settlement agreements between the parties.
Repatha®
Total Repatha® sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | | | Six months ended June 30, | | | | |
| 2020 | | 2019 | | Change | | 2020 | | 2019 | | Change |
Repatha® — U.S. | $ | 115 | | | $ | 91 | | | 26 | % | | $ | 239 | | | $ | 174 | | | 37 | % |
Repatha® — ROW | 85 | | | 61 | | | 39 | % | | 190 | | | 119 | | | 60 | % |
Total Repatha® | $ | 200 | | | $ | 152 | | | 32 | % | | $ | 429 | | | $ | 293 | | | 46 | % |
The increase in global Repatha® sales for the three and six months ended June 30, 2020, was driven primarily by higher unit demand, offset partially by lower net selling price. The pace of new prescription growth slowed during the second quarter as a result of the COVID-19 pandemic.
Other products
Other product sales by geographic region were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | | | Six months ended June 30, | | | | |
| 2020 | | 2019 | | Change | | 2020 | | 2019 | | Change |
Nplate®— U.S. | $ | 107 | | | $ | 122 | | | (12) | % | | $ | 234 | | | $ | 236 | | | (1) | % |
Nplate®— ROW | 86 | | | 79 | | | 9 | % | | 177 | | | 154 | | | 15 | % |
Vectibix®— U.S. | 79 | | | 79 | | | — | % | | 159 | | | 157 | | | 1 | % |
Vectibix®— ROW | 116 | | | 117 | | | (1) | % | | 238 | | | 209 | | | 14 | % |
Parsabiv® — U.S. | 160 | | | 148 | | | 8 | % | | 306 | | | 257 | | | 19 | % |
Parsabiv® — ROW | 26 | | | 20 | | | 30 | % | | 55 | | | 37 | | | 49 | % |
EPOGEN® — U.S. | 161 | | | 223 | | | (28) | % | | 316 | | | 442 | | | (29) | % |
MVASI®— U.S. | 149 | | | — | | | * | | 257 | | | — | | | * |
MVASI®— ROW | 23 | | | — | | | * | | 30 | | | — | | | * |
KANJINTI®— U.S. | 101 | | | — | | | * | | 197 | | | — | | | * |
KANJINTI®— ROW | 22 | | | 30 | | | (27) | % | | 45 | | | 54 | | | (17) | % |
Sensipar® — U.S. | 32 | | | 43 | | | (26) | % | | 74 | | | 178 | | | (58) | % |
Sensipar®/Mimpara® — ROW | 49 | | | 79 | | | (38) | % | | 130 | | | 157 | | | (17) | % |
EVENITY® — U.S. | 40 | | | 3 | | | * | | 77 | | | 3 | | | * |
EVENITY®— ROW | 61 | | | 25 | | | * | | 124 | | | 42 | | | * |
BLINCYTO® — U.S. | 56 | | | 39 | | | 44 | % | | 113 | | | 79 | | | 43 | % |
BLINCYTO® — ROW | 37 | | | 39 | | | (5) | % | | 74 | | | 68 | | | 9 | % |
Aimovig® — U.S. | 98 | | | 83 | | | 18 | % | | 169 | | | 142 | | | 19 | % |
AMGEVITATM — ROW | 62 | | | 52 | | | 19 | % | | 148 | | | 83 | | | 78 | % |
NEUPOGEN®— U.S. | 28 | | | 55 | | | (49) | % | | 73 | | | 105 | | | (30) | % |
NEUPOGEN®— ROW | 21 | | | 20 | | | 5 | % | | 41 | | | 43 | | | (5) | % |
Other — U.S. | 23 | | | 27 | | | (15) | % | | 47 | | | 50 | | | (6) | % |
Other — ROW | 37 | | | 52 | | | (29) | % | | 77 | | | 90 | | | (14) | % |
Total other products | $ | 1,574 | | | $ | 1,335 | | | 18 | % | | $ | 3,161 | | | $ | 2,586 | | | 22 | % |
Total U.S. — other products | $ | 1,034 | | | $ | 822 | | | 26 | % | | $ | 2,022 | | | $ | 1,649 | | | 23 | % |
Total ROW — other products | 540 | | | 513 | | | 5 | % | | 1,139 | | | 937 | | | 22 | % |
Total other products | $ | 1,574 | | | $ | 1,335 | | | 18 | % | | $ | 3,161 | | | $ | 2,586 | | | 22 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | Six months ended June 30, | | |
| 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
MVASI® — U.S. | $ | 206 | | | $ | 149 | | | 38 | % | | $ | 430 | | | $ | 257 | | | 67 | % |
MVASI® — ROW | 88 | | | 23 | | | * | | 158 | | | 30 | | | * |
Nplate® — U.S. | 136 | | | 107 | | | 27 | % | | 248 | | | 234 | | | 6 | % |
Nplate® — ROW | 109 | | | 86 | | | 27 | % | | 224 | | | 177 | | | 27 | % |
Vectibix® — U.S. | 92 | | | 79 | | | 16 | % | | 171 | | | 159 | | | 8 | % |
Vectibix®— ROW | 147 | | | 116 | | | 27 | % | | 259 | | | 238 | | | 9 | % |
KANJINTI® — U.S. | 132 | | | 101 | | | 31 | % | | 262 | | | 197 | | | 33 | % |
KANJINTI® — ROW | 24 | | | 22 | | | 9 | % | | 55 | | | 45 | | | 22 | % |
EPOGEN® — U.S. | 130 | | | 161 | | | (19) | % | | 255 | | | 316 | | | (19) | % |
EVENITY® — U.S. | 79 | | | 40 | | | 98 | % | | 136 | | | 77 | | | 77 | % |
EVENITY®— ROW | 52 | | | 61 | | | (15) | % | | 102 | | | 124 | | | (18) | % |
BLINCYTO® — U.S. | 62 | | | 56 | | | 11 | % | | 127 | | | 113 | | | 12 | % |
BLINCYTO® — ROW | 46 | | | 37 | | | 24 | % | | 88 | | | 74 | | | 19 | % |
AMGEVITA™ — ROW | 107 | | | 62 | | | 73 | % | | 213 | | | 148 | | | 44 | % |
Parsabiv® — U.S. | 37 | | | 160 | | | (77) | % | | 83 | | | 306 | | | (73) | % |
Parsabiv® — ROW | 34 | | | 26 | | | 31 | % | | 67 | | | 55 | | | 22 | % |
Aimovig® — U.S. | 82 | | | 98 | | | (16) | % | | 148 | | | 169 | | | (12) | % |
NEUPOGEN® — U.S. | 36 | | | 28 | | | 29 | % | | 54 | | | 73 | | | (26) | % |
NEUPOGEN® — ROW | 15 | | | 21 | | | (29) | % | | 31 | | | 41 | | | (24) | % |
Sensipar® — U.S. | 4 | | | 32 | | | (88) | % | | 4 | | | 74 | | | (95) | % |
Sensipar®/Mimpara™ — ROW | 20 | | | 49 | | | (59) | % | | 43 | | | 130 | | | (67) | % |
Other — U.S. | 47 | | | 23 | | | * | | 89 | | | 47 | | | 89 | % |
Other — ROW | 30 | | | 37 | | | (19) | % | | 60 | | | 77 | | | (22) | % |
Total other products | $ | 1,715 | | | $ | 1,574 | | | 9 | % | | $ | 3,307 | | | $ | 3,161 | | | 5 | % |
Total U.S. — other products | $ | 1,043 | | | $ | 1,034 | | | 1 | % | | $ | 2,007 | | | $ | 2,022 | | | (1) | % |
Total ROW — other products | 672 | | | 540 | | | 24 | % | | 1,300 | | | 1,139 | | | 14 | % |
Total other products | $ | 1,715 | | | $ | 1,574 | | | 9 | % | | $ | 3,307 | | | $ | 3,161 | | | 5 | % |
* Change in excess of 100%.
Operating expenses
Operating expenses were as follows (dollar amounts in millions):
| | | Three months ended June 30, | | | Six months ended June 30, | | | | Three months ended June 30, | | Six months ended June 30, | |
| | 2020 | | 2019 | | Change | | 2020 | | 2019 | | Change | | 2021 | | 2020 | | Change | | 2021 | | 2020 | | Change |
Operating expenses: | Operating expenses: | | | | | | | | | | | | Operating expenses: | | | | | | | | | | | |
Cost of sales | Cost of sales | $ | 1,488 | | | $ | 1,012 | | | 47 | % | | $ | 3,001 | | | $ | 2,067 | | | 45 | % | Cost of sales | $ | 1,637 | | | $ | 1,488 | | | 10 | % | | $ | 3,127 | | | $ | 3,001 | | | 4 | % |
% of product sales | % of product sales | 25.2 | % | | 18.2 | % | | 25.4 | % | | 19.0 | % | | % of product sales | 26.8 | % | | 25.2 | % | | 26.7 | % | | 25.4 | % | |
% of total revenues | % of total revenues | 24.0 | % | | 17.2 | % | | 24.3 | % | | 18.1 | % | | % of total revenues | 25.1 | % | | 24.0 | % | | 25.2 | % | | 24.3 | % | |
Research and development | Research and development | $ | 964 | | | $ | 924 | | | 4 | % | | $ | 1,916 | | | $ | 1,803 | | | 6 | % | Research and development | $ | 1,082 | | | $ | 964 | | | 12 | % | | $ | 2,049 | | | $ | 1,916 | | | 7 | % |
% of product sales | % of product sales | 16.3 | % | | 16.6 | % | | 16.2 | % | | 16.6 | % | | % of product sales | 17.7 | % | | 16.3 | % | | 17.5 | % | | 16.2 | % | |
% of total revenues | % of total revenues | 15.5 | % | | 15.7 | % | | 15.5 | % | | 15.8 | % | | % of total revenues | 16.6 | % | | 15.5 | % | | 16.5 | % | | 15.5 | % | |
Acquired in-process research and development | | Acquired in-process research and development | $ | 1,505 | | | $ | — | | | NM | | $ | 1,505 | | | $ | — | | | NM |
% of product sales | | % of product sales | 24.6 | % | | — | % | | 12.9 | % | | — | % | |
% of total revenues | | % of total revenues | 23.1 | % | | — | % | | 12.1 | % | | — | % | |
Selling, general and administrative | Selling, general and administrative | $ | 1,295 | | | $ | 1,260 | | | 3 | % | | $ | 2,611 | | | $ | 2,414 | | | 8 | % | Selling, general and administrative | $ | 1,384 | | | $ | 1,295 | | | 7 | % | | $ | 2,638 | | | $ | 2,611 | | | 1 | % |
% of product sales | % of product sales | 21.9 | % | | 22.6 | % | | 22.1 | % | | 22.2 | % | | % of product sales | 22.6 | % | | 21.9 | % | | 22.5 | % | | 22.1 | % | |
% of total revenues | % of total revenues | 20.9 | % | | 21.5 | % | | 21.1 | % | | 21.1 | % | | % of total revenues | 21.2 | % | | 20.9 | % | | 21.2 | % | | 21.1 | % | |
Other | Other | $ | 136 | | | $ | (3) | | | * | | $ | 161 | | | $ | (6) | | | * | Other | $ | 90 | | | $ | 136 | | | (34) | % | | $ | 151 | | | $ | 161 | | | (6) | % |
NM - Not meaningful
* Change in excess of 100%.
Cost of sales
Cost of sales increased to 24.0%25.1% and 24.3%25.2% of total revenues for the three and six months ended June 30, 2020,2021, respectively, primarily driven by the amortization of expenses related to our acquisition of Otezla®unfavorable product mix and by the benefit of Hurricane Maria insurance proceeds in the prior year,higher profit share and royalty expenses, partially offset partially by lower manufacturing costs.amortization expense from acquisition-related assets.
Research and development
The increases in R&D expense for the three and six months ended June 30, 2020,2021, were primarily driven by higher research and early pipeline spend and late-stage program support, including AMG 510 (sotorasib) and biosimilar programs, and higher marketed-product support for Otezla®, offset partially by recoveries from our collaboration with BeiGene that reduced expenses in late-stage program support and inrecent business development activities.
Acquired in-process research and early pipeline.development
Selling, general and administrative
The increases in SG&AAcquired IPR&D expense for the three and six months ended June 30, 2020,2021, is related to the bemarituzumab program acquired as part of the Five Prime acquisition.
Selling, general and administrative
The increase in Selling, general and administrative (SG&A) expense for the three months ended June 30, 2021, was driven primarily by Otezla® commercial- and acquisition-related expenses,higher marketed-product support.
The increase in SG&A expense for the six months ended June 30, 2021, was driven by higher marketed-product support, partially offset partially by lower spend mainly duefavorable adjustments to the COVID-19 pandemic.estimated U.S. healthcare reform federal excise fees.
Other
Other operating expenses for the three and six months ended June 30, 2021, consisted primarily of expenses related to cost savings initiatives. Other operating expenses for the three and six months ended June 30, 2020, consisted of legal settlement expenses. Other operating expenses for the three and six months ended June 30, 2019, included changes in the fair values of contingent consideration liabilities related to business combinations.
See the Overview and Selected financial information sections above for discussion of impacts to operating expenses from the COVID-19 pandemic.
Nonoperating expense/income and income taxes
Nonoperating expense/income and income taxes were as follows (dollar amounts in millions):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | | | Six months ended June 30, | | |
| 2020 | | 2019 | | 2020 | | 2019 |
Interest expense, net | $ | 296 | | | $ | 332 | | | $ | 642 | | | $ | 675 | |
Interest and other income, net | $ | 3 | | | $ | 218 | | | $ | 14 | | | $ | 403 | |
Provision for income taxes | $ | 227 | | | $ | 385 | | | $ | 422 | | | $ | 707 | |
Effective tax rate | 11.2 | % | | 15.0 | % | | 10.4 | % | | 14.5 | % |
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | Six months ended June 30, |
| 2021 | | 2020 | | 2021 | | 2020 |
Interest expense, net | $ | (281) | | | $ | (296) | | | $ | (566) | | | $ | (642) | |
Other income, net | $ | 11 | | | $ | 3 | | | $ | 24 | | | $ | 14 | |
Provision for income taxes | $ | 94 | | | $ | 227 | | | $ | 305 | | | $ | 422 | |
Effective tax rate | 16.8 | % | | 11.2 | % | | 12.6 | % | | 10.4 | % |
Interest expense, net
The decrease in Interest expense, net, for the three months ended June 30, 2020,2021, was primarily due primarily to lower LIBOR rates in the current year period on debt for which we effectively pay a variable rate of interest through the use of interest rate swaps, partially offset partially by a higher averageoverall debt balance.outstanding in the current year period.
The decrease in Interest expense, net, for the six months ended June 30, 2020,2021, was primarily due primarily to net costs associated with the early retirement of debt in the first quarter of the prior year and lower LIBOR rates in the current year period on debt for which we effectively pay a variable rate of interest through the use of interest rate swaps, partially offset partially by net costs associated withhigher overall debt outstanding in the early retirement of debt.current year period.
Interest and otherOther income, net
The decreaseincrease in Interest and otherOther income, net, for the three andmonths ended June 30, 2021, was primarily due to lower losses in connection with our BeiGene investment, partially offset by gains recognized on our investments in limited partnerships in the prior year period.
The increase in Other income, net, for the six months ended June 30, 2020,2021, was primarily due primarily to reduced interest income as a result of lower average cash balances and a declinehigher gains recognized on our investments in interest yields.limited partnerships in the current year, partially offset by gains recognized in the prior year period on our interest-bearing securities.
Income taxes
The decreaseincrease in our effective tax rate for the three and six months ended June 30, 2020,2021, was primarily due primarily to net favorable itemsthe non-deductible IPR&D expense arising from the acquisition of Five Prime.
The Administration and Congress are considering significant changes to existing tax law, including an increase in the quarter, amortization related tocorporate tax rate and the Otezla® acquisitiontax rate on foreign earnings. These changes could substantially increase U.S. taxation of our operations both in and changes in jurisdictional mix of earnings.
On March 27, 2020, in response to the COVID-19 pandemic, the president ofoutside the United States, signedincluding the Coronavirus Aid, Relief,U.S. territory of Puerto Rico. In addition, the Organization for Economic Co-operation and Economic Security (CARES) Act, which provides additional economic stimulusDevelopment (OECD) recently reached agreement to address the impactalign countries on a minimum corporate tax rate and an expansion of the COVID-19 pandemic. We do not expect there to be any significant benefit to our incometaxing rights of market countries. If enacted, this agreement could result in tax provision as a result ofincreases in both the CARES Act,United States and we continue to monitor for any potential tax legislation related to the COVID-19 pandemic.foreign jurisdictions.
As previously disclosed,In 2017, we received an RAR and a modified RAR from the IRS for the years 2010, 2011 and 2012. The RAR proposes to make2012 proposing significant adjustments that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. In November 2017, we received a modified RAR that revised the IRS’s calculations but continued to propose substantial adjustments. We disagree with the proposed adjustments and calculations and are pursuing resolution with the IRS administrative appeals office, which currently has jurisdiction over the matter. If we are unable to reach resolution, we will vigorously contest the proposed adjustments through the judicial process. In addition, as previously reported, in April 2020, we received draft NOPAs and subsequently in May 2020, we received an RAR from the IRS for the years 2013, 2014 and 2015, which are similar to the proposed adjustments for the years 2010, 2011 and 2012 that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued a resolution with the IRS administrative appeals office. As previously reported, we were unable to reach resolution with the IRS appeals office. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Notices for 2010, 2011 and 2012 that we received in May and July 2021. The duplicate Notices seek to increase our U.S. taxable income by an amount that would result in additional federal tax of approximately $3.6 billion, plus interest. Any additional tax that could be imposed would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings. In any event, we firmly believe that the IRS’s positions in the Notices are without merit and we will vigorously contest the Notices through the judicial process.
In addition, in 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015 also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico, similar to those proposed for the years 2010, 2011 and 2012. We disagree with the proposed adjustments and calculations and will pursueare pursuing resolution with the IRS administrative appeals office. We are currently under examination by the IRS for the years 2016, 2017 and 2018. We are also currently under examination by a number of other state and foreign tax jurisdictions.
Final resolution of these complex matters is not likely within the next 12 months and could have a material impact on our condensed consolidated financial statements.months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate resolutionoutcome of any tax matters may result in payments substantially greater or less than amounts accrued.accrued as noted above and could have a material adverse impact on our condensed consolidated financial statements.
See Note 3,4, Income taxes, to the condensed consolidated financial statements for further discussion.
Financial condition, liquidity and capital resources
Selected financial data waswere as follows (in millions):
| | | June 30, 2020 | | December 31, 2019 | | June 30, 2021 | | December 31, 2020 |
Cash, cash equivalents and marketable securities | Cash, cash equivalents and marketable securities | $ | 11,421 | | | $ | 8,911 | | Cash, cash equivalents and marketable securities | $ | 8,082 | | | $ | 10,647 | |
Total assets | Total assets | $ | 65,011 | | | $ | 59,707 | | Total assets | $ | 59,773 | | | $ | 62,948 | |
Current portion of long-term debt | Current portion of long-term debt | $ | 91 | | | $ | 2,953 | | Current portion of long-term debt | $ | 4,324 | | | $ | 91 | |
Long-term debt | Long-term debt | $ | 34,133 | | | $ | 26,950 | | Long-term debt | $ | 28,458 | | | $ | 32,895 | |
Stockholders’ equity | Stockholders’ equity | $ | 10,659 | | | $ | 9,673 | | Stockholders’ equity | $ | 8,247 | | | $ | 9,409 | |
Cash, cash equivalents and marketable securities
We have global access to our $11.4 billionOur balance of cash, cash equivalents and marketable securities.securities was $8.1 billion at June 30, 2021. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.
Capital allocation
Consistent with the objective to optimize our capital structure, we deploy our accumulated cash balances in a strategic manner and consider a number of alternatives, including strategic transactions (including those that expand our portfolio of products in areas of therapeutic interest), repayment of debt, payment of dividends and stock repurchases.
We intend to continue to invest in our business while returning capital to stockholders through the payment of cash dividends and stock repurchases, thereby reflecting our confidence in the future cash flows of our business.business and our desire to optimize our cost of capital. The timing and amount of future dividends and stock repurchases will vary based on a number of factors, including future capital requirements for strategic transactions, availability of financing on acceptable terms, debt service requirements, our credit rating, changes to applicable tax laws or corporate laws, changes to our business model and periodic determination by our Board of Directors that cash dividends and/or stock repurchases are in the best interests of stockholders and are in compliance with applicable laws and the Company’s agreements. In addition, the timing and amount of stock repurchases may also be affected by our overall level of cash, stock price and blackout periods, during which we are restricted from repurchasing stock. The manner of stock repurchases may include private block purchases, tender offers and market transactions.
In March 20202021 and December 2019,2020, the Board of Directors declared a quarterly cash dividendsdividend of $1.60$1.76 per share of common stock, which were paid on June 8, 20202021 and March 6, 2020,8, 2021, respectively, an increase of 10% over the quarterly cash dividend paid in each quarter of 2019.in 2020. In July 2020,2021, the Board of Directors declared a quarterly dividend of $1.60$1.76 per share, which will be paid on September 8, 2020.2021.
We have also returned capital to stockholders through our stock repurchase program. During the six months ended June 30, 2020,2021, we executed trades to repurchase $1.5$2.5 billion of common stock. As of June 30, 2020, $4.92021, $3.9 billion of authorization remained available under our stock repurchase program.
As a result of stock repurchases and quarterly dividend payments, we have an accumulated deficit as of June 30, 20202021 and December 31, 2019.2020. Our accumulated deficit is not expectedanticipated to affect our future ability to operate, repurchase stock, pay dividends or repay our debt given our continuing profitability and strong financial position.
We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, to meet capital expenditure and debt service requirements, to fund our plans to pay dividends and repurchase stock and to fulfill other business initiatives we planexpect to strategically pursue, including acquisitions and licensing activities. We anticipate that our liquidity needs can be met through a variety of sources, including cash provided by operating activities, sales of marketable securities, equity markets and borrowings through(including commercial paper and/or syndicated credit facilities and access to other domestic and foreign debt markets and equity markets. For example, we issued $5.0 billion of long-term debt during the three months ended March 31, 2020, to payoff long-term debt maturing in the near term, and $4.0 billion of long-term debt during three months ended June 30, 2020, for general corporate purposes, including, enhancing our working capital position.markets). See our Annual Report on Form 10-K for the year ended December 31, 2019,2020, Part I, Item 1A. Risk Factors—Global economic conditions may negatively affect us and may magnify certain risks that affect our business.
Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant whichthat requires that weus to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of June 30, 2020.2021.
Cash flows
Our summarized cash flow activity was as follows (in millions):
| | | | | | | | | | | |
| Six months ended June 30, | | |
| 2020 | | 2019 |
Net cash provided by operating activities | $ | 4,976 | | | $ | 3,259 | |
Net cash (used in) provided by investing activities | $ | (2,389) | | | $ | 6,300 | |
Net cash provided by (used in) financing activities | $ | 521 | | | $ | (10,979) | |
| | | | | | | | | | | |
| Six months ended June 30, |
| 2021 | | 2020 |
Net cash provided by operating activities | $ | 4,035 | | | $ | 4,976 | |
Net cash provided by (used in) investing activities | $ | 890 | | | $ | (2,389) | |
Net cash (used in) provided by financing activities | $ | (4,561) | | | $ | 521 | |
Operating
Cash provided by operating activities is expected to be our primary recurring source of funds. Cash provided by operating activities during the six months ended June 30, 2020, increased compared with2021, decreased primarily due to a difference in the same periodtiming of payments to tax authorities and the monetization of interest rate swaps in the prior year, due primarily to the favorable timing of repatriation and federal tax payments and current year monetization of interest rate swap contracts along with the timing of other working capital items,partially offset partially due toby the timing of collections from customers, in part, as a result of our recent the impact of the Otezla® acquisition of Otezla®.in the prior year.
Investing
Cash provided by investing activities during the six months ended June 30, 2021, was primarily due to net cash inflows related to marketable securities of $2.9 billion, partially offset by the acquisition of Five Prime for $1.6 billion and capital expenditures of $351 million. Cash used in investing activities during the six months ended June 30, 2020, was primarily due primarily to our $2.6 billion equity investment in BeiGene and capital expenditures of $300 million, partially offset by net cash inflows related to marketable securities of $607 million. We currently estimate 2021 spending on capital projects to be approximately $900 million.
Financing
Cash provided by investingused in financing activities during the six months ended June 30, 2019,2021, was primarily due primarily to net cash inflows relatedpayments to marketable securitiesrepurchase our common stock of $6.6$2.5 billion and the payment of dividends of $2.0 billion. Capital expenditures for the six months ended June 30, 2020 and 2019, were $300 million and $260 million, respectively. We currently estimate 2020 spending on capital projects to be approximately $600 million.
Financing
Cash provided by financing activities during the six months ended June 30, 2020, was primarily due primarily to net proceeds from the issuance of debt of $9.0 billion, partially offset substantially by the repayment of debt of $5.0 billion, the payment of dividends of $1.9 billion and payments to repurchase our common stock of $1.5 billion. Cash used in financing activities during the six months ended June 30, 2019, was due primarily to payments to repurchase our common stock of $5.4 billion, repayment of debt of $3.7 billion and payment of dividends of $1.8 billion. See Note 9, Financing arrangements, and Note 10, Stockholders’ equity, to the condensed consolidated financial statements for further discussion.
Critical accounting policies
The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2019.
During the six months ended June 30, 2020, our critical accounting policies were changed to include our assessment of impairment of equity method investments. We review the carrying value of our equity method investments whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We record impairment losses on our equity method investments if we deem the impairment to be other-than-temporary. We deem an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time and the extent to which the fair value is below the carrying value, volatility of the security price, the financial condition of the issuer, changes in technology that may impair the earnings potential of the investment and our intent and ability to retain the investment to allow for a recovery in fair value. We believe our judgments used in assessing impairment of equity method investments are based on reasonable assumptions given the facts and circumstances as of the related dates of the assessments.2020.
| | | | | |
Item 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
Information about our market risk is disclosed in Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2019,2020, and is incorporated herein by reference. Except as noteddiscussed below, there have beenwere no material changes during the six months ended June 30, 2020,2021, to the information provided in Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2019.2020.
DuringInterest rate sensitive financial instruments
To achieve a desired mix of fixed and floating interest rate debt, we entered into additional interest rate swap contracts with an aggregate notional amount of $1.5 billion during the sixthree months ended June 30, 2020, we issued $9.0 billion in long-term debt with a weighted-average maturity2021. As of approximately 16 years and redeemed/repaid approximately $5.0June 30, 2021, an aggregate notional amount of $7.4 billion of debt, all with maturitiesinterest rate swap contracts was outstanding. These interest rate swap contracts effectively converted a fixed interest rate coupon to a floating-rate LIBOR-based coupon over the life of less than two years. These changes increased the sensitivity of fluctuations in fair value of our outstanding long-term debt resulting from changes in market interest rates.respective notes. A hypothetical 100 basis point decreaseincrease in interest rates relative to interest rates at June 30, 2020 and December 31, 2019,2021, would have resulted in increasesa reduction in fair value of $4.5 billion and $3.0 billion, respectively, inapproximately $390 million on our interest rate swap contracts on that date. The analysis for the aggregate fair values of our outstanding long-term debt on each of these dates. These amounts dointerest rate swap contracts does not consider the impact that hypothetical changes in interest rates would have on our associated interest rate swap and cross-currency swap contracts.
During the six months ended June 30, 2020, we terminated interest rate swaps with an aggregate notional amountrelated fair value of $5.2 billion with respectdebt that these interest-rate-sensitive instruments were designed to certain of our long-term debt, which resulted in the receipt of $576 million of cash and reduced counterparty credit risk. Immediately following termination of these contracts, we entered into new interest rate swap agreements at then-current interest rates on the same $5.2 billion principal amount of notes. See Note 9, Financing arrangements, and Note 12, Derivative instruments, to the condensed consolidated financial statements for further discussion.offset.
| | | | | |
Item 4. | CONTROLS AND PROCEDURES |
We maintain “disclosure controls and procedures,” as such term is defined under the Securities Exchange Act Rule 13a-15(e), that are designed to ensure that information required to be disclosed in Amgen’s Exchange Act reports isgets recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information isgets accumulated and communicated to Amgen’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to facilitate timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, Amgen’s management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, Amgen’s management necessarily was required to apply its judgment in evaluating the cost-benefitcost–benefit relationship of possible controls and procedures. We have carried out an evaluation under the supervision and with the participation of our management, including Amgen’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of Amgen’s disclosure controls and procedures. Based uponon their evaluation and subject to the foregoing, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2020.2021.
Management determined that as of June 30, 2020, there were2021, no changes in our internal control over financial reporting thathad occurred during the fiscal quarter then ended that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.
PART II — OTHER INFORMATION
See NoteNotes 12 and 13, Contingencies and commitments, to the condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q for the periods ended March 31, 20202021 and June 30, 2020,2021, respectively, for discussions that are limited to certain recent developments concerning our legal proceedings. Those discussions should be read in conjunction with Note 19, Contingencies and commitments, to the consolidated financial statements in Part IV of our Annual Report on Form 10-K for the year ended December 31, 2019.
2020.
This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management’s assumptions. These statements are not guarantees of future performance, and they involve certain risks, uncertainties and assumptions that are difficult to predict. You should carefully consider the risks and uncertainties our business faces. The risks described below are not the only ones we face. Our business is also subject to the risks that affect many other companies, such as employment relations, general economic conditions, geopolitical events and international operations. Further, additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price.
Below we provide in supplemental form the material changes to our risk factors that occurred during the past quarter. Our risk factors disclosed in Part I, Item 1A, of our Annual Report, on Form 10-K for the year ended December 31, 2020, provide additional disclosure for these supplemental risks and are incorporated herein by reference.
RISKS RELATED TO ECONOMIC CONDITIONS AND OPERATING A GLOBAL BUSINESS, INCLUDING DURING THE COVID-19 PANDEMIC
The COVID-19 pandemic, and the effort to mitigate the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, manufacturing, supply chains, distribution systems, product development, product sales, business and results of operations.
The novel coronavirus identified in late 2019, SARS-CoV-2, which causes the disease known as COVID-19, is an ongoing global pandemic that has resulted in public and governmental efforts to contain or slow the spread of the disease, including widespread shelter-in-place orders, social distancing interventions, quarantines, travel restrictions and various forms of operational shutdowns. The COVID-19 pandemic and the resulting measures implemented in response to the pandemic are adversely affecting, and are expected to continue to adversely affect, our business (including our R&D, clinical trials, operations, manufacturing, supply chains, distribution systems, product development and sales activities), the business activities of our suppliers, customers, third-party payers and our patients. See our Annual Report on Form 10-K for the year ended December 31, 2020, Part I, Item 1A. Risk Factors—The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations.
The novel coronavirus identifiedoperations;see also Our current products and products in late 2019, SARS-CoV-2, which causes the disease known as COVID-19, is an ongoing global pandemic that has resulteddevelopment cannot be sold without regulatory approval;and see also We must conduct clinical trials in publichumans before we commercialize and governmental efforts to containsell any of our product candidates or slow the spread of the disease, including widespread shelter-in-place orders, social distancing interventions, quarantines, travel restrictions and various forms of operational shutdowns and/or re-shutdowns. The COVID-19 pandemic and the resulting measures implemented in responseexisting products for new indications. Due to the pandemic is adversely affecting, and is expected to continue to adversely affect, a number of our business activities (including our research and development activities, clinical trials, operations, supply chains, distribution systems, product development and sales) as well as our suppliers, customers, third-party payers and patients. Due to these measures and their effects, we have experienced, and expect to continue to experience, unpredictable reductions in demand for certain of our products, and,exacerbated by COVID-19 surges resulting in some cases, have experienced, and could continue to experience, unpredictable increases in demand for certain of our products.
Our clinical trials have been, and are expected to continue to be, adversely affected by the COVID-19 pandemic. We have clinical work ongoing at investigational sites across the globe. A number of clinical trial sites have restricted site visits and have imposed restrictions on the initiation of new clinical trials and patient visits, to protect both site staff and patients from possible COVID-19 exposure that has stopped or slowed clinical trial activities. In response to the safety concerns related to COVID-19, we suspended enrollment and screening in clinical trials where sites are unable to perform clinical trial work due to COVID-19 or there is uncertainty around the ability of sites to ensure subject safety or data integrity. Further, the COVID-19 pandemic is expected to adversely affect our ability to continue enrollment of certain required post-marketing studies, including pediatric studies. The disruption caused by the COVID-19 pandemic to our clinical trials and our clinical trial plans and timelines may have a significant adverse effect on our product development and launches, and, in turn, on future product sales, business and results of operations. For example, to ensure patient safety we initially paused enrollment of our AMG 510 (sotorasib) Phase 1 combination cohort with Keytruda® and Phase 3 lung cancer study, and the interruption in enrollment may ultimately affect the timeline of these studies. Additionally, while we are investing in research and collaborations to potentially develop treatments for COVID-19, such activities may not result in therapeutic candidates, product approvalsrepeated shut-downs and/or significant commercial value being derived from potential COVID-19-related medicines.
We have experienced, and we will continue to experience, regulatory delays, including delays in receiving regulatory advice, reviews of applications, or performance of inspections required for approvals as a result of the COVID-19 pandemic. The pandemic may also result in greater regulatory uncertainty. For example, the FDA and the European Medicines Agency have issued guidance to provide biopharmaceutical manufacturers greater flexibilitydisruptions in certain regulatory areas, including protocol deviations and adverse event reporting. However, such flexibility may result in greater uncertainty regarding the expectations of such health authorities in relation to this guidance. Additionally, there may be delays in ongoing or new patent office or court patent proceedings in the U.S. or internationally that may delay the outcome of such proceedings. Such delays and disruptions may have a significant adverse effect on our product development and launches, product sales, business and results of operations.
In response to COVID-19, we have activated our applicable business continuity plans, including suspending U.S. in-person meetings and interactions with the healthcare community and professionals in a substantial number of states, suspending, as a general matter, all international business travel and the majority of domestic travel within the United States, and all U.S. employees who are able to work from home have been doing so since mid-March 2020. Our ability to perform critical functions and maintain operations could be adversely affected as a result of such workforce restrictions, and the COVID-19-related support programs we have put into place for our staff, suppliers and customers are increasing our operating expenses and reducing the efficiency of our operations. Notwithstanding such support programs, the COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third parties on which we rely. If members of our management and other key personnel in critical functions across our organization are unable to perform their duties or have limited availability due to COVID-19, we may not be able to execute on our business strategy and our operations may be adversely affected. We may also experience limitations in employee resources, including as a result of sickness of employees or their families. Additionally, disruptions in public and private infrastructure, including transportation and supply chains, have further adversely affected the efficiency of our business operations. Also, the transition of the majority of our workforce to a remote work environment in response to COVID-19, as have a number of our third-party service providers, may exacerbate certain risks to our business, including, but not limited to, an increased demand for information technology resources, increased risk of social engineering and other cybersecurity attacks, and increased risk of unauthorized dissemination of sensitive personal information or proprietary or confidential information about us or our service providers or other third-parties. In April 2020, a vendor that provides information technology services to us experienced a cybersecurity incident that required us to disconnect our systems from this vendor. While we do not believe this cybersecurity incident has had a significant adverse effect on our operations, an extended service outage, particularly where a vendor is the single source from which we obtain services, or where a cybersecurity incident significantly affects the operation of our systems, could have a material adverse effect on our business. We may experience significant adverse effects on our commercial and clinical manufacturing activities, our operations, and our cybersecurity, and our suppliers and vendors may experience significant disruptions to their manufacturing activities and operations, and cybersecurity, as a result of the COVID-19 pandemic.geographies.
Federal, state and local, and international governmental policies and initiatives designed to reduce the transmission of COVID-19 also have resulted in the cancellation or delay of diagnostic, elective, specialty and other procedures and appointments to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. These measures and challenges will likely continue to varying degrees for the duration of the pandemic which is uncertain, and have significantly reduced patient access to, and administration of, certain of our drugs. For example, Prolia® is a product requiringrequires administration by a healthcare provider in doctors’ offices or other healthcare settings that are affected by COVID-19. The U.S. label for Prolia® instructs healthcare professionals who discontinue Prolia® to transition the patient to an alternative antiresorptive, including oral treatments that do not require administration by a healthcare provider. Further, as a result of COVID-19, oncology patients, in consultation with their doctors, may be selecting therapies that are less immunosuppressive therapies or therapies that do not require administration in a hospital setting, potentially adversely affecting certain of our products. Our general medicine products have benefited from 90-day supply availability for existing patients butAlso, new patients have been, and are expected to continue to be, less likely to be diagnosed and/or to start these therapeutics during the pandemic.pandemic, and these effects, together with the lower treatment rates
during the pandemic, have had, and are expected to continue to have, a cumulative negative effect on the commercial performance of our business. The decrease in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which we expect to continue to impact our business during the second half of the year. Once the pandemic subsides, we anticipate there willcould be a substantial backlog of patients seeking appointments with physicians relating to a variety of medical conditions, and as a result, patients seeking treatment with certain of our products may have to navigate limitedlower provider capacity, and this limitedlower provider capacity could have a continued adverse effect on our sales following the opening up of various geographies and/or the end of the pandemic. Further, the effects of the COVID-19 pandemic may result in long-term shifts in preferences among healthcare professionals and patients toward treatments that do not require administration by healthcare professionals or visits to medical facilities.
The legislative and regulatory environment governing our businesses is dynamic and changing frequently in response to COVID-19. More than a dozen states have taken action to help patients maintain access to prescription drugs during the COVID-19 pandemic including requiring state-regulated commercial plans to cover 90-day fills and emergency fills in certain circumstances. At the federal level, legislation has been proposed seeking to incentivize greater drug manufacturing in the United States with the stated goal of improving supply reliability in the United States. One such legislative proposal would prohibit the U.S. Department of Veterans Affairs from purchasing certain drugs that have active pharmaceutical ingredients
manufactured outside the United States. While we perform a substantial majority of our commercial manufacturing activities in the United States, including in the U.S. territory of Puerto Rico, and a substantial majority of our clinical manufacturing activities at our facility in Thousand Oaks, California, the passage of such legislation could result in foreign governments enacting retaliatory legislation or regulatory actions, which may have an adverse effect on our product sales, business and results of operations internationally. The COVID-19 pandemic has also resulted in increased interest in compulsory licenses, march-in rights or other governmental interventions, both in the United States and internationally, related to the procurement of drugs, such as the WHO’s COVID-19 Technology Access Pool initiative, which provides an approach for sharing all intellectual property, information and clinical trial data necessary to enable generic drug manufacturing. Pursuant to the declaration of a national emergency in March 2020 under the Stafford Act, state and local governments may request access to discounted pricing for certain items related to the COVID-19 response. The CARES Act implements initiatives to provide advanced payments from Medicare to healthcare providers, clinics and physicians and to require Medicare plans to provide up to a 90-day supply of Part D drugs. However, despite such initiatives and government support, there may be adverse effects on the timing and collectability of our customer receivables as a result of the COVID-19 pandemic. See our Annual Report on Form 10-K for the year ended December 31, 2019, Part I, Item 1A. Risk Factors—Concentration of sales at certain of our wholesaler distributors and at one free-standing dialysis clinic business and consolidation of private payers may negatively affect our business. The COVID-19 pandemic has also resulted in a significant increase in unemployment in the United States which may continue after the pandemic. Such a significant increase in unemployment is expected to lead to a substantial reduction in disposable income and access to health insurance which could adversely affect our product sales. Further, the substantial pressures placed on governmental and payor budgets as a result of the COVID-19 pandemic and the projected governmental budget shortfalls caused by significantly reduced economic activity during and potentially after the COVID-19 pandemic may result in greater and continued downward price pressure on biopharmaceutical products and increased intensity of stakeholder negotiations across the biopharmaceutical value chain. For example, on July 24, 2020, the Administration announced a number of executive orders intended to reduce the cost of biopharmaceuticals for patients that have the potential to increase the risks described and discussed previously in our Annual Report on Form 10-K for the year ended December 31, 2019, Part I, Item 1A. Risk Factors—Our sales depend on coverage and reimbursement from third-party payers, and pricing and reimbursement pressures may affect our profitability,and such risks could materially adversely affect our product sales, business, profitability, results of operations, cash flows and financial position.
In recent weeks, the continued global spread of COVID-19 has also led to disruption and volatility in the global capital markets. We have certain assets, including equity investments, that are exposed to market fluctuations that could, in a sustained market disruption, result in impairments. Further, the economic downturn resulting from this global pandemic has precipitated a global recession which may be of an extended duration. See our Annual Report on Form 10-K for the year ended December 31, 2019, Part I, Item 1A. Risk Factors—Global economic conditions may negatively affect us and may magnify certain risks that affect our business.
As the pandemic continues, and if conditions worsen or if the duration of the pandemic extends significantly, we expect to experience additional adverse effects on our development, operational and commercial activities, customer purchases and our collections of accounts receivable, it is unclear which adverse effects may be material, and itreceivable. It remains uncertain the degree to which these adverse effects would impact our future operational and commercial activities, customer purchases and our collections even ifas conditions begin to improve. With the recent relaxation of restrictions on business operations and in-person gatherings thereThere has been a resurgence in COVID-19 infections in numerous jurisdictions in the first half of 2021, resulting in the reinstatement of stricter restrictions and shutdowns.shutdowns in a number of jurisdictions, including in the U.S., Europe and Asia Pacific regions. It is expected that therethe pandemic will be ancontinue to ebb and flow, to the pandemic with different jurisdictions having higher levels of infections than others over the course of the pandemic. In additionNew variants of the SARS-CoV-2 virus have emerged, and have been shown to existing travel restrictions, jurisdictionsbe present in many geographies, and appear to spread more easily and quickly than other variants. Further, although some studies suggest that antibodies generated with currently authorized vaccines may be effective against these variants, it remains uncertain whether currently available vaccines will retain their efficacy against current and/or future variants of the virus. Jurisdictions may implement, continue or reinstate border closures, impose or reimpose prolonged quarantines and further restrict travel and business activity, which could significantly affect our ability to support our operations and customers and the ability of our employees to get to their workplaces to discover, study, develop and produce our product candidates and products, disrupt the movement of our products through the supply chain, and further prevent or discourage patients from participating in our clinical trials, seeking healthcare services and the administration of certain of our products. Further, in connection with the global outbreak and spread of COVID-19 and in an effort to increase the wider availability of needed medical products, we or our suppliers may elect to, or governments may require us or our suppliers to, allocate manufacturing capacity (for example pursuant to the U.S. Defense Production Act) in a way that adversely affects our regular operations, customer relationships and financial results. In the U.S., on January 21, 2021, President Biden issued an Executive Order instructing federal agencies to use all available legal authorities, including the Defense Production Act, to improve current and future pandemic response and biological threat preparedness. The rapid reallocation of resources for the treatment and prevention of COVID-19 including(including the production of COVID-19 vaccinations or related therapies, such as our agreement to contribute to the production of Lilly’s COVID-19 antibody therapies) and/or disruptions and shortages in the global supply chain caused by the pandemic, could also result in increased competition for, or reduced availability of, materials used in the development, manufacturing, distribution, or distributionadministration of our products. For example, during the second quarter of 2021, an industry-wide shortage of certain lab kit supplies necessary for some activities that support our clinical trials has developed that we are actively monitoring and managing. In addition, unpredictable increases in demand for certain of our products could exceed our capacity to meet such demand, which could adversely affect our financial results and customer relationships.
The COVID-19 pandemic and the volatile global economic conditions stemming from it may precipitate or amplify the other risks described in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2019,2020, which could materially adversely affect our business, operations and financial conditions and results. For example, if a natural disaster or other potentially disruptive event occurs concurrently with the COVID-19 pandemic, such disaster or event could deplete our inventory levels and we could experience a disruption to our manufacturing or ability to supply our products. Further, the global pandemic has exacerbated geopolitical tensions, and some countries, such as China, may be especially vulnerable to such
dynamics. If relations between the U.S.United States and China or other governments deteriorates, our business and investments in China or other such markets may also be adversely affected. See our Annual Report on Form 10-K for the year ended December 31, 2020, Part I, Item 1A. Risk Factors—Our sales and operations are subject to the risks of doing business internationally, including in emerging markets.
The rapid development and fluidity of the pandemic preclude any prediction as to the ultimate effect of COVID-19 on us. The duration of the measures being taken by the authorities to mitigate against the spread of COVID-19 (including the distribution and/or availability of vaccines), and the extent to which such measures are effective, if at all, remain highly uncertain. We believe theThe magnitude and degree of COVID-19’s adverse effect on our business (including our product development, product sales, businesses, operating results and resulting cash flowsflows) and financial condition will be driven by the severity and duration of the pandemic, the pandemic’s effect on the United States and global economies and the timing, scope and effectiveness of federal, state, local and international governmental responses to the pandemic. However, ifIf mitigation of the spread continues on at or near its current trajectory or mitigationpandemic continues to require similar levels offurther shelter-in-place and shut-down orders such effectand/or restrictions on individual and/or group conduct, any adverse effects of the COVID-19 pandemic will likely grow and could be enduring and our business and financial position could be materially
adversely affected.
A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our information technology systems, network-connected control systems and/or our data, interrupt the operation of our business and/or affect our reputation.
To achieve our business objectives, we rely on sophisticated information technology systems, including software, mobile applications, cloud services and network-connected control systems, some of which are managed, hosted, provided or serviced by third parties. Internal or external events that compromise the confidentiality, integrity and availability of our systems and data may significantly interrupt the operation of our business, result in significant costs and/or adversely affect our reputation.
Our information technology systems are highly integrated into our business, including our R&D efforts, our clinical and commercial manufacturing processes and our product sales and distribution processes. Further, as the majority of our employees are working remotely, our reliance on our and third-party information technology systems has increased substantially and is expected to continue to increase. The complexity and interconnected nature of our systems makes them potentially vulnerable to breakdown or other service interruptions. Our systems are also subject to frequent cyberattacks. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity and are becoming increasingly difficult to detect. Such attacks could include the use of harmful and virulent malware, including ransomware or other denials of service, that can be deployed through various means, including the software supply chain, e-mail, malicious websites and/or the use of social engineering. We have also experienced unsuccessful denial of service attacks against our network, and although such attacks did not succeed, there can be no assurance that our efforts to guard against the wide and growing variety of potential attack techniques will be successful in the future. Attacks such as those experienced by governmental entities (including those that approve and/or regulate our products, such as the European Medicines Agency (EMA)) and other multi-national companies, including some of our peers, could leave us unable to utilize key business systems or access or protect important data, and could have a material adverse effect on our ability to operate our business, including developing, gaining regulatory approval for, manufacturing, selling and/or distributing our products. For example, in 2017, a pharmaceutical company experienced a cyberattack involving virulent malware that significantly disrupted its operations, including its research and sales operations and the production of some of its medicines and vaccines. As a result of the cyberattack, its orders and sales for certain products in certain markets were negatively affected. In December 2020, SolarWinds Corporation, a leading provider of software for monitoring and managing information technology infrastructure, disclosed that it had suffered a cybersecurity incident whereby attackers had inserted malicious code into legitimate software updates for its products that were installed by myriad private and government customers, enabling the attackers to access a backdoor to such systems. See our Annual Report on Form 10-K for the year ended December 31, 2020, Part I, Item 1A. Risk Factors—The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations for a discussion of the cyberattack on the EMA.
Our systems also contain and utilize a high volume of sensitive data, including intellectual property, trade secrets, financial information, regulatory information, strategic plans, sales trends and forecasts, litigation materials and/or personal information belonging to us, our staff, our patients, customers and/or other parties. In some cases, we utilize third-party service providers to process, store, manage or transmit such data, which may increase our risk. Intentional or inadvertent data privacy or security breaches (including cyberattacks) resulting from attacks or lapses by employees, service providers (including providers of information technology-specific services), nation states (including groups associated with or supported by foreign intelligence agencies), organized crime organizations, “hacktivists” or others, create risks that our sensitive data may be exposed to unauthorized persons, our competitors, or the public. For example, a supplier recently experienced a data breach in which an unauthorized third party acquired access to certain information provided to the supplier in the course of its provision of services to us, including business documents and certain personally identifiable patient information (not including social security or other financial or health insurance information). As required, we promptly notified the applicable state attorneys general and the individuals whose personally identifiable information was affected of this data breach at the supplier. Although the supplier data breach did not result in a material adverse effect on our business, there can be no assurance that a similar future cybersecurity incident would not result in a material adverse effect on our business or results of operations.
Domestic and global government regulators, our business partners, suppliers with whom we do business, companies that provide us or our partners with business services and companies we may acquire may face similar risks, and security breaches of their systems could adversely affect our security, leave us without access to important systems, products, raw materials, components, services or information or expose our confidential data or sensitive personal information. For example, in 2019, two vendors that perform testing and analytical services that we use in developing and manufacturing our products have experienced cyberattacks, and in April and September of 2020, vendors that provide us with information technology services and clinical data services, respectively, each experienced ransomware attacks. Although there was no breach of our systems,
each of these incidents required us to disconnect our systems from those vendors’ systems. While we were able to reconnect our systems following restoration of these vendor’s capabilities without significantly affecting product availability, a more extended service outage affecting these or other vendors, particularly where such vendor is the single source from which we obtain the services, could have a material adverse effect on our business or results of operations. In addition, we distribute our products in the United States primarily through three pharmaceutical wholesalers, and a security breach that impairs the distribution operations of our wholesalers could significantly impair our ability to deliver our products to healthcare providers and patients.
Although we have experienced system breakdowns, attacks and information security breaches, we do not believe such breakdowns, attacks and breaches have had a material adverse effect on our business or results of operations. We continue to invest in the monitoring, protection and resilience of our critical and/or sensitive data and systems. However, there can be no assurances that our efforts will detect, prevent or fully recover systems or data from all breakdowns, service interruptions, attacks and/or breaches of our systems that could adversely affect our business and operations and/or result in the loss or exposure of critical, proprietary, private, confidential or otherwise sensitive data, which could result in material financial, legal, business or reputational harm to us or negatively affect our stock price. While we maintain cyber-liability insurance, our insurance is not sufficient to cover us against all losses that could potentially result from a service interruption, breach of our systems or loss of our critical or sensitive data.
We are also subject to various laws and regulations globally regarding privacy and data protection, including laws and regulations relating to the collection, storage, handling, use, disclosure, transfer and security of personal data. The legislative and regulatory environment regarding privacy and data protection is continuously evolving and developing and the subject of significant attention globally. For example, we are subject to the European Union’s General Data Protection Regulation, which became effective in May 2018, and the California Consumer Privacy Act of 2018 (CCPA), which became effective in January 2020, both of which provide for substantial penalties for non-compliance. The CCPA was amended in late 2020, to create the California Privacy Rights Act to create opt in requirements for the use of sensitive personal data and the formation of a new dedicated agency for the enforcement of the law, the California Privacy Protection Agency. Since then, Virginia and Colorado both passed similar consumer privacy laws that will go into effect in 2023. Other jurisdictions where we operate continue to propose similar legislation and/or regulations with others expected to pass in 2021. Failure to comply with these current and future laws could result in significant penalties and reputational harm and could have a material adverse effect on our business and results of operations.
RISKS RELATED TO GOVERNMENT REGULATIONS AND THIRD-PARTY POLICIES
Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability.
Sales of our products depend on the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans. Governments and private payers continue to pursue initiatives to manage drug utilization and contain costs. These payers are increasingly focused on the effectiveness, benefits and costs of similar treatments, which could result in lower reimbursement rates for our products or narrower populations for whom payers will reimburse. Continued intense public scrutiny of the price of drugs and other healthcare costs, together with payer dynamics, have limited, and are likely to continue to limit, our ability to set or adjust the price of our products based on their value, which could have a material adverse effect on our business. In the United States, particularly over the past few years, a number of legislative and regulatory proposals have been introduced in an attempt to lower drug prices. These include proposals that would allow the U.S. government to negotiate drug price directly, limit drug reimbursement based on prices abroad or permit importation of drugs from Canada. Proposals focused on drug pricing have been implemented and are likely to continue to be proposed and may be adopted and implemented in some form. See our Annual Report on Form 10-K for the year ended December 31, 2020, Part I, Item 1A. Risk Factors—Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability.
—Changing U.S. federal coverage and reimbursement policies and practices have affected and may continue to affect access to, pricing and sales of our products
A substantial portion of our U.S. business relies on reimbursement from federal government healthcare programs and commercial insurance plans regulated by federal and state governments. See our Annual Report on Form 10-K for the year ended December 31, 2020, Part I, Item 1. Business—Reimbursement. Our business has been and will continue to be affected by legislative actions changing U.S. federal reimbursement policy. Congress has been focused on drug pricing reforms and oversight since 2018, and that activity continues today. For example, in 2020, Amgen participated in House Oversight and Reform Committee hearings on drug pricing practices. Additionally, in 2019 and 2020, a number of other Congressional committees debated drug pricing reform proposals. For example, in 2019, the Senate Finance Committee advanced a bill that would, among other things, penalize pharmaceutical manufacturers for raising prices on drugs covered by Medicare Parts B
and/or D faster than the rate of inflation, cap out-of-pocket expenses for Medicare Part D beneficiaries and require higher/additional manufacturer discounts in Medicare Part D. Additionally, in late 2019, a drug-pricing bill, H.R. 3, passed the House of Representatives, which would, among other things, enable direct price negotiations by the federal government on certain drugs (with the maximum price paid by Medicare capped by prices derived from an international index), includes a penalty for failing to reach agreement with the government and requires that manufacturers offer these negotiated prices to other payers. We expect H.R. 3 to again be debated by Congress in the coming months. Most recently, Congress passed the American Rescue Plan Act of 2021 to provide additional stimulus money and support for COVID relief. As part of that legislation, a provision that is expected to be implemented in 2024 was included that has the effect of increasing the Medicaid rebate liability for some medicines that increase prices in excess of inflation. There are other outstanding proposals that have been introduced by the prior Administration that, if enacted and implemented in whole or in part, could also affect access to and sales of our products, including, but not limited to, proposals to allow importation of prescription medications from Canada or other countries and to set Medicare payment rates using international price referencing. Further, in mid-2020, the prior Administration announced a number of Executive Orders intended to reduce the cost of biopharmaceuticals for patients, including a most favored nation (MFN) policy for Medicare Parts B and D, under which the Health & Human Services (HHS) was directed to take steps to implement payment models that set Medicare purchase prices based on the lowest price available in economically comparable countries for certain Part B and Part D medicines. In September 2020, in response to the corresponding Executive Order, HHS released a final rule to allow states (or other nonfederal government entities) to submit proposals to the FDA allowing for the importation of certain nonbiologic prescription drugs from Canada. Currently, the rule is being challenged by litigation, however, should such litigation be unsuccessful and should the Secretary of HHS authorize state proposals for importation, this rule could allow the importation of Canadian versions of certain of Amgen’s products (including Otezla®), that could have a material adverse effect on Amgen’s business. Further, in November 2020, also in response to the corresponding Executive Order, HHS released an interim final rule to implement the MFN pricing approach. If implemented, the MFN rule would set the reimbursement rate for 50 Medicare Part B drugs (including our products, such as Prolia®, XGEVA®, KYPROLIS®, Neulasta®, Nplate®, EPOGEN® and Aranesp®) equal to the lowest adjusted price for such products of the 22 OECD nations. Lawsuits have been filed by certain trade groups challenging the implementation of this MFN rule based on, among other things, procedural defects. Late in 2020, in the case filed by the Biotechnology Innovation Organization (BIO) and others, the U.S. District Court for the Northern District of California issued a preliminary injunction preventing the rule from taking effect nationwide, pending the government’s completion of required administrative procedures. The case was subsequently stayed by the court. On July 29, 2021, the court granted the parties’ request for the stay to remain in place and ordered the parties to file their joint status report by September 27, 2021. Another case, filed by the Pharmaceutical Research and Manufacturers of America and others in the U.S. District Court for the District of Maryland, was also stayed until either a final rule based on the MFN interim rule is published in the Federal Register, or until the court orders a lifting of the stay based on, among other things, the status of the nationwide preliminary injunction issued in the BIO case. Notwithstanding these stays, the MFN rule’s approach to drug pricing and other similar approaches, remain of interest. Further, despite the change in Administration, we expect continued significant focus on healthcare and similar drug pricing proposals for the foreseeable future, including proposals similar to the MFN rule or other proposals that would grant the HHS secretary the authority to negotiate drug prices directly with manufacturers.
Our business has been, and is expected to continue to be, affected by changes in U.S. federal reimbursement policy resulting from federal regulations and federal demonstration projects. Over the past three years, federal agencies, including the Centers for Medicare & Medicaid Services (CMS), announced a number of recommendations, policies, proposals and demonstration projects addressing drug pricing. CMS is the federal agency responsible for administering Medicare and overseeing state Medicaid programs and Health Insurance Marketplaces and has substantial power to implement policy changes or demonstration projects that can quickly and significantly affect how drugs, including our products, are covered and reimbursed. CMS issued guidance to allow certain Medicare plans offered by private insurance companies to require that patients receiving Medicare Part B drugs first try a drug preferred by the plan before covering another therapy (Step Therapy) and lowered reimbursement rates for new Medicare Part B drugs. Further, HHS issued a final rule under Medicare Part D revising the regulations under the federal antikickback statute to encourage Pharmacy Benefit Managers (PBMs) to use rebates received from biopharmaceutical manufacturers to reduce patient cost-sharing at the point of sale. While the implementation date for the rule is January 1, 2023, the rule remains subject to litigation, there are numerous logistical hurdles to overcome before it can be effectively implemented, and it is unclear how PBMs will respond and what the current Administration’s position is on such rule. Further, while the prior Administration finalized a rule (effective January 1, 2022) mandating price and cost-sharing transparency for almost all health plans and insurers in the individual and group commercial markets, it also is unclear how the current Administration views this rule and how plans and PBMs may respond when it goes into effect. Separately, the Administration is seeking information on how best to implement new reporting requirements relating to the cost of pharmacy benefits, including premiums for drug coverage, manufacturer rebates and the most utilized drugs under group health plans. Such reporting requirements begin no later than December 27, 2021. It is unclear how group health plans and health insurers may respond. The Administration also could develop and seek to advance a range of policy proposals that could impact U.S. federal reimbursement policy for drugs and biologics, including changes to Medicare Part B.
CMS policy changes and demonstration projects to test new care, delivery and payment models can significantly affect how drugs, including our products, are covered and reimbursed. In end-stage renal disease (ESRD), CMS uses bundled payment rates. Between 2018 and 2020, Sensipar® and Parsabiv®, our calcimimetics that are used in dialysis clinics, were eligible for temporary drug add-on payment adjustments (TDAPA) to the bundled rate. In November 2020, CMS released its final rule ending the TDAPA for calcimimetics and adjusting ESRD Prospective Payment System bundled rates on January 1, 2021 by $9.93 per dialysis treatment for calcimimetics. As a result, sales of Parsabiv® have been materially adversely affected by this rule change. Additionally, CMS created a new mandatory payment model, effective January 1, 2021, focused on encouraging greater use of home dialysis and kidney transplants for ESRD patients that could result in changes to treatment of dialysis patients, including reduction of the use of our ESAs. Further, in November 2019, CMS announced additional voluntary payment models for nephrologists and dialysis facility partners that also seek to encourage home dialysis and preemptive transplantation through increased risk sharing, but the start date of such programs has been pushed back to January 1, 2022. CMS has also solicited suggestions regarding other potential care models. In 2016, CMS initiated the Oncology Care Model demonstration, which provides participating physician practices with performance-based financial incentives that aim to manage or reduce Medicare costs without negatively affecting the efficacy of care, that has been extended by one year (to 2022) due to COVID-19. We believe the Oncology Care Model has reduced utilization of certain of our oncology products by participating physician practices and expect it to continue to do so in the future. Additionally, in late 2019, CMS announced a request for information on the Oncology Care First model, a new voluntary model that builds on the Oncology Care Model. CMS has indicated a continued interest in exploring demonstrations of mandatory models, and may propose both new mandatory payment models in the future that could adversely affect our business. CMS recently finalized a rule that, starting January 1, 2023, unless a manufacturer can ensure that the full amount of manufacturer patient assistance programs is passed on to the patient, such amount will be treated as a price reduction that will be taken into account when reporting our Best Price and/or Average Manufacturer Price. Given the use by PBMs and insurers of copay accumulator adjustment programs to apply such patient assistance for the benefit of such companies and not to defray costs to patients, it could be difficult to impossible for manufacturers to ensure that the full value of such amounts is being passed on to the patient. This new policy, if implemented, would have significant implications for our ability to offer copay assistance programs.
In this dynamic environment, particularly in light of the pressures on healthcare budgets as a result of the pandemic, we are unable to predict which or how many federal policy, legislative, regulatory, executive or administrative changes may ultimately be, or effectively estimate the consequences to our business if, enacted and implemented. However, to the extent that these or other federal government initiatives further decrease or modify the coverage or reimbursement available for our products, require that we pay increased rebates or shift other costs to us, limit or affect our decisions regarding the pricing of or otherwise reduce the use of our U.S. products, or limit our ability to offer co-pay payment assistance to commercial patients, such actions could have a material adverse effect on our business and results of operations.
We also face risks relating to the reporting of pricing data that affects the reimbursement of and discounts provided for our products. U.S. government price reporting regulations are complex and may require a biopharmaceutical manufacturer to update certain previously submitted data. If our submitted pricing data are incorrect, we may become subject to substantial fines and penalties or other government enforcement actions, which could have a material adverse effect on our business and results of operations. In addition, as a result of restating previously reported price data, we also may be required to pay additional rebates and provide additional discounts.
The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability.
We are subject to income and other taxes in the United States and other jurisdictions in which we do business. As a result, our provision for income taxes is derived from a combination of applicable tax rates in the various places we operate. Significant judgment is required for determining our provision for income tax.
One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts, and such tax authorities (including the IRS) are becoming more aggressive in their audits and are particularly focused on such matters. In 2017, we received a RAR and a modified RAR from the IRS for the years 2010, 2011 and 2012 proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. As previously reported, we disagreed with the proposed adjustments and calculations and pursued a resolution with the IRS administrative appeals office. However, we were unable to reach resolution with the IRS appeals office. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicative Notices for 2010, 2011 and 2012 that we received in May and July 2021 which seek to increase our U.S. taxable income. We firmly believe that the IRS’ positions set forth in the Notices are without merit, and we will vigorously contest the Notices through the judicial
process. See Note 4, Income taxes, to the condensed consolidated financial statements.
In addition, in 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015 also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010, 2011 and 2012. We disagree with the 2013, 2014 and 2015 proposed adjustments and calculations and are pursuing resolution with the IRS administrative appeals office. We are currently under examination by the IRS for the years 2016, 2017 and 2018. We are also currently under examination by a number of other state and foreign tax jurisdictions.
Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse effect on the results of our operations.
Our provision for income taxes and results of operations cash flows and financial positionin the future could be materially adversely affected.
affected by changes to our operating structure, changes in the mix of income and expenses in countries with differing tax rates, changes in the valuation of deferred tax assets and liabilities and changes in applicable tax laws, regulations or administrative interpretations thereof. The Tax Cuts and Jobs Act (the 2017 Tax Act) is complex and a large volume of regulations and guidance has been issued and could be subject to different interpretations. We could face audit challenges to our application of the 2017 Tax Act. The Administration and Congress are considering significant changes to existing tax law, including an increase in the corporate tax rate and the tax rate on foreign earnings. These changes could substantially increase U.S. taxation of our operations both in and outside the United States, including the U.S. territory of Puerto Rico. Further, the OECD recently reached agreement to align countries on a minimum corporate tax rate and an expansion of the taxing rights of market countries. If enacted, this agreement could result in tax increases in both the United States and foreign jurisdictions. Changes to existing tax law in the U.S., the U.S. territory of Puerto Rico, or other jurisdictions that would likely result in tax increases where we do business and could have a material adverse effect on the results of our operations.
| | | | | |
Item 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
During the three months ended June 30, 2020,2021, we had one outstanding stock repurchase program, under which the repurchase activity was as follows:
| Period | Period | | Total number of shares purchased | | Average price paid per share (1) | | Total number of shares purchased as part of publicly announced program | | Maximum dollar value that may yet be purchased under the program(2) | Period | | Total number of shares purchased | | Average price paid per share (1) | | Total number of shares purchased as part of publicly announced program | | Maximum dollar value that may yet be purchased under the program(2) |
April 1 - 30 | April 1 - 30 | | — | | | $ | — | | | — | | | $ | 5,540,776,983 | | April 1 - 30 | | 1,912,921 | | | $ | 244.13 | | | 1,912,921 | | | $ | 5,044,280,273 | |
May 1 - 31 | May 1 - 31 | | 809,677 | | | $ | 227.93 | | | 809,677 | | | $ | 5,356,226,673 | | May 1 - 31 | | 2,425,697 | | | $ | 248.21 | | | 2,425,697 | | | $ | 4,442,191,440 | |
June 1 - 30 | June 1 - 30 | | 1,787,649 | | | $ | 227.46 | | | 1,787,649 | | | $ | 4,949,614,503 | | June 1 - 30 | | 2,180,367 | | | $ | 239.80 | | | 2,180,367 | | | $ | 3,919,349,391 | |
Total | Total | | 2,597,326 | | | $ | 227.60 | | | 2,597,326 | | | Total | | 6,518,985 | | | $ | 244.20 | | | 6,518,985 | | |
___________
(1) Average price paid per share includes related expenses.
(2) In December 2019,March 2021, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $4.0$3.4 billion.
Reference is made to the Index to Exhibits included herein.
INDEX TO EXHIBITS
| | | | | | | | |
Exhibit No. | | Description |
2.1 | | |
| | |
2.2 | | |
| | |
2.3 | | |
| | |
2.4 | | |
| | |
2.5 | | |
| | |
2.6 | | |
| | |
3.1 | | |
| | |
3.2 | | |
| | |
4.1 | | |
| | |
4.2 | | Form of Indenture, dated January 1, 1992. (Filed as an exhibit to Form S-3 Registration Statement filed on December 19, 1991 and incorporated herein by reference.) |
| | |
4.3 | | |
| | |
4.4 | | |
| | |
4.5 | | |
| | |
4.6 | | |
| | |
4.7 | | |
| | |
4.8 | | |
| | |
4.9 | | |
| | |
4.10 | | |
| | |
4.11 | | |
| | |
| | | | | | | | |
4.13 | | |
| | |
4.14 | | |
| | |
4.15 | | |
| | |
4.16 | | |
| | |
4.17 | | |
| | |
4.18 | | |
| | |
4.19 | | |
| | |
4.20 | | |
| | |
4.21 | | |
| | |
4.22 | | |
| | |
4.23 | | |
| | |
4.24 | | |
| | |
4.25 | | |
| | |
4.26 | | |
| | |
4.27 | | |
| | |
4.28 | | |
| | |
4.29 | | |
| | |
4.31 | | Officer’s Certificate of Amgen Inc., dated as of August 17, 2020, including forms of the Company’s 2.770% Senior Notes due 2053. (Filed as an exhibit to Form 8-K on August 18, 2020 and incorporated herein by reference.) | | | 4.32 | | Registration Rights Agreement, dated as of August 17, 2020, by and among Amgen Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, as lead dealer managers, and BNP Paribas Securities Corp., Deutsche Bank Securities Inc., RBC Capital Markets, LLC, Blaylock Van, LLC and Siebert Williams Shank & Co., LLC, as co-dealer managers. (Filed as an exhibit to Form 8-K on August 18, 2020 and incorporated herein by reference.) | | | | 10.1+ | | | | | | 10.2+ | | | | | | 10.3+ | | | | | | 10.4+ | | | | | | 10.5+ | | | | | | 10.6+ | | | | | | 10.7+ | | | | | | 10.8+ | | | | | | 10.9+ | | | | | | 10.10+ | | | | | | 10.11+ | | | | | | 10.12+ | | | | | | 10.13+ | | | | | | 10.14+ | | | | | | 10.15+ | | |
| | | | | | | | | 10.19+ | | | | | | 10.20+ | | | | | | 10.21+ | | | | | | 10.22+ | | | | | | 10.23+ | | | | | | 10.24+10.23+ | | | | | | 10.2510.24 | | Second Amended and Restated Credit Agreement, dated December 12, 2019, among Amgen Inc., the Banks therein named, Citibank, N.A., as administrative agent, and JPMorgan Chase Bank, N.A., as syndication agent. (Filed as an exhibit to Form 8-K on December 12, 2019 and incorporated herein by reference.) | | | | 10.2610.25 | | | | | | 10.2710.26 | | | | | | 10.2810.27 | | | | | | 10.2910.28 | | | | | | 10.3010.29 | | | | | | 10.3110.30 | | | | | | 10.3210.31 | | | | | |
| | | | | | | | | 10.3510.34 | | | | | | 10.3610.35 | | | | | | 10.3710.36 | | | | | | 10.3810.37 | | | | | | 10.3910.38 | | | | | | 10.4010.39* | | | | | | 10.41 | | | | | | 10.4210.40 | | | | | | 10.4310.41 | | | | | | 10.4410.42 | | | | | | 10.4510.43 | | | | | | 10.4610.44 | | | | | | 10.4710.45 | | | | | | 10.4810.46 | | | | | |
| | | | | | | | | 10.49*10.47 | | Amendment Nos. 2 through 6 to the March 30, 2012 Collaboration Agreement between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, dated May 2 and 27 and October 2, 2016, January 31, 2018, and May 15, 2020, respectively (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2020 on July 29, 2020 and incorporated herein by reference.) | | | | 10.48 | | | | | | 10.49* | | | | | | 31* | | | | | | 32** | | | | | | 101.INS | | Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inlineInline XBRL document. | | | | 101.SCH* | | Inline XBRL Taxonomy Extension Schema Document. | | | | 101.CAL* | | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | | | | 101.DEF* | | Inline XBRL Taxonomy Extension Definition Linkbase Document. | | | | 101.LAB* | | Inline XBRL Taxonomy Extension Label Linkbase Document. | | | | 101.PRE* | | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | | | | 104 | | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
____________________________ (* = filed herewith) (** = furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended) (+ = management contract or compensatory plan or arrangement)
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized. | | | | | | | | | | | | | | | | | Amgen Inc. | | | | | (Registrant) | | | | | | | | Date: | July 28, 2020August 3, 2021 | By: | | /S/ PETER H. GRIFFITH | | | | | Peter H. Griffith | | | | | Executive Vice President and Chief Financial Officer | | | | | (Principal Financial Officer) |
|